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Abstract 
 
 
Viruses in the genus Orthobunyavirus (family Bunyaviridae) are classified serologically 
into 18 serogroups. The viruses have a tripartite genome of negative sense RNA composed 
of large (L), medium (M) and small (S) segments. The L segment encodes the polymerase 
protein, the M segment encodes two glycoproteins, Gc and Gn, and a non-structural protein 
(NSm), and the S segment encodes nucleocapsid (N) and NSs proteins, in overlapping 
reading frames (ORF). The NSs proteins of Bunyamwera and California serogroup viruses 
have been shown to play a role in inhibiting host cell protein synthesis and preventing 
induction of interferon in infected cells. 
 
To-date, viruses in only 4 serogroups: Bunyamwera, California, Group C and Simbu, have 
been studied intensively. Therefore, this study was conducted with the aim to sequence the 
S RNA segments of representative viruses in the other 14 orthobunyavirus serogroups, to 
analyse virus-encoded proteins synthesised in infected cells, and to investigate their ability 
to cause shutoff of host protein synthesis. 
 
S RNA segment sequences were obtained from cloned RT-PCR products. They were 
compared with the available sequences and each other. Complete S RNA sequences of 
Anopheles A (ANAV) and Tacaiuma virus (TCMV) [Anopheles A serogroup], Anopheles 
B (ANBV) and Boraceia virus (BORV) [Anopheles B serogroup], Eretmapodites (E147V) 
and Nyando virus (NDV)[Nyando serogroup], Bwamba virus (BWAV) [Bwamba 
serogroup], M’Poko virus (MPOV) [Turlock serogroup], Tete (TETEV) and Batama virus 
(BMAV) [Tete serogroup], and Gamboa (GAMV) and San Juan 2441 virus (SJ244V) 
[Gamboa serogroup], and partial sequences of Patois virus (PATV) [Patois serogroup], 
Guama (GMAV) and Bertioga virus (BERV) [Guama serogroup], Capim virus (CAPV) 
[Capim serogroup] and Palestina virus  (PLSV) [Minatitlan serogroup] were obtained. 
Complete S segment sequences revealed that viruses in the same serogroup have same 
length of N and NSs proteins, except for the viruses in Gamboa serogroup which were 
found to have two lengths of NSs protein. Viruses in 4 serogroups (Anopheles A, 
Anopheles B, Tete and Capim) were found not to encode an NSs ORF, presenting the first 
report of naturally isolated orthobunyaviruses without an NSs protein. Most of these 
viruses were found to have longer N proteins compared to those with NSs protein, with the 
largest N protein observed to date in TETEV and BMAV (258 amino acids). Other viruses 
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(EREV, NDV, GAMV, SJ2441V, BWAV and MPOV) were found to encode both N and 
NSs proteins in their S segment with the largest and smallest NSs protein detected to date 
in SJ2441V (137 amino acids) and MPOV (70 amino acids) respectively. The conserved 
CA rich motif in 5’ non coding region (NCR) of Bunyamwera and California serogroups 
viruses was absent in BWAV and MPOV, while ANBV and BORV were found to have 
two copies of this motif. Repeated sequences, as observed previously in the 5’ NCR of 
genomic-sense RNA of Lumbo virus (LUMV), were also detected in BWAV and TCMV S 
RNA segments.  
 
Sequence comparisons and phylogenetic analyses of the sequences determined in this 
study were in agreement with previous serological classification of the viruses, except for 
BERV and TCMV. BERV, in the Guama serogroup, was found to have a closer 
relationship with CAPV compared to GMAV. However high sequence identities (>70%) 
were observed between these 3 viruses, suggesting that they are derived from the same 
ancestor. N protein and nucleotide sequence identities of TCMV with ANAV were only 
53% and 59% respectively. However, Neighbour-Joining (NJ) plot based on complete N 
amino acid sequence and Maximum Parsimony (MP) plot based on partial N sequence 
supported previous serological classification which placed this virus in the same clade as 
ANAV.  
 
This study first reports on the proteins synthesised by Bakau, Bwamba, Koongol, Gamboa, 
Minatitlan, Olifantsvlei and Tete serogroup viruses. Analysis of radio-labelled cell extracts 
revealed similar protein migration patterns for all the studied viruses compared with other 
viruses in the genus Orthobunyavirus. Shutoff of host cell protein synthesis, similar to that 
seen in Bunyamwera virus (BUNV)-infected cells was only observed in ACAV, BAKV, 
BWAV, CAPV, PAHV, PATV and WONV-infected cells. However, this shutoff was 
found not related to the presence of NSs protein. In general, viruses in the same serogroup 
were found to have almost same size of plaque and plaque-size did not correlate with the 
presence of NSs protein and the virulence of the virus in the mice.  
 
In vitro transcription and translation (TnT) using rabbit reticulocyte and wheat germ lysate 
expression systems further confirmed the sequencing results that no NSs protein was 
expressed from S cDNA clones of ANAV, TCMV, ANBV, BORV, BMAV and TETEV. S 
RNA segments shutoff almost similar to BUNV-infected cells was observed in A549 cells 
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infected with TCMV, suggesting that TCMV might use a different mechanism to induce 
shutoff. No significant shutoff was observed in Hep2, Hep2/V and C6/36 cells infected 
with any of the viruses. 
 
RT-PCR specific for IFN- ß mRNA in 293 infected cells and IFN reporter gene assays 
revealed that TCMV was capable of counteracting IFN production similar to wt BUNV, 
whereas the other NSs minus viruses (ANAV, ANBV, BORV, TETEV and BMAV) were 
found to be capable of inducing IFN in infected cells. However, only low level of IFN- ß 
mRNA and weak activation of the IFN- ß promoter was detected in ANAV and BMAV-
infected cells.  
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1 Introduction 
 
 
1.1 The Bunyaviridae 
 
1.1.1 Virion characteristics and properties  
 
The family Bunyaviridae is a large group of more than 350 viruses which are mainly 
arthropod-borne. The members of this family share characteristics such as particle 
morphology, molecular composition, mode of transmission, genome structure and coding 
strategies (Fenner, 1975). The viruses are spherical in shape with a diameter of 80-110 nm, 
with two surface glycoproteins (Gc and Gn) embedded in a lipid envelope. The envelope is 
usually derived from cellular Golgi membranes or rarely from surface membranes, and 
surrounds the tripartite single-stranded negative sense RNA genome. The three segments 
are designated large (L), medium (M) and small (S) (Bishop et al., 1980). The segments 
are present in virions as ribonucleoproteins (RNPs) and each of them consists of a single 
genomic RNA encapsidated by the viral nucleocapsid (N) and L proteins (Fig. 1.1) 
(Obijeski et al., 1976).  
 
The buoyant densities of virions in sucrose and CsCl are 1.16-1.18 and 1.20-1.21 g/cm3 
respectively, and virus particles are labile to heat, lipid solvents, detergents, formaldehyde, 
70% ethanol and ultraviolet radiation (Bishop et al., 1980). The composition of virus 
particles was found to be 1-2% RNA, 58% protein, 20-30% lipid and 2-7% carbohydrates 
by weight (Obijeski and Murphy, 1977). 
 
Members of the Bunyaviridae family are divided into five genera: Orthobunyavirus, 
Hantavirus, Nairovirus, Phlebobovirus and Tospovirus, based on their serological 
relationships and supported by biochemical analyses (Elliott, 1990). They are commonly 
referred as orthobunyaviruses, hantaviruses, nairoviruses, phleboviruses and tospoviruses, 
respectively (Elliott, 1997). 
 
The lengths of the S, M and L segments vary among genera, ranging from 6.3-13 kb for the 
L segment, 3.5-5 kb for the M segment and 0.8-2.9 kb for the S segment. The sizes and 
coding strategies of proteins encoded by viruses with in each genus are similar (Fig. 1.2A, 
1.2B, 1.2C and Table 1.1) (Elliott, 1990). The 3' and 5' terminal nucleotide sequences of  
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Fig. 1.1. Schematic structure of an Orthobunyavirus virion. The surface 
glycoproteins Gc  (     ) and Gn (   ) are embedded in lipid bilayer as 
heterodimers. The three nucleocapsids are helical, circular and 
comprise one each of the unique ssRNAs (L, M and S) encapsidated 
by N protein (    ) and associated with the L protein (    ) to form 
ribonucleoproteins (RNP). The size of the virion is about 80-120 nm. 
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A. L segment 
 
 
 
 
 
 
 
Fig. 1.2 Coding strategies of Bunyaviridae genome segments. Genomic RNAs are 
represented by purple boxes, black boxes indicate 3’/5’ NCR, mRNAs are 
shown as green boxes, red boxes indicate host-derived primer sequence 
at 5’ end, and arrowheads indicate truncated 3’ end, and nt indicates 
nucleotides. Gene products, with their size in kilodaltons (kDa) are 
represented by light and dark blue boxes. Two examples of Phlebovirus 
M segments are given which differ with respect to the presence or 
absence of NSm (Adapted from Elliott, 1996). 
 
 
 
 
3’ 5’ 
5’ 3’ 
    259 kDa 
3’ 5’ 
6530 nt 
     247 kDa 
12225 nt 
259 kDa 
6875 nt 
5’ 
5’ 3’ 
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Bunyavirus 
BUNV 
Hantavirus 
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B. M segment 
 
 
 
 
 
 
 
 
3’ 
5’ 
NSm 14 kDa    Gn  55 kDa               Gc  62 kDa 
3’ 
3’ 
3’ 
3’ 
5’ 
5’ 
5’ 
5’ 
3’ 5’ 
3616 nt 
4888 nt 
3884 nt 
3231 nt 
4821 nt 
          Gc 70 kDa                          Gn  55 kDa 
Gn 35 kDa                    Gc  73 kDa 
           Gc 72 kDa             Gn  67 kDa 
   Gn 46 kDa                  Gc  75 kDa 
NSm 37 kDa 
Gn 32 kDa   NSm 18 kDa     Gc  110 kDa 
4458 nt 
Bunyavirus 
BUNV 
Hantavirus 
HTNV 
Nairovirus 
DUGV 
Phlebovirus 
RFV 
Phlebovirus 
UUKV 
Tospovirus 
TSWV 
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C. S segment 
 
 
 
 
 
 
 
3’ 5’ 
N  23 kDa 
N  29 kDa 
NSs  52 kDa 
2916nt 
N  28 kDa 
NSs  32 kDa 
N  50 kDa 
N  48 kDa 
NSs  11 kDa 
1720 nt 
1712 nt 
1696 nt 
5’ 
5’ 
5’ 
5’ 3’ 
3’ 
3’ 
3’ 
Bunyavirus 
BUNV 
Hantavirus 
HTNV 
Nairovirus 
DUGV 
Phlebovirus 
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961 nt 
Tospovirus 
TSWV 
 28 
 
 
 
                                          GENUS RNA  
 
Protein Orthobunyavirus Hantavirus Nairovirus Phlebovirus Tospovirus 
 
L segment 
      L 
  kDa 
 
259-263 
   kDa 
 
246-247 
     kDa 
 
459 
     kDa 
 
238-241 
     kDa 
 
330-332 
 
M segment 
      Gn 
      Gc 
      NSm 
 
 
29-41 
108-120 
15-18 
 
 
68-76 
52-58 
none 
 
 
30-45 
72-84 
78-85, 92-115 
 
 
50-70 
55-75 
None or 78 
 
 
52-58 
72-78 
34 
 
L segment 
      N 
      NSs 
 
 
19-25 
10-13 
 
 
50-54 
none 
 
 
48-54 
none 
 
 
24-30 
29-31 
 
 
52 
29 
 
                   
Table 1.1 Pattern of  Bunyaviridae protein sizes (kDa) (Taken from Elliott, 2001).
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the three RNA segments are conserved within a genus, but differ from those of other 
genera (Figure 1.3). They are base-paired, forming non-covalently closed and circular 
RNAs (Obijeski et al., 1976). In most of the orthobunyaviruses, the terminal 11 bases of S, 
M and L segment are complementary except a non-canonical pairing at the position 9 and -
9 (Fig. 1.4) (Elliott, 1990). The viral mRNAs are truncated at the 3' end compared to the 
genomic RNAs but they do not appear to be polyadenylated (Bishop et al., 1980). 
 
In contrast to the other enveloped RNA viruses, bunyaviruses do not have an internal 
matrix protein, suggesting that morphogenesis of the virus involves the RNPs interacting 
directly with the cytoplasmic tails of the glycoproteins embedded in the Golgi membrane 
(Smith and Pifat, 1982). Viral RNA transcription is primed by host RNA sequences 
derived by a “cap-snatching” process which is similar to that of orthomyxoviruses 
(Kolakofsky and Hacker, 1991).  Virus replication occurs in the host cell cytoplasm and 
virions mature by budding into intracytoplasmic vesicles from the internal membranes of 
the Golgi apparatus (Bishop et al., 1980; Schmaljohn and Dalrymple 1983; Elliott, 1990).  
 
Bunyavirus particles are composed of four structural proteins: two external glycoproteins 
(Gc and Gn) encoded by the M segment, the N protein encoded by the S segment and the L 
transcriptase protein encoded by the L segment. Schematic representations of the genome, 
coding strategies and encoded products from a representative member of each genus are 
shown in Figures 1.2A, 1.2B and 1.2C. Viruses in Orthobunyavirus, Phlebovirus and 
Tospovirus genera also encode non-structural (NS) proteins such as NSm on the M 
segment and NSs on the S segment (Elliott et al., 1991). The N and NSs proteins of 
orthobunyaviruses are encoded in overlapping open reading frame (ORF) of the virion 
complementary S RNA, whereas the NSs protein of phleboviruses and tospoviruses, and 
NSm protein of tospoviruses are encoded in ambisense coding strategies (Figures 1.2B and 
C). Two NSm proteins about 70 and 85 kDa are encoded by Dugbe virus (DUGV) in the 
Nairovirus genus, which are precursors for the viral glycoproteins (Marriott et al., 1992). 
For phleboviruses, the NSm protein is encoded by M segment of Rift Valley Fever virus 
(RVFV) as part of the glycoprotein precursor, whereas Uukuniemi virus (UUKV) does not 
encode an NSm. The ORF of each segment is flanked by 3’/5’ non-coding region (NCRs) 
sequences (Obijeski et al., 1980). No NS protein is encoded by the S and M segments of 
hantaviruses (Elliott et al., 1991).  
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Orthobunyavirus   3’ UCAUCACAU--- 
     5’ AGUAGUGUG--- 
 
 
Hantavirus    3’ AUCAUCAUCUG--- 
     5’ UAGUAGUAUGC--- 
 
 
Nairovirus    3’ AGAGUUUCU--- 
     5’ UCUCAAAGA--- 
 
 
Phlebovirus    3’ UGUGUUUC--- 
     5’ ACACAAAG--- 
 
 
Tospovirus    3’ UCUCGUUA--- 
     5’ AGAGCAAU--- 
 
 
 
 
 
 
 
Fig. 1.3. Terminal consensus sequences of the S, M and L genome segments of each 
genus of the family Bunyaviridae (Elliott, 1996). 
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  U G   C-G-A    A-C- 
  / \ / \      /       \   / 
  3´ U-C-A-U-C-A-C-A-U-G-A-G-G-U-G-G-A-U-U-U-U-G-A-A        U-A  
S   |   |   |  |   |  |  |   |   |  |  |   |  |   |  |   |   |   |   |  |   |  |  |   |             |  |  
  5´ A-G-U-A-G-U-G-U-G-C-U-C-C-A-C-C-U-A-A-A-A-C-U-U          A-U 
                     \        /   \ 
                       A-A-A   A-C- 
      S 
 
 
 
          A-G       U     A- 
          /    \         / \       / 
  3´ U-C-A-U-C-A-C-A-U-G-A-U-G-G-C-U-A-U-G-U      U-G-U-U-G-G-A-A 
M   |   |   |  |   |  |  |   |   |  |  |   |  |   |      |   |   |   |  |         |  |   |        |  |   |  |  
  5´ A-G-U-A-G-U-G-U-G-C-U-A-C-C-G-A-U-A-C-A      A-C-A-G-C-C-U-U 
                    \     /         \ 
         A-A           G- 
      M 
   
   
 
 
 
      A             A-U  U- 
      / \      /   \/ 
  3´ U-C-A-U-C-A-C-A-U-G-A-G-G-A-U-G-U-A-U-U-C-U-U-U-U-A-A    U  
L                |   |   |  |  |   |  |   |  |   |   |   |   |  |   |  |  |   |  |   |   |  |   |  |  |   |   |      |  
  5´ A-G-U-A-G-U-G-U-G-C-U-C-C-U-A-C-A-U-A-A-G-A-A-A-A-U-U     A 
                  \    / \ 
                   G-U   C- 
      L 
 
 
 
 
 
 
 
Fig. 1.4 Complementary sequences and possible base-paired structures between 
the 3’ and 5’ termini of BUNV genomic RNA segments. The terminal 11 
nucleotides (left of black line) are conserved in all genome segments; red 
letters represent the next four nucleotides (only 3 in M segment) which 
are conserved for each segment within the orthobunyaviruses, and blue 
letters represent the non-canonical pairing at position 9 and -9 (Taken 
from Elliott et al., 1991). 
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Except for hantaviruses which have no arthropod vector and are transmitted by rodent 
excretions, viruses in each genus have their specific biting arthropods for their 
transmission; orthobunyaviruses are transmitted by mainly mosquitoes or midges, 
nairoviruses mainly by ticks, phleboviruses mainly by sandflies or ticks, and tospoviruses 
are transmitted by thrips (Bishop and Shope, 1979; Pringle, 1996).  
 
1.1.2 Classification of the viruses 
 
Serological tests based on complement fixation (CF), hemagglutination inhibition (HI), 
indirect immunofluorescent antibody (IFA) and viral neutralisation (VN) were used to 
study the antigenic relationships among viruses in the Bunyaviridae family and their 
classification into genus or serogroup (Hunt and Calisher, 1979; Karabatsos, 1985). Many 
bunyaviruses are still uncharacterised and remain outside the existing generic structure 
(Zeller et al., 1989).  
 
VN and HI assays are used to detect the relationships among the viral glycoproteins, while 
the CF assay is used to detect the relationships among the conserved N proteins (Beaty and 
Bishop, 1988). Viruses are grouped into a genus based on the CF test, while VN and HI 
tests are used to divide them into serogroups (Calisher, 1996). Because of the antigenic 
relationships between Bunyamwera virus (BUNV) and certain other groups of viruses, 
Casals and Whitman (1960) and Whitman and Shope (1962) suggested placing the viruses 
into the Bunyamwera supergroup. This supergroup was later known as Bunyavirus genus 
in the family of Bunyaviridae because of their similarity in molecular, morphogenetic, 
structure and mode of replication (Fig. 1.5) (Bishop et al., 1980). The International 
Committee for Taxonomy of Viruses later decided to rename this genus as 
Orthobunyavirus (Elliott et al., 2000). Based on varying degrees of their serological 
relationships, viruses in the Orthobunyavirus, Phlebovirus and Nairovirus are further 
divided into serogroups, complexes, subtypes, variants, varieties and strains.  
 
 
1.2 The Orthobunyavirus genus 
 
There are more than 170 viruses in this genus which are divided into 18 serogroups; 
Anopheles A, Anopheles B, Bakau, Bunyamwera, Bwamba, Capim, California, Gamboa,  
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Fig. 1.5. Antigenic relationships among viruses and serogroups within genus 
Orthobunyavirus. Anopheles A, Bakau and Nyando serogroups are not 
included in this figure (Taken from Calisher, 1988). 
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Guama, Group C, Koongol, Minatitlan, Nyando, Olifanstlei, Patois, Simbu, Tete and 
Turlock, with a few additional as yet ungrouped viruses (Calisher, 1996). 
 
1.2.1 Transmission of  orthobunyaviruses  
 
Members of this genus are capable of replicating alternately in vertebrates and several 
arthropod vectors. Their life cycle involves two types of vertebrate hosts, amplifier and 
dead end hosts (Fig. 1.6). For example in La Crosse virus (LACV) life cycle, chipmunks 
serve as an amplifier host where the infection is asymptomatic. During the viremic stage, 
infection of further mosquitoes occurs following ingestion of a blood meal.  In this cycle, 
humans are considered a dead-end host as they are unlikely to transmit the virus back to 
mosquito and they became infected through the biting of infected mosquitoes (Borucki et 
al., 2002). Venereal and transovarial transmission in certain arthropod vectors has been 
reported for some members of the genus (Bishop et al., 1980; Thompson and Beaty, 1977). 
These two modes of infection are important for the maintenance of the virus in the 
mosquito population, especially during the winter season (Beaty and Bishop, 1988).  
 
1.2.2 Impact of orthobunyavirus disease 
 
Some members in the Orthobunyavirus genus are capable of causing disease in humans 
such as LACV, Cache Valley virus (CVV), Tahyna virus (TAHV) and Oropouche virus 
(OROV) (Elliott, 1997). BUNV, the prototype member of the family Bunyaviridae and the 
genus of Orthobunyavirus, causes febrile illness with headache, arthralgia and rash in 
humans in Sub-Saharan Africa (Nichol, 2001). In 1998, Garissa virus, a reassortant of 
BUNV and Batai virus (BATV) was isolated and found to be responsible for causing 
hemorrhagic fever outbreaks in Kenya and Somalia (Bowen et al., 2001). LACV and 
Jamestown Canyon virus (JCV) have been reported to be responsible for the majority of 
paediatric viral encephalitis cases in the United States (US) (Kappus et al., 1983). CVV has 
also been reported to be related to meningitis cases in humans in the US (Sexton et al., 
1997; Campbell et al., 2006). OROV has been shown to cause an acute febrile dengue-like 
illness called Oropouche fever in Brazil, South America, Trinidad, Panama and Peru 
(Pinheiro et al., 1981; Saeed et al., 2000). 
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Fig. 1.6 Transmission cycle of La Crosse virus of Orthobunyavirus genus. This 
cycle involves two types of vertebrate hosts; small mammals as an 
amplifier-host and humans as dead-end host. Mosquitoes are the vector 
for this virus, which are capable of transovarial and venereal 
transmission of this virus (Taken from Borucki et al., 2002). 
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These viruses not only pose threat to humans. Some members in the Simbu serogroup 
could cause severe disease in animals. Akabane virus (AKAV) and Aino virus (AINV) 
were found to be associated with abortions, stillbirths, and congenital defects in cattle, 
sheep and goat (Inaba et al., 1975). These viruses are widely distributed in Southeast Asia, 
Australia, and East Asia leading to a devastating economic impact on the livestock in these 
countries. CVV which is found throughout the United States, Canada and Mexico, is 
associated with fetal death, stillbirths and multiple congenital malformations in sheep 
(Edwards et al., 1989) 
 
1.2.3 Epidemiology 
 
1.2.3.1 Anopheles A serogroup  
 
With the exception of Tacaiuma virus (TCMV), which was also isolated from humans and 
primates, most members of this serogroup were isolated from various mosquitoes 
especially Anopheline and Culicine recovered in South and North America (Karabatsos, 
1985).  Data obtained from serology surveys indicate that some of the viruses in this 
serogroup cause natural infections in a range of species in Brazil such as livestock animals, 
birds and rodents. Serologic cross-reaction has been detected between Anopheles A and 
California serogroup viruses (Bishop, 1996).  
 
1.2.3.2 Anopheles B serogroup  
 
These viruses were obtained from mosquitoes collected in South America. Little is known 
about their vertebrate hosts (Karabatsos, 1985). 
 
1.2.3.3 Bakau serogroup  
 
Viruses in this serogroup were isolated from mosquitoes and ticks in Asia and Africa 
(Karabatsos, 1985). BAKV, Tanjong Rabok (TRV) and Telok Forest (TFV) viruses were 
isolated from monkeys. Serological surveys indicated that they also infect birds, bats, 
flying squirrels and rodents. Although antibody surveys have indicated that the viruses 
infect humans, no isolation has been made to date (Bishop, 1996). 
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1.2.3.4 Bunyamwera serogroup  
 
Most of the viruses in this serogroup are transmitted by mosquitoes, except for Lokern 
(LOKV) and Main Drain (MDV), which have also been isolated from Culicoides 
(Karabatsos, 1985).  Many of the viruses such as BUNV, Germiston (GERV), Guaroa 
(GROV), BATV, Ilesha (ILEV), Shokwe (SHOV), Wyeomyia (WYOV) and Xingu 
(XINV) have been isolated from human. Some of the viruses such as BUNV, GERV, 
GROV, BATV, ILEV, Tensaw (TENV) and WYOV are associated with human infections 
(Karabatsos, 1985). MDV was isolated from horses with encephalitis. WYOV has been 
reported in South and North America while BATV has been detected in Asia (Karabatsos, 
1985). BUNV was first isolated from Aedes mosquitoes in Uganda in 1943 and also from 
viremic humans in Africa (Karabatsos, 1985). Antibodies to this virus have been detected 
in humans, primates, rodents, birds and livestock animals. CVV has been isolated from a 
variety of mosquitoes in North America and infection of sheep causes embryonic and fetal 
death, stillbirth, and multiple congenital malformations (Edwards et al., 1989; McConnell 
et al., 1987). Recently, this virus has also been associated with infection in humans (Sexton 
et al., 1997; Campbell et al., 2006). 
 
1.2.3.5 Bwamba serogroup 
 
Viruses in this serogroup are geographically restricted to Africa and most of them were 
isolated from humans with febrile illness (Karabatsos, 1985). Bwamba virus (BWAV) was 
first isolated in 1937 from an infected man in Bwamba, Uganda. Antibodies to these 
viruses have been detected in humans, livestock animals, and avian sera in Africa (Bishop 
and Shope, 1979). These viruses are serologically related to the California serogroup 
(Casals, 1963). 
 
1.2.3.6 Group C serogroup 
 
These viruses have been isolated from mosquitoes, rodents and marsupials in South and 
North America (Karabatsos, 1985). Some of the viruses such as Carapayu (CARV), 
Oriboca (ORIV), Itaqui (ITQV), Nepuyo (NEPV), Apeu (APEUV), Marituba (MTBV), 
Murutucu (MURV), Restan (RESV), Ossa (OSSAV) and Madrid (MADV) viruses have 
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been associated with human disease such as self-limited and dengue-like illness including 
fever, headache, myalgia, nausea, vomiting and weakness (Nunes, 2005).  
 
1.2.3.7 California serogroup 
 
The prototype virus of this serogroup, California encephalitis (CEV) was isolated in 1943 
from mosquitoes in North America (Hammon and Reeves, 1952). Viruses in this serogroup 
have a widespread distribution covering North and South America, Europe, Asia and 
Africa (Calisher, 1983). Besides mosquito vectors, these viruses have also been obtained 
from rodents and other animals (Karabatsos, 1985). Many of the viruses such as CEV, 
JCV, LACV, Inkoo (INKV), Snowshoe hare (SSHV), TAHV and Trivittatus (TVTV) 
cause infection in humans with encephalitic symptoms. 
 
1.2.3.8 Capim serogroup 
 
Culex mosquitoes serve as vectors for viruses in this serogroup. These viruses are 
associated with rodent hosts and a number of livestock animals, but no infection has been 
reported in humans. These viruses have been detected only in North and South America 
(Karabatsos, 1985). 
 
1.2.3.9 Gamboa serogroup 
 
These viruses have been isolated from Culicine mosquitoes collected in Central and South 
America (Karabatsos, 1985). Their natural vertebrate hosts are not known and none of the 
viruses infect humans (Bishop, 1996). 
 
1.2.3.10 Guama serogroup 
 
These viruses are restricted to South and North America. Mosquitoes of many different 
genera can act as vectors, and the viruses are associated with rodent and marsupial hosts 
(Karabatsos, 1985). They have also been isolated from birds, bats and a variety of livestock 
animals. Some of the viruses such as Catu (CATV) and Guama (GMAV) viruses have 
been associated with disease in humans (Vasconcelos et al., 2001). 
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1.2.3.11 Koongol serogroup 
 
To date only two viruses were identified in this serogroup, Koongol (KOOV) and Wongol 
(WONV) viruses which were isolated from Culex annulirostris mosquitoes in Australia 
(Doherty et al., 1963). Although antibodies to these viruses were detected in cattle and 
other vertebrates such as marsupials and birds, no virus isolation has been made from these 
animals (Bishop and Shope, 1979). 
 
1.2.3.12 Minatitlan serogroup 
 
Only two viruses, Minatitlan (MNTV) and Palestina (PLSV) have been identified in this 
serogroup, which were isolated from Culex mosquitoes and hamsters in Mexico and 
Equador (Karabatsos, 1985). To date, no information is available on their vertebrate host 
and infection in humans. 
 
1.2.3.13 Nyando serogroup 
 
Viruses in this serogroup have been isolated from mosquitoes in Africa. Nyando virus 
(NDV) has been recovered from humans with a febrile illness in central Africa and 
antibodies to this virus have been detected in human sera in Kenya and Uganda 
(Karabatsos, 1985). 
 
1.2.3.14 Olifantsvlei serogroup 
 
These viruses are geographically restricted to Africa and were isolated from Culex 
mosquitoes. Little is known about their vertebrate hosts and these viruses have no 
association with disease in humans (Karabatsos, 1985). 
 
1.2.3.15 Patois serogroup 
 
 These viruses are geographically restricted to Central, North and South America. They are 
vectored by mosquitoes and are associated with rodent hosts. Although serological surveys 
indicated that Patois (PATV) and Zelga (ZELV) viruses infect humans, to date, no 
isolation has been made from them (Karabatsos, 1985). 
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1.2.3.16   Simbu serogroup 
 
These viruses are widely distributed in Asia, Australia, Africa, North and South America 
(Karabatsos, 1985). They are vectored by culicoids and mosquitoes. Some of the viruses 
have been recovered from birds and a number of vertebrate species including cattle and 
pigs. Some of them are human pathogens such as OROV and Shuni virus (SHUV), while 
AKAV and AINV are of significant veterinary importance (Karabatsos, 1985). OROV 
infects hundreds of human in Brazil. Serological survey results indicated that this virus can 
also infects monkeys, birds and rodents (Bishop, 1996). 
 
1.2.3.17  Tete serogroup 
 
Most of the viruses in this serogroup were isolated from birds and are vectored by Ixodid 
ticks or Culicoides species (Karabatsos, 1985). They have been isolated in Europe, Asia 
and Africa but none of them has been associated with human disease (Karabatsos, 1985). 
 
1.2.3.18  Turlock serogroup 
 
Viruses in this serogroup are vectored by Culicine mosquitoes from North and South 
America, Africa, Asia and Europe. Some of the viruses such as Turlock (TURV) and 
Umbre virus (UMBV) have been isolated from birds (Karabatsos, 1985). 
 
1.2.4 Genome organisation and protein function of orthobunyaviruses 
 
The genome of BUNV was the first virus in this family to be sequenced completely and 
has a size of 12294 nucleotides, of which 95.3% encodes amino acids (Elliott, 1989). The 
genome is richer in A + U than C + G residues (Elliott, 1990).  
 
1.2.4.1  L segment and protein 
 
Based on published sequences of complete L segment of Bunyamwera, California and 
Simbu serogroup viruses, their size lengths are in the range of 6.8-6.9 kb. This segment 
encodes the L protein (RNA dependent RNA polymerase) in a negative-sense coding 
strategy (Figure 1.2A). In virus-infected cells, only small amounts of this protein are 
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detected (Elliott et al., 1991). To date, no other coding region beside polymerase ORF was 
reported in this segment (Elliott, 1989). Examination of the mRNAs synthesized by 
recombinant L protein revealed that they contain a 5’ cap and host derived-primer 
sequence which is needed for transcription, suggesting that L protein has an endonuclease 
activity to mediate the ‘cap-snatching’ process (Jin and Elliott, 1993). Overall, little 
homology was observed between the L proteins of viruses in different genera. However, 
amino acid sequence alignment of LACV L protein with sequence of other polymerases 
from other members of Bunyaviridae, has identified the presence of conserved motifs 
containing a polymerase module common to all RNA dependent polymerase (Roberts et 
al.1995). It has been shown that the L protein of California serogroup viruses also plays a 
role in mouse neurovirulence and neurovasiveness, but the mechanism behind it is still 
unclear (Endres et al., 1991). 
 
1.2.4.2 M segment and protein 
 
Published nucleotide sequences of the M segments of orthobunyaviruses revealed that they 
are 4458-4534 nucleotides in length (Eshita and Bishop, 1984; Lees et al., 1986; Grady et 
al., 1987; Pardigon et al., 1988; Brockus et al., 1999; Campbell and Huang, 1999; Wang et 
al., 2001; Yanase et al., 2003). Similar to the N protein, the M sequences of the viruses 
from different serogroups exhibit limited sequence homology, while viruses in the same 
serogroup showed closer similarity, about 66% for Gn, 50% for NSm and 40% for Gc 
protein (Pringle, 1991).  
 
The M segment of orthobunyaviruses encodes 3 proteins, two surface glycoproteins: Gc 
(108 to 125 kDa) and Gn (29 to 41 kDa), and a non-structural protein, NSm (15-18 kDa) in 
the form of a polyprotein precursor. The polyprotein has not been detected in infected 
cells, suggesting that it is co-translationally cleaved to give the mature proteins (Lappin et 
al., 1994). The gene order of the M segment of orthobunyaviruses is 5’-Gn-NSm-Gc-3’in 
the genome-complementary sense (Figure 1.2B) (Fazakerley et al., 1988, Fuller and 
Bishop, 1982; Nakitare and Elliott, 1993).  
 
Alignment of the M segment sequences of Bunyamwera and California serogroup viruses 
identified three potential glycosylation sites that are relatively rich in cysteine, and N and 
C terminal hydrophobic domains which are conserved in Gc and Gn proteins of these 
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viruses (Lees et al., 1986; Pardigon et al., 1988; Brockus and Grimstad, 1999). However, 
OROV was found to have only two glycosylation sites of which only that in Gc was 
conserved with the other two serogroups (Wang et al., 2001). These conserved regions are 
believed to involve in neutralising and protective epitopes (Wang et al., 1993).  Najjar et 
al. (1985) have suggested that these protective epitopes are clustered within a single 
immunodominant antigenic site. The conserved regions in the Gn glycoprotein are found to 
contain type-specific antigenic determinants for hemagglutinating and neutralizing 
antibodies that are used to place the viruses into serogroups (Cheng et al., 2000). The Gn 
glycoprotein also contains the Golgi targeting and/or retention signals which are required 
for the Gc to interact with Gn to localize to Golgi compartment (Lappin et al, 1994; Bupp 
et al, 1996; Shi et.al., 2004). It has been shown that the N terminal domain of NSm is also 
required for the virus growth in cell cultures (Pollitt et al., 2006). Furthermore, NSm also 
contains some hydrophobic and non-hydrophobic domains that may be required for virus 
assembly and as an internal signal sequence for Gc glycoprotein (Shi et al., 2006). 
 
The Gc is found to be responsible for fusion activity and also as a major determinant for 
viral attachment to mammalian cells (Pobjecky et al., 1986; Pekosz et al., 1995). 
Homologies with Sindbis virus E1 have suggested that LACV Gc is a class II viral fusion 
protein (Plassmeyer et al., 2005). Beside the L protein, the Gc protein is also shown to play 
a major role in determining the virus virulence (Gonzalez-Scarano et al., 1985; Elliott, 
1990).  
 
1.2.4.3  S segment and proteins 
 
1.2.4.3.1  Nucleocapsid (N) protein 
 
The N protein is the most abundant protein and first to be expressed in virus-infected cells. 
Alignment of nucleotide and amino acid sequences of three serogroup viruses of 
Orthobunyavirus genus (Bunyamwera, California and Simbu) revealed the presence of 
certain conserved regions in their N proteins (Akashi et al., 1984; Dunn et al., 1994; 
Bowen et al., 1995; Saeed et al., 2001). These regions have been suggested to be associated 
with the complement fixation antibodies that cross-react among the viruses in the same 
genus (reviewed by Calisher, 1996). Nucleotide and amino acid sequence comparisons of 
these viruses reveal no sequence identity between viruses in different genera but with at 
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least 40% identity between the viruses in the same genus (Dunn et al., 1994; Bowen et al., 
1995; Saeed et al., 2001; Nunes et al., 2005). As mentioned in Section 1.1.1, N is used to 
encapsidate the genomic and antigenomic RNA to form RNPs (Jin and Elliott, 1991). The 
N protein of BUNV was shown to bind specifically to the 5′ terminus of the S genome 
segment, which may contain the signal to initiate N encapsidation (Osborne and Elliott, 
2000). Residues 17 to 20 at the amino terminus of N protein contain the motif FDPE 
conserved in almost all orthobunyaviruses and have been suggested to be structurally 
essential for N protein folding and/or stability (Leonard et al., 2005). 
 
1.2.4.3.2  The NSs protein 
 
For orthobunyaviruses, the NSs protein is translated from the same mRNA species as N 
protein using an alternative start codon in an overlapping reading frames +1 frame (Akashi 
and Bishop, 1983; Elliott, 1989). The size of NSs protein of orthobunyaviruses is between 
10-13 kDa (Table 1.1). Most NSs proteins in Bunyamwera and California serogroup 
viruses are initiated with a double methionine whereas this feature is not shown by Group 
C and Simbu serogroup viruses. There is no sequence conservation between the NSs 
proteins of the viruses in different genera but some sequence identities were observed 
within the viruses in the same genus (Dunn et al., 1994). 
 
A lot of studies have been carried out to determine the functions of the orthobunyavirus 
NSs protein. For BUNV, it was found to contribute to the viral pathogenesis by acting as 
an interferon antagonist that blocks the transcriptional activation of IFN-β (Weber et al., 
2002). It is also able to inhibit host cell protein synthesis (Bridgen et al., 2001) and capable 
in delaying the early stage cell death by inhibiting IRF-3 mediated apoptosis (Kohl et al., 
2003). In contrast to other IFN antagonists, NSs inhibits dsRNA-dependent IFN induction 
but has no effect on the dsRNA-activated PKR and RNase L systems (Streihtenfeld et al., 
2003). Furthermore, the NSs protein of LACV was also found to be able to counteract 
RNA silencing directed against cellular and viral RNA (Soldan et al., 2005). The functions 
of NSs protein will be discussed in detail in sections 1.4.1, 1.4.2 and 1.4.3. 
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1.2.4.3.3 Non-coding region (NCR). 
 
The ORF of each RNA segment of bunyaviruses are flanked by 3’/5’ NCRs. Although the 
terminal 11 nucleotides of these NCRs are conserved between the three segments within a 
genus (Section 1.1.1), the internal regions are unique to each segment and largely non-
conserved between different viruses (Haaster and Bishop, 1980). Mini-replicon systems 
based on reporter genes flanked by NCR sequences have been developed for BUNV 
(Weber et al., 2001; Kohl et al., 2006) and LACV (Blakqori et al., 2003), which 
demonstrated that the presence of NCRs alone are adequate to allow transcription, 
replication, encapsidation and packaging of mini-genome segments by viral proteins. By 
using this system, Kohl et al. (2004) have showed that the terminal 15 nt sequences of the 
3’/5’ NCR are required for BUNV S promoter to be functional. These complementary 
sequences are thought to be important in providing signals for recognition by the virus-
encoded polymerase and are involved in packaging of the viral genome (Elliott, 1990). 
Furthermore, the cooperation between 3’ and 5’ NCR sequences through base-pairing 
interaction is found to be required for BUNV RNA synthesis (Barr and Wertz, 2004). In 
addition, Barr and Wertz (2005) have showed that the non-canonical (G-U) at position 9 
and -9 (Figure 1.4) is crucial for the signalling of BUNV transcription.  
 
Recombinant BUNV with deletions in the 3’/5’ NCR have shown that the 5' NCR is 
essential for viral growth, while the internal 3' NCR is important for the regulation of viral 
RNA synthesis (Lowen and Elliott, 2005). Furthermore, competition assays with a variety 
of viral RNAs have identified a region within the 5’ terminus of the BUN S segment for 
which N had a high preference for binding to the 5’ end of the S segment, suggesting that 
this site may constitute the signal for the initiation of encapsidation by N (Osborne and 
Elliott, 2000). Computer-assisted RNA folding models used by Kohl et al. (2006) revealed 
that a conserved sequence within nt 20-33 of the 3’/5’ end of the genome segments was 
necessary for efficient transcription. The 5’ NCRs of S segment genome also contain 
transcription termination signals which are responsible for the truncation of BUN S-
segment mRNA (Elliott, 1990; Schmaljohn, 1996). The GU-rich region in the 5’NCR has 
been shown to play an essential role in directing this termination (Lowen and Elliott, 
2005). Barr et al. (2006) have identified two transcription termination signals located in 
5’NCR of BUNV: one at the nt 91(3’ GUCGAC 5’) which plays a major role in 
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termination signalling and the other one is a functionally independent termination signal at 
the nt 59 (3’ UGUCG 5’). 
 
A recombinant virus called BUN MLM, in which the L segment open reading frame 
(ORF) is flanked by the M segment NCRs, was employed to investigate the segment-
specific functions of the NCRs. In comparison to wt virus, BUN MLM virus was shown to 
be attenuated in cultured mammalian cells, had slower disease progression in mice, 
produced a smaller plaque size, expressed reduced levels of L mRNA and RNA 
polymerase protein, synthesized less L genomic and anti-genomic RNA, and had an 
increased particle-to-PFU ratio. The rescued of this BUN MLM mutant virus indicates that 
BUN NCRs have different efficiency in packaging of the viral genome (Lowen et al., 
2005).  
 
1.2.5 Virus replication 
 
The process of bunyavirus replication involves attachment and penetration of the virus into 
the cell, primary transcription and translation, replication of the viral RNA, secondary 
transcription and translation, virus assembly and morphogenesis, and release of the virus 
from cells (Fig. 1.7). 
 
1.2.5.1 Attachment and entry 
Attachment is mediated by an interaction of the viral glycoproteins with unknown host 
receptor, while entry of the virus into the host cell and uncoating are thought to occur by 
receptor-mediated endocytosis of virions and fusion of viral membranes with endosomal 
membranes. The viral genomes and polymerase are released into the cytoplasm, where 
primary transcription is initiated (Schmaljohn and Hooper, 2001). The only cellular 
receptor identified is the β3 integrin family which was used for cell attachment of some 
hantaviruses (Gavrilovskaya et al., 1999) but it is unlikely that the same receptor is used by 
other genera (Pekosz et al., 1995). Treatment of LAC virions with proteases (bromelain or 
pronase), which only degraded Gc, was found to abolish the infectivity of the virus to 
vertebrate host cells, suggesting that Gc is responsible in binding to vertebrate host cells 
(Kingsford and Hill, 1983), while Gn is shown to be responsible for the binding to 
mosquito cell lines and midgut cells (Ludwig et al., 1991). Exposing the endosomes at low  
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Fig. 1.7 Replication cycle of viruses in the family Bunyaviridae.  Viruses enter the 
cell by receptor-mediated endocytosis (I). RNPs are released through 
fusion process of the viral envelope with the endosomal membrane (II). 
Three segments of genomic RNA are transcribed to mRNA by virion-
associated polymerase; S and L mRNAs are translated by free ribosomes 
in the cytoplasm and M mRNAs by ER-bound ribosomes (III). 
Processing and glycosylation of envelope protein Gc and Gn (IV).  Newly 
synthesized viral proteins mediate the replication of genomic RNAs to 
antigenomic RNAs, the templates to synthesize new genomic RNAs (V). 
Budding of the virus in the Golgi, assembly and release from the cells by 
endocytosis (VI)(Courtesy  from Dr. Alain Kohl). 
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pH is thought to promote conformational change in Gc, causes fusion of the viral and cell 
membrane, suggesting a role of Gc in virus entry. Furthermore, treating the cells with 
ammonium chloride to prevent the acidification of endosomes inhibited infection by CEV 
(Hacker and Hardy, 1997). However, expression of Gc alone was found not to cause cell-
cell fusion, suggesting that an interaction of Gc and Gn is needed for the membrane to be 
fused (Bupp et al., 1996). 
 
1.2.5.2 Transcription and replication of RNA 
 
Bunyavirus transcription involves the synthesis of mRNAs by virion-associated RNA 
polymerase or transcriptase which is complementary to genomic templates using host cell-
derived capped primers. Primary translation involves the translation of L and S segment 
mRNAs by free ribosomes and M segment mRNAs by membrane-bound ribosomes to 
yield the viral structural and non-structural proteins. Primary glycosylation and co-
translational cleavage of a precursor to yield envelope proteins (Gc and Gn) and NSm for 
some of the viruses occurs at the endoplasmic reticulum (ER) (Bishop, 1996). During this 
process, the L protein also copies vRNA into antigenomic RNA (Schmaljohn and Hooper, 
2001). A model for transcription and replication of the family Bunyaviridae is presented in 
Figure 1.8. 
 
Primary transcription of the vRNA to complementary mRNA is initiated by interaction of 
the virion-dependent RNA polymerase with the three viral RNAs (Bouloy and Hannoun, 
1976; Bishop, 1996; Schmaljohn and Hooper, 2001). Studies on co-expression of viral 
proteins using minigenome RNAs have demonstrated that L and N proteins are necessary 
for the transcription process, implying that only RNPs and not free RNA act as a template 
(Dunn et al., 1995). In this transcription process, polymerase starts to synthesise mRNA at 
the 3’ end of template with a capped primer and stop at nt 50-91 before the 5’ end of the 
template, in response to mRNA termination signal (Barr et al., 2006).  
 
The cap-snatching of the transcription process resulted in the presence of viral mRNAs that 
contain non-templated, host-derived capped primers (about 10 to 20 heterologous 
nucleotides) at the 5' terminus and are about 50-100 nucleotides shorter than full-length 
transcript but not polyadenylated at the 3’ end ( Eshita et al., 1985; Hacker et al., 1990; Jin 
and Elliott, 1993; ). This cap-snatching mechanism was proven by the study of Patterson et  
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Fig. 1.8. Bunyavirus transcription and replication strategies. (A)  from negative 
sense genome segments, and (B) from ambisense genome segments. Black 
boxes represent 5’ cap structures. Solid blue boxes represent mRNAs, 
brown boxes represent nucleocapsid protein of genomic and antigenomic 
RNPs,  pink circles represent L protein, red circles represent N protein 
and green and brown chain represent viral proteins. 
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al. (1984) which showed that purified LACV virions possess an endonuclease activity 
which specifically cleaves alfalfa mosaic virus RNA 4 containing a methylated cap group 
which could be selected by anti-cap antibodies (Patterson et al., 1990). Sequencing the 5’ 
terminal region of the viral mRNAs revealed that these host-derived capped primers are 
rich in C and G residues and possess a U or a C adjacent to the viral sequence (Bouloy et 
al., 1990). Cleavage of the capped primers is mediated by endonuclease activity of the L 
protein (Jin and Elliott, 1993). However, unlike the influenza virus, this process occurs in 
the cell cytoplasm (Rossier et al., 1986) and is not affected by actinomycin D or α-
amanitin (Vezza et al., 1979).  
 
Efficient transcription of bunyaviruses requires simultaneous translation (Bellocq et al., 
1987; Bouloy, 1991). It has been shown in vitro that full length mRNAs could be 
synthesized only in the presence of rabbit reticulocyte lysate, which was active in 
translation (Bouloy, 1991). Blocking of translation resulted in the synthesis of incomplete 
viral transcripts, suggesting that the translation of the nascent bunyavirus mRNA is 
required to prevent premature termination of the transcription process (Bellocq and 
Kolakofsky 1987). 
 
After primary transcription and translation, replication, which involves the synthesis of 
antigenomes to act as template for synthesis of further genomic strands, occurs 
(Kolakofsky and Hacker, 1991). However replication does not involve the ‘cap-snatching’ 
mechanism as no host primer sequences are observed at the 5’end of antigenomic RNA, 
suggesting that initiation is at the exact 5’ end of the RNA and is primer independent 
(Bishop et al, 1983). Therefore a switch from transcription to replication is required. For 
bunyaviruses, the polymerase protein must first function as cap-dependent endonuclease to 
generate a primer for transcription and then switch to a process of independently initiating 
transcription to produce a full-length of complementary RNA (cRNA). Most likely some 
viral or host factor is required to initiate RNA replication and to suppress the transcription-
termination signal responsible for the generation of truncated mRNA (Bishop, 1996).  
However, the mechanism involved has yet to be defined. It is likely that viral proteins such 
as L, N and NSs might be involved in this process since addition of translational inhibitors 
such as cycloheximide was found to prevent genome replication and secondary 
transcription (Vezza et al., 1979).  
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1.2.5.3 Morphogenesis and release of the virus from the cell 
Maturation of Bunyavirus is usually occurs by budding at the smooth membrane vesicles 
in the Golgi complex (Lyons and Heyduk, 1973; Murphy et al., 1973). During this process, 
RNPs are also present at the same site, suggesting that budding is induced by a 
transmembrane recognition between the viral glycoproteins and the N protein (Smith and 
Pifat, 1982). The new virions are then released by exocytosis, which involves fusion of 
cytoplasmic vesicles with the plasma membrane (Matsuoka et al., 1991). This process was 
found to be inhibited by monensin, a monovalent ionophore (Cash, 1982).  
The Golgi targeting and retention signal of BUNV glycoproteins was shown to reside in 
the transmembrane domain (TMD) of the Gn protein (Shi et al., 2004). The role of NSm in 
transport and Golgi retention are not known. However, Shi et al. (2006) have shown that 
domain I and part of domain II of the N-terminal region of NSm are required for virus 
assembly and hydrophobic domain V of C-terminal region may be function as an internal 
signal sequence for the Gc glycoprotein. 
 
 
1.3 Virus evolution  
 
Two major mechanisms are involved in the evolution of RNA viruses: genetic drift and 
genetic shift (Holland and Domingo, 1998). Genetic drift occurs through the accumulation 
of point mutations, deletions, duplications and inversions of viral RNA because of the 
RNA-dependent RNA polymerases lack the proofreading capabilities during the genome 
replication process. Genetic shift occurs through the reassortment of viral RNA segments 
resulted from a mixed infection in host cells (Beaty et al., 1985; Beaty and Calisher, 1991; 
Pringle, 1996; Elliott, 1996). Reassortment has been demonstrated to occur only between 
closely related viruses within the same serogroup but not with the viruses from different 
serogroups (Pringle, 1996).  
 
Naturally occurring reassortant viruses have been reported to occur among Bunyamwera 
(Dunn et al., 1994; Bowen et al, 2001), Simbu (Akashi et al., 1997; Saeed et al., 2001), 
Group C (Nunes et al., 2005), California (Chandler et al., 1991) and Patois serogroup 
viruses (Ushijima et al., 1981). Studies of these reassortants have shown that they usually 
share the same L and S segments but different M RNA segment (Pringle, 1996). This 
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reassortment could confer beneficial traits on the progeny reassortants (Elliott, 1990), 
which sometimes could lead to the emergence of a variant with different pathogenicity and 
tropism (Elliott, 1996). Amongst orthobunyaviruses, Garissa virus, which caused 
haemorrhagic fever outbreaks in East Africa, was found to have the L and S segment 
sequences almost identical to those of BUNV and the M segment sequence closely related 
to BATV, an orthobunyavirus first detected in Malaysia and which has not been isolated 
from humans (Briese et al., 2006). 
 
The chances of dual infection and natural reassortment of orthobunyaviruses are enhanced 
in the arthropod vector, especially in ticks because they feed on different hosts at different 
life stages (Bishop, 1996). This may be one of the main reasons contributing to the 
existence of so many virus serotypes, subtypes, variants and varieties of these viruses 
(Bishop, 1996). In the case of transovarial transmission, the viruses may persist through 
generations of infected arthropods without being transmitted to a vertebrate host and this 
can promote the emergence of a new strain of viruses via both genetic drift and genetic 
shift (Beaty and Bishop, 1988; Calisher, 1988).  
 
 Pringle (1996) has suggested that there are different gene pools within the different 
serogroups in the genus Orthobunyavirus (Figure 1.9). In this figure, he summarised the 
outcome of in vitro heterologous recombination experiments which involved the crossing 
of ts mutants and determining the phenotypes and genotypes of non-ts reassortments. In 
this study, all the six viruses in the California serogroup were able to exchange genome 
segments.  However in the Bunyamwera serogroup viruses, only five out of eight were able 
to exchange segments. The three viruses: MDV, Kairi virus (KRIV) and GROV are 
genetically isolated and less able to reassort, suggesting that the pattern of restriction 
within the Bunyamwera serogroup is in agreement with their serological relationships 
(Hunt and Calisher, 1979); the more divergent their antigenic relationship, the greater the 
degree of restriction for the virus to reassort. It also illustrates that the tendency of the 
viruses to undergo reassortment is not related to the known geographical range of these 
viruses. For example in MAGV which is thought to be limited to South America, can 
exchange genome segments with African, Eurasian and North American Bunyamwera 
serogroup viruses, suggesting that there is no genetic barrier for these viruses to reassort 
(Iroegbu and Pringle, 1981). In contrast, Northway (NORV), MDV and KRIV, which are 
reported only in North America cannot reassort among themselves, suggesting that  
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Fig. 1.9. Patterns of genome subunit exchange among members of the genus 
Orthobunyavirus. The large rectangles enclose serologically related 
viruses. Viruses which can exchange genome sub-units by genetic 
reassortment and can be regarded as a common gene pool are contained 
within the same heavily lined box. Viruses in different boxes cannot 
exchange genome sub-units although they belong to the same serogroup. 
The viruses are arranged vertically by geographic range; all except Batai, 
Tahyna, and Sathuperi are restricted to a single continent (Taken from 
Pringle, 1991)  
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restricted host-vector pairing has led to the genetic isolation and stability of the virus 
(Calisher, 1988).   
 
Based on CF tests, GROV was previously included in the Bunyamwera serogroup virus. 
However, with NT tests, it exhibits some reactivity similar to California serogroup viruses 
(Whitman and Shope, 1962), and therefore is considered as a bridging virus or reassortant 
virus between Bunyamwera and California serogroups (Bowen et al., 1995; Pringle, 1996). 
However, sequencing of both S (Dunn et al., 1994) and M segment (Briese et al., 2004) has 
showed that it has closer relationship to Bunyamwera than California serogroup, therefore 
confirming that GROV is a bridging virus between these two serogroups.  
. 
 
1.4 Effect of virus replication in host cells 
 
1.4.1 Effects on host-cell metabolism 
 
Shutoff of host protein synthesis has been noted in mammalian cells infected with 
orthobunyaviruses (Lazdins and Holmes, 1979; McPhee and Westaway, 1981; Bridgen et 
al., 2001; Blakqori and Weber, 2005) and some phleboviruses (Ikegami et al., 2006). It has 
been suggested that the shutoff of host protein synthesis caused by LACV in mammalian 
cells could be due to mRNA instability produced by the virus, most probably mediated by 
the endonuclease activity of the viral transcriptase during the cap-snatching process (Raju 
and Kolakofsky, 1988). A drastic reduction in shutoff has been observed in cells infected 
with BUNdelNSs, a mutant BUNV lacking the NSs protein, suggesting that NSs plays an 
important role in the shutoff of host protein synthesis (Bridgen et al., 2001). No shutoff 
was observed in cells infected with hantaviruses and nairoviruses which do not encode the 
NSs protein in their S segment (Elliott et al., 1984; Watret et al., 1985). Shutoff is 
important in decreasing competition between the virus and cell for cellular factors such as 
transcription and translation components (Lyles, 2000).  
 
1.4.2 Effects on host antiviral response 
 
Production of interferon (IFN) in infected cells is the first line of host defence against virus 
infection. Infected cells secrete α/β IFN which stimulates the neighbouring cells to 
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synthesize antiviral factors, thereby limiting the spread of virus infection (Weber et al., 
2002). Induction and activation of specific host molecules by IFN blocks virus infection at 
several levels, including transcription, translation and RNA degradation. Viruses have 
evolved several ways for evading the IFN responses; sequestering double-stranded RNA or 
inhibition of activation of the double-stranded RNA-dependent protein kinase R (PKR), 
NF-kB, and other IFN regulatory factors (IRF), e.g., IRF-1 and IRF-3, and inhibition of 
IFN signalling at different levels (signalling of IFN receptors, JAK/STAT activation, and 
signalling of p48 and ISGF3 transcriptional factors) (Liu et al., 2005). The onset of IFN- 
α/β response in virus-infected cells occurs on viral entry and release of viral components, 
including ds-RNA intermediates (Figure. 1.10). These viral components activate the 
transcription factors IRF-3, IRF7 and NF-kB, and activated transcription factor 2 (ATF-2). 
Secreted IFN- α/β binds to the IFN alpha receptor (IFNAR) on the surface of both infected 
and neighbouring cells, resulting in activation of Janus kinase (JAK) and signal transducer 
and activator  of  transcription (STAT) pathway and transcription of numerous genes from 
promoters containing IFN-stimulated regulatory elements (ISRE), resulting in the 
induction of antiviral state (Munoz-Jordan et al., 2003).  
 
For orthobunyaviruses, the NSs protein of BUNV and LACV has been found to suppress 
induction of IFN-α/β, inhibit the action of small interfering RNAs and interfere with host-
cell apoptosis signalling pathway. Mutant viruses, BUNdelNSs and rLACVdelNSs, which 
do not express NSs protein,  were found to be strong inducers of IFN- α/β. IFN induction 
by BUNdelNSs correlated with the activation of NF-kB and the IFN transcription factor 
IRF-3 by the virally-produced double-stranded RNA (dsRNA). In IFN-nonresponsive cells 
and mice, both BUNdelNSs and wt BUNV were found to replicate almost to the same 
level. However in IFN-competent systems, wild-type BUNV grew more efficiently than 
BUNdelNSs, confirming that the NSs protein is an IFN antagonist that blocks the 
transcriptional activation of IFN-alpha/beta (Weber et al., 2002) and has a role in 
contributing to viral pathogenesis (Bridgen et al., 2001). 
 
The NSs protein of BUNV inhibits IFN-β gene expression in the mammalian host by 
dysregulating the phosphorylation at serine 2 in the heptapeptide repeat (YSPTSPS) of the 
C-terminal domain (CTD) of RNA polymerase (RNAP) II, which would prevent the 
elongation step of transcription without disturbing initiation of transcription. Interestingly, 
no interference with CTD phosphorylation of RNAP II was observed in insect cells  
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Fig. 1.10. Mechanism of type I IFN induction, signaling and action. (A) ds RNA 
(by-product of virus replication) activates the transcription factors NF-
kB and IRF-3. These actions are required for full activation of the IFN-
ß promoter. IRF-3 is phosphorylated by the kinases IKK and TBK-1 
which are activated by the RNA-sensing complex of RIG-I, MDA5 and 
IPS-1/MAVS. A second signaling pathway involves endosomal TLR-3 
and TRIF.  (B) Newly synthesized IFN- ß binds to the type I IFN 
receptor (IFNAR) and activates the expression of numerous ISGs via 
the JAK/STAT pathway. IRF-7 amplifies the IFN response by inducing 
the expression of several IFN- ß subtypes. SOCS and PIAS are negative 
regulators of the JAKSTAT pathway. Mx, ISG20, OAS and PKR are 
proteins with antiviral activity (Taken from Haller et al., 2006). 
 
 
 
 
 
 
 
 
A B 
 56 
(Thomas et al, 2004). The ability to inhibit both host transcription and the interferon 
response is linked to the interaction of BUNV NSs protein with the MED8 component of 
Mediator, a protein complex necessary for host mRNA production. The interacting domain 
on NSs was mapped to the C-terminal region, which contains 3 amino acids (LPS motif) 
conserved among orthobunyavirus NSs proteins. A recombinant virus in which the 
interacting domain in NSs was deleted had strongly reduced ability to inhibit host protein 
expression and was unable to inhibit the interferon response (Leonard et al., 2006). 
  
1.4.3 Apoptosis of the infected cells 
. 
Apoptosis is the process by which abnormally behaving cells are induced to die to cause 
minimum disruption to neighboring cells. This mechanism is necessary in clearance or 
removal of infected, cancerous or damaged cells. If there is no clearance, the cell will die 
necrotically, releasing harmful intracellular components. Successful viral replication 
requires not only the efficient production and spread of progeny, but also evasion of host 
defense mechanisms that limit replication by killing infected cells. In addition to inducing 
immune and inflammatory responses, infection by most viruses triggers apoptosis or 
programmed cell death of the infected cell (Aigner, 2002).  
 
Some viruses seem to use apoptosis as a mechanism of cell killing and virus spread. The 
NSs protein of California serogroup viruses has been shown to have some sequence 
similarity to Reaper, a proapoptotic protein from Drosophila. Although NSs protein is 
lacking in the Reaper N-terminal motif critical for Inhibitor of Apoptosis (IAP) inhibition, 
they do retain other functions of Reaper at their conserved C-terminal regions. Similar to 
Reaper, NSs protein of California serogroup viruses also induces mitochondrial 
cytochrome c release and caspase activation in cell-free extracts and promotes neuronal 
apoptosis and mortality in a mouse model. Independent of caspase activation, NSs proteins 
of these viruses also share with Reaper the ability to directly inhibit cellular protein 
translation (Colon-Ramos et al., 2003) 
 
In mammalian cells, the NSs protein of BUNV has been found to delay cell death in the 
early stages of BUNV infection by inhibiting IRF-3-mediated apoptosis. BUNdelNSs, 
which does not express NSs was found to induce apoptosis more rapidly than wt BUNV. 
Screening for apoptosis pathways revealed that both BUNV and BUNdelNSs could 
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activate the proapoptotic transcription factor IRF-3, but only BUNV was able to suppress 
signaling downstream of IRF-3 (Kohl et al., 2003). However in contrast with BUNV NSs 
protein, the NSs protein of LACV was found to exhibit a strong proapoptotic response 
(Blakqori and Weber, 2005).  
 
1.4.4 Persistent infection 
 
Infection of mammalian cells by orthobunyaviruses is generally cytolytic while infection 
of mosquito cells e.g. Aedes albopictus C6/36 cells is asymptomatic and persistent (Rossier 
et al., 1988; Scallan and Elliott, 1992). Persistent infection resulted in generation of viruses 
with variable genetic and phenotypic characteristics (Elliott and Wilkie, 1986). Reduction 
of viral RNA and protein synthesized, and the presence of defective RNAs in infected cells 
were suggested to contribute to maintenance of persistence (Newton et al., 1981). 
 
1.4.5 Defective interfering RNA 
 
Passages at high multiplicity of infection (e.g. moi 10) of BUNV in insect and mammalian 
cells have been reported to produce defective interfering (DI) particles (Kascsak and 
Lyons, 1978; Newton et al., 1981). In general, the presence of DI particle has been shown 
to interfere with the virus growth and contributed to the establishment of persistent 
infection (Giachetti and Holland, 1989). DI RNAs which have deletions in L were 
described before in BUNV (Patel and Elliott, 1992). However these deletions were found 
still in-frame, allowing the translation of truncated L polypeptides to occur, suggesting that 
the signals necessary for replication, transcription and translation are still retained and this 
interference only occurred at certain steps in the replication process. The presence of 
defective L RNA segments and resultant DI particles were also reported in GERV 
(Cunningham and Szilagyi, 1987). 
 
 
1.5 Phylogenetic  and sequence analyses of Orthobunyavirus genus 
 
Because of the high error rate of RNA polymerase during RNA replication, RNA viruses 
have been shown continually to evolve rapidly in vivo and in vitro (Holland et al., 1982). 
For orthobunyaviruses, analyses of oligonucleotide fingerprints of a number of LACV 
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isolates from various ecological niches have showed that every isolate has a different L, M 
and S genome sequence, suggesting that genetic drift plays a major role in orthobunyavirus 
evolution (El Said et al., 1979; Klimas et al., 1981). 
 
Although serological techniques have mostly been used to characterise the viruses in 
Bunyaviridae family, there are yet many isolates which cannot be characterised using these 
methods and remain as unclassified viruses. Based on numbers and genetic diversity of 
these viruses, it is very difficult to get a panel of monoclonal antibodies (MAbs) that could 
recognise all epitopes of the viruses (Kingsford, 1991). Therefore other techniques are 
needed especially for new virus isolates. 
 
Gene sequencing is found to be a rapid and accurate method for characterisation of viruses. 
Furthermore, there is also a need to understand at the molecular level the basis of genetic 
diversity and its direct result on antigenic relationship, host susceptibility, pathogenesis, 
transmission by vector, etc (Kingsford, 1991). In addition, sequencing data will also 
provide us information on the gene functions of the viral proteins in replication and protein 
recognition by the immune system (Elliott, 1990). 
 
1.5.1 Sequences and phylogenetic analysis of S segment  
 
Data on the presently available S segment sequences of Bunyamwera, California, Group C 
and Simbu serogroup viruses clearly show that the patterns of sequence relationships are 
mostly in agreement to the previous serological classification (Dunn et al., 1994; Bowen et 
al., 1995; Saeed et al., 2001; Nunes et al., 2005).  
 
Comparison of the sequences of the S segments of 34 viruses in four serogroups of the 
Orthobunyavirus genus (Bunyamwera, California, Group C and Simbu) revealed that the 
lengths of the segments are between 850 to 1077 nucleotides, with variable lengths of 3’/5’ 
NCR (Dunn et al., 1994; Bowen et al., 1995; Saeed et al., 2001; Nunes et al., 2005). The 
GU-rich motif in the 3’NCR of the positive-sense RNA is conserved in Bunyamwera, 
Group C and California serogroup viruses but this motif was not present in Simbu 
serogroup viruses (Dunn et al., 1994; Bowen et al., 1995; Nunes et al., 2005). The 3’ NCR 
of positive-sense RNA of Bunyamwera, California, Group C and Simbu serogroup viruses 
are always longer than 5’NCR. The longest 3’NCR was observed in Lumbo virus 
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(LUMV), which was found to have a duplicated sequence including two GU-rich motifs 
which are separated by 79 nt (Dunn et al., 1994). Nucleotide alignment of the terminal 
3’/5’ NCR of positive-sense S RNA sequences of California serogroup viruses revealed 
that the first 33 nt of 5’ terminus and the first 22 nt of the 3’ terminus were highly 
conserved between viruses within this serogroup (Bowen et al., 1995). 
 
The encoded N proteins are 233 amino acid residues for Bunyamwera and Simbu 
serogroups, except for OROV and Jatobal virus (JATV), which have 231 amino acids, 234 
amino acids for Group C and 235 amino acids for California serogroup. The NSs proteins 
of the orthobunyaviruses are found to be more variable, 91 to 96 amino acids for Simbu 
serogroup, 83 to 109 amino acids for Bunyamwera serogroup, 92 or 97 amino acids for 
California serogroup and 91 or 98 for Group C serogroup, with a lower sequence identity 
and fewer conserved residues between viruses in different serogroups (Dunn et al., 1994; 
Bowen et al., 1995; Saeed et al., 2001; Nunes et al., 2005).  
 
In general, viruses within the same serogroup exhibit close similarity between each other 
(Pringle, 1991). N amino acid sequence identity of the viruses in the same serogroup is 
found to be more than 62% identity, and between serogroups is more than 40% (Dunn et 
al., 1994; Bowen et al., 1995; Saeed et al., 2001; Nunes et al., 2005), with Group C viruses 
closer to Simbu serogroup and Bunyamwera serogroup viruses closer to California 
serogroup. Viruses in Group C and Simbu serogroups were found to display larger 
divergence in the N sequence (more than 40% divergence) compared to Bunyamwera and 
California serogroup viruses (Saeed et al., 2001; Nunes et al., 2005). The possible reasons 
for these divergences might be that these viruses existed earlier than Bunyamwera and 
California serogroup viruses, and they have broader geographical distribution and vector 
association compared to Bunyamwera and California serogroup viruses (Saeed et al., 
2001).  
 
Alignments of the N and NSs protein sequences of the viruses in Bunyamwera, California 
and Simbu serogroups revealed that conserved amino acid motifs of the N protein are 
located at amino acid residues 39 to 43, 90 to 116 and 125 to 165. These regions might be 
responsible in inducing the CF antibodies that cross react between the viruses in the genus 
Orthobunyavirus and might be functional domains that are responsible in the interaction of 
N protein with L protein or viral RNA (Dunn et al., 1994; Bowen et al., 1995). Alignments 
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of the NSs protein of Bunyamwera and California serogroup viruses identified the 
variation in length to be at the carboxy terminus, and the presence of a conserved amino 
acid motif LPS near this terminus. However this LPS motif was not observed in GROV, 
Group C and Simbu serogroup viruses. The NSs protein was found to be more divergent 
than the N protein (Dunn et al., 1994). 
 
Phylogenetic analysis of Bunyamwera and California serogroup viruses by Bowen et al. 
(1995) led the authors to conclude that the trend in orthobunyaviruses evolution is toward a 
smaller NSs protein by truncation at the carboxy terminus. However, GROV is found not 
to fit this pattern, with its NSs protein being shortened at both amino and carboxy termini, 
resulting a very short NSs (83 residues) and low identity with other members of the 
Bunyamwera serogroup. Shortening of NSs has been suggested as an evolutionary 
advantage to the S segment of the virus by freeing additional ORF codons from the 
constraint of encoding both N and NSs proteins (Bowen et al., 1995).  
 
Based on phylogenetic analyses of N ORF of viruses in Bunyamwera, California, Group C 
and Simbu serogroups (Fig. 1.11), each serogroup was divided into several clades. For 
example, viruses in Bunyamwera serogroup are divided into four clades; BUN, GER, GRO 
and KRI (Dunn et al., 1994), California serogroup into three clades; MEL, CE and TVT 
(Bowen et al., 1995), Group C serogroup into three clades; I, II, III with MADV 
representing a distinct lineage (Nunes et al., 2005) and Simbu serogroup into five clades; I, 
II, III, IV and V (Saeed et al., 2001). 
 
Viruses in Bunyamwera and California serogroups are found to have 16 nt between the 
spacing of N and NSs AUG initiation codon, while Group C and Simbu serogroups are 
found to have 19 nt (Dunn et al., 1994; Bowen et al., 1995; Saeed et al., 2001; Nunes et al., 
2005). However, GROV is found not to follow these spacing with 31 nt (Dunn et al., 
1994). With the exception of GROV, GERV, AINV and Group C viruses, most of the 
viruses in California (Bowen et al., 1995), and Bunyamwera (Dunn et al., 1994) 
serogroups and certain OROV strains in Simbu serogroup (Saeed et al., 2001) start their 
NSs ORF with two successive ATG codons. 
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Fig. 1.11.  Phylogenetic tree of aligned N ORF of members of the Bunyamwera, 
California, Group C and Simbu serogroups. The tree was constructed 
by the Neighbor-Joining (NJ) method. Numbers adjacent to each 
branch represent bootstrap support calculated for 100 replicates. The 
viruses in each serogroup were divided into several complexes: 
Bunyamwera serogroup into BUN, KRI, GRO and MD complexes, 
California serogroup into CE, MEL and TVT complexes; Group C 
into 3 groups (I, II and III), with the exception of MADV which was 
outside the group and Simbu serogroup into 5 groups (I, II, III, V and 
IV) ( Generated using references from Dunn et al., 1994; Bowen et al., 
1995; Nunes et al., 2005; Saeed et al., 2001) 
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1.5.2 Sequences and phylogenetic analysis of M segment  
 
Comparison of the M segment sequences of BUNV (Lees et al., 1986), LACV (Grady et 
al., 1987) and GERV (Pardigon et al., 1988) with SSHV (Eshita and Bishop, 1984) 
revealed an overall identity of 60% for Gc, 50% for NSm and 40% for Gn with the 
conserved sequence of –Lys-Ser-Leu-Arg-Ala/Val-Ala-Arg- at the carboxy terminal of Gc 
(Elliott 1990). Phylogenetic analyses of M sequences of viruses in the California serogroup 
(Campbell and Huang, 1999) and some viruses in Simbu serogroup (Wang et al., 2001) 
were found to be consistent with the previously reported phylogeny based on S RNA 
sequences (Bowen et al., 1995 and Saeed et al., 2001). However, the phylogenetic tree of 
AKAV, AINV and PEAV in the Simbu serogroup based on the M ORF sequences revealed 
that PEAV first forms a cluster with AKAV, and is distant from AINV, while the tree 
based on N ORF sequences showed closer relationships of Peaton virus (PEAV) with 
AKAV and AINV. This suggested that RNA segment reassortment had occurred among 
the ancestors of these viruses (Yanase et al., 2003). Based on complete S and partial M 
segment sequences of Group C viruses, reassortments were also observed in these viruses 
(Nunes et al., 2005).  
 
1.5.3 Sequences and phylogenetic analysis of L segment  
 
To date, only limited sequence data are available for the L segments of orthobunyaviruses. 
Comparisons of these sequences data indicate that generally little similarity was observed 
between viruses in the different genera. However, phylogenetic analysis of these viruses 
was found to be correlated with their current serological classification (Elliott, 1996). 
Comparison of the L protein sequences of BUNV with LACV and SSHV reveal that 46 
amino acid residues of the amino-terminal show strong identity (63%) (Elliott,1989). 
Phylogenetic analyses of the complete L sequences of nine members of four genera 
revealed that orthobunyaviruses are more related to TSWV in Tospovirus genus than the 
other genera (Roberts et al, 1995). Sequence comparison of L amino acid sequences of 
OROV, BUNV and LACV showed that BUNV and LACV are more closely related to each 
other than to OROV.  
 
Sequence data of the viruses from other serogroups in Orthobunyavirus genus are needed. 
Therefore, in this study, I made an attempt to sequence viruses in the other 14 serogroups 
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to give fuller understanding of their phylogenetic relationships and to provide a greater 
insight of their evolution.  
 
 
1.6 Aims of the project 
 
The main objective of this project was to sequence the S segments of the viruses in the 
unstudied 14 serogroups of the Orthobunyavirus genus and to compare these sequences 
between themselves and with the published sequences of other orthobunyaviruses. The S 
segment was chosen in this study because it displays relatively large sequence divergence 
(Dunn et al., 1994), and also because of its size, being the smallest (less than 1000 
nucleotides) among the three segments. I hope in this study to get a clearer picture of the 
phylogenetic relationships and evolution of the viruses in all eighteen serogroups of viruses 
in the Orthobunyavirus genus.  
 
The second objective was to better characterize the viruses in terms of their ability to grow 
in different cell lines, analysis of viral-encoded proteins synthesised in infected cells and 
investigation of the function of the NSs protein in inhibiting the production of interferon 
and causing shutoff of host protein synthesis.  
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2 Materials and Methods 
 
 
2.1 Materials 
 
2.1.1 Media 
 
2.1.1.1 Cell culture media 
 
Foetal bovine serum (FBS), Dulbecco modified Eagle’s medium (DMEM), Glasgow’s 
modified Eagle’s medium (GMEM), Liebowitz (L15) medium, and L-glutamine were 
purchased from Invitrogen. 1x trypsin (0.025%) and versene (0.02% EDTA) were 
purchased from Sigma. 
 
2.1.1.2 Plaque assay medium 
 
Minimum essential medium 2x (MEM) (Gibco BRL) supplemented with 2% FBS and 2 
mM L-glutamine,  
 
2.1.2 Cells  
 
A549 is a cell line derived from human alveolar basal epithelium. This cell was obtained 
from MRC Virology Unit, University of Glasgow. 
 
293 is a cell line derived from human embryo kidney (Graham et al., 1977), which was 
obtained from Prof. Rick Randall. 
 
BHK-21 clone 13 (Macpherson and Stoker, 1962), a cell line derived from baby hamster 
kidney.  
 
C6/36 cells (Igarashi, 1978) were derived from the mosquito Aedes albopictus 
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Hep2 and Hep2/V cells were obtained from Prof Rick Randall. Hep2 is a human negroid 
cervical carcinoma cell line and Hep2/SV5-V is a Hep2 cell expressing the V protein of 
Simian virus 5 (SV5) (Andrejeva et al., 2002). 
 
LLCMK2 (ATCC CCL 7) is a monkey kidney cell line. 
 
Vero-E6 (ATCC no. CRL-1586) is an African green monkey kidney cell line. 
 
BHK-21 cells were maintained in GMEM supplemented with 10% FBS, 2 mM L-
glutamine and 10% tryptose phosphate broth (TPB) (Gibco BRL).  A549, Vero-E6, 293, 
Hep2, Hep2/V and LLCMK2 cells were maintained in DMEM containing 10% FBS and 2 
mM L-glutamine. C6/36 cells were maintained in L-15 medium supplemented with 10% 
FBS, 2 mM L-glutamine and 10% TPB. 
 
Except for C6/36 cells which were incubated at 28oC in a tightly sealed container, the other 
cells were grown at 37oC in the presence of 5% CO2 in a humidified incubator. 
 
2.1.3 Enzymes 
 
Restriction endonuclease enzymes, T4 RNA and DNA ligases, and calf intestinal 
phosphatase (CIP) were purchased from Promega. All the reactions using these enzymes 
were carried out according to the manufacturer’s instructions. 
 
2.1.4 Reagents, chemicals and solutions 
 
2.1.4.1 Reagents and chemicals. 
 
All chemicals and reagents as listed below were purchased from BDH Chemical Ltd, 
Fisher Scientific or Sigma Chemicals except as stated. 
 
DNA loading buffer: 0.25% (w/v) bromophenol blue; 20% (w/v) Ficoll 400; 0.1 M 
Na2EDTA, pH8.0; 1% SDS; 0.25% (w/v) xylene cyanol;  
 
Ampicillin, agarose HSA, and DNA size markers were purchased from Research Biolabs.  
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Ethidium bromide and nuclease-free water were purchased from Promega. 
 
10x Tris-borate EDTA (TBE): 1.0 M Tris; 0.9 M boric acid; 0.01 M EDTA was obtained 
from Invitrogen.  
 
Multi-purpose agarose was obtained from Roche.  
 
Penicillin/Streptomycin: 10 000 U/ml penicillin and 10 000 µg/ml streptomycin sulphate in 
0.85% saline solution was purchased from Gibco BRL.  
 
Phosphate buffered saline (PBS): 170 mM NaCl; 3.4 mM KCl; 10 mM Na2HPO4; 1.8 mM 
KH2PO4, pH 7.4; 0.68 mM CaCl2; 0.49 mM MgCl2. 
 
lysis buffer (0.15 M NaCl; 0.05 M Tris HCl, pH7.5; 0.6% NP40). 
 
2.1.4.2 Oligonucleotides/ primers 
 
Oligonucleotides were purchased from Sigma-Genosys. Sequences of the oligonucleotides 
used are listed in Table 2.1. 
 
2.1.4.3  Reverse Transcription (RT) and Polymerase Chain Reaction (PCR) 
 
Access RT-PCR one step system, Taq DNA polymerase, 10 mM deoxynucleotide 
triphosphate (dNTPs), Avian myeloblastosis virus (AMV) reverse transcriptase, and 
recombinant ribonuclease inhibitor (RNasin) were purchased from Promega.  
 
5’/3’ RACE (rapid amplification of cDNA ends) (2nd generation) kit was obtained from 
Roche.  
 
2.1.4.4 Competent cell preparation, transformation,  and plasmid extraction 
 
Ampicillin (Penbritin): 50 mg/ml 
 
L- broth (LB): 10 g NaCl; 10 g bactopeptone; 5 g yeast extract per litre. 
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Oligonucleotide Sequences (5’-3’) Reference 
BUN S+ AGTAGTGTACTCCAC Dunn et al., 
1994 
BUN S- AGTAGTGTGCTCCAC Dunn et al., 
1994 
S13+ GTCACAGTAGTGTACYCC This study 
S13- CTGACAGTAGTGTGCYCC This study 
S25F GTCACAGTAGTGTACTCCACWDNAA This study 
S400F TCCCAGGAACAGAAATGTT This study 
S400R AACATTTCTGTTCCTGGGA This study 
MPO400PR AGAAACATTTCTGCACCWG This study 
S350F TCATCAACCCAATTGCTGA This study 
ORO2S AGTAGTGTGCTCCACAT Saeed et al., 
2001 
BWAPR CTGTATATGCCAATTGCTAGTGG This study 
BERPF CTGCTGCAGCCAGAGCCTTCCT This study 
BUNCAL2 CCCCTACCACCCACCC Bowen et al., 
2001 
CAPPF ATCGTGAACCCGATTGCTG This study 
CAPPR AGTGAACGTAGCAGTGCCAA This study 
PGTR AAAAACATCTCTGTGCCAGG This study 
GMAPF GTCTGCTGCAGCCAGAAACTTCT This study 
GMAPR GCTCKRTARATTCCRATTGC This study 
NIFFF TTAAGGATTTTCTTCCTCAATGC This study 
NNHR ACTTGTTGTGGTTATT This study 
PATNNHR CAACCATAACCCAAGACTGG This study 
PATPF CTCTGTAGATCCCGATGGCAAGTGG This study 
PLSPF TCATAAACCCGATTGCAGCA This study 
SJPF CTGCAAGAATGATTGAGTTCTTC This study 
Oligo (dT) 
anchor primer 
(OAP) 
GACCACGCGTATCGATGTCGACT 
TTTTTTTTTTTTTTTV 
RACE kit 
(Roche) 
PCR anchor GACCACGCGTATCGATGTCGAC RACE kit 
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primer (AP) (Roche) 
DT88 GAAGAGAAGGTGGAAATGGCGTTTTGG[3d_A] Li et al., 
2005 
DT89 CCAAAACGCCATTTCCACCTTCTCTTC Li et al., 
2005 
Exo-oligo 
random hexamer 
NNnnN Polidoros et 
al., 2006 
InvR TGGACATAAGCCGTAGCATG Polidoros et 
al., 2006 
5’ Xba/BUN S+ TCTAGAAGTAGTGTACTCCAC 
 
This study 
5’Kpn/BUN S-. GGTACCAGTAGTGTGCTCCAC 
 
This study 
IFN-βF GACGCCGCATTGACCATCTA Spiegel et 
al., 2005 
IFN-βR CCTTAGGATTTCCACTCTGACT Spiegel et 
al., 2005 
human γ-actin F GCCGGTCGCAATGGAAGAAGA Spiegel et 
al., 2005 
human γ-actin R CATGGCCGGGGTGTTGAAGGTC Spiegel et 
al., 2005 
 
Table 2.1. Sequences of the oligonucleotides used. [3d_A] indicates endocypin- blocked 
adapter primer, D stands for A/G/T, K for G/T, N for A/C/G/T, R for A/G, V for A/C/G, W 
for A/T and Y for C/T. 
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LB agar: L-broth plus 1.5% (w/v) agarose. 
 
transformation and storage buffer (TSB): L-broth + 10% PEG (3350 Mwt); 5% DMSO; 10 
mM MgCl2; 10 mM MgSO4. 
 
TSB glucose: 0.36% (w/v) glucose in TSB.  
 
QIAquick gel extraction kit, Mini and Midi plasmid preparation kits were obtained from 
Qiagen. 
 
 5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside (X-gal) and isopropyl-1-thio-ß-D-
galactoside (IPTG) were obtained from Invitrogen.  
 
2.1.4.5 Transfection of cultured cells. 
 
Lipofectamine 2000 was purchased from Invitrogen  
 
Luciferase reporter gene assay kit was obtained from Promega. 
 
2.1.4.6 RNA preparation 
 
TRIzol reagent (a mono-phasic solution of phenol and guanidine isothiocyanate) was 
obtained from Invitrogen. 
 
diethyl pyrocarbonate (DEPC)-treated dH2O: DEPC was added to double distilled water to 
0.01%, mixed and incubated overnight at room temperature before autoclaving. 
 
2.1.4.7 In vivo protein labelling, polyacrylamide gel electrophoresis (PAGE) and in 
vitro transcription and translation (TnT). 
 
Acrylamide/bis-acrylamide stock solution: 30% (w/v) acrylamide; 0.8% bis-acrylamide, 
final ratio 37.5:1. 
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ammonium persulphate (APS) was obtained from BioRad.  
 
DMEM without methionine solution was obtained from Gibco BRL. 
gel fixing buffer: 50% (v/v) methanol; 10% (v/v) acetic acid; 40% dH2O. 
 
sodium dodecylsulphate (SDS): 10% (w/v) in dH2O. 
 
TEMED (N,N,N’,N’ tetramethylethylenediamine) was purchased from BioRad. 
 
10x Tris-glycine buffer: 2.4 M Tris; 1.9 M glycine.   
 
Running buffer: 1x Tris-glycine buffer; 10% SDS.  
 
Protein dissociation mix: 125mM Tris, pH 6.8; 4% (w/v) SDS; 20% (v/v) glycerol; 0.1% 
(w/v) bromophenol blue; 10% (w/v) 2-mercaptoethanol. 
 
Resolving gel buffer (RGB): 59.0 g Tris; 4.0 g SDS in 1000 ml of dH2O, pH 8.9. 
 
Stacking gel buffer (SGB): 59.0 g Tris; 4.0 g SDS in 1000 ml of dH2O; pH 6.7 
 
NUPAGE 6-12 % gradient pre-cast polyacrylamide gel was purchased from Invitrogen.  
 
Transcription and Translation (TnT) kit was obtained from Promega. 
 
2.1.5 Plasmids 
 
pGEMT easy vector was purchased together with pGEMT easy cloning kit from Promega. 
 
pRL-SV40 contained the Renilla luciferase gene under the control of the constitutive 
Simian virus 40  (SV-40) promoter and phRL-CMV contained the Renilla luciferase gene 
under the control of the cytomegalovirus (CMV) immediate-early promoter. These 
plasmids were purchased from Promega. 
 
pBluescript2 KS plus was obtained from Stratagene. 
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pT7ribo and pT7riboBUNS (Dunn et al., 1995) containing full coding sequence of  BUNV 
S segment and IFN-β reporter plasmid, pIF∆(-125)lucter (King and Goodbourn, 1994) 
were supplied by Prof.R.M Elliott.  
 
2.1.6 Bacterial strains 
 
Two bacterial strains were used for growth and maintenance of the plasmids: 
 
E.coli DH5α: Ф80d lacZ, ∆M15, recA1, gyrA96, thi-1, hsdR17 (rk-,mk+), relA1, supE44, 
relA1, deoR, ∆(lacZYA-argF) U169, phoA. 
 
E.coli JM109: endA1, recA1, gyrA96, thi-1, hsdR17 (rk-,mk+), relA1, supE44, ∆(lac-
proAB),[F’, traD36, proAB,lac/qZ∆M15]. 
 
2.1.7 Viruses 
 
Two viruses of each serogroup were used in this study (Table 2.2). The viruses were 
obtained from Dr. R.E. Shope, University of Texas Medical Branch, Galveston, Texas. 
Most of the viruses were in the form of freeze-dried infected mouse brain homogenates.  
 
 
2.2 METHODS 
 
2.2.1 Maintenance of mammalian and insect cell lines 
 
Mammalian cell lines (A549, BHK-21, Vero-E6, Hep2 and Hep2/V) were maintained in 
medium-(80 cm2) or large-sized (175 cm2) tissue culture flasks and were split every three 
to four days. To passage the cells, the monolayers were rinsed twice with versene solution.  
Then, 1 ml or 2 ml of 1x trypsin solution diluted in versene was added to each medium or 
large flask, respectively. After incubation at 37oC for 5 min, cells were resuspended in 3 ml 
growth medium by vigorously pipetting up and down. Additional growth medium was 
added to the cell suspension to give a final volume of 5 ml for a medium flask and 10 ml  
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Serogroup Virus Virus 
strain 
Passage cell 
and no. of 
passage 
(pass) 
Isolation 
reference 
no. 
Date of 
freeze 
drying virus 
stock 
Country of 
origin 
Vector Isolation 
year 
Anopheles 
A (ANAV) 
- Mouse Pass 
9 
- 23/12/1984 South 
America 
(SA) 
Mosquito 1940 Anopheles 
A 
Tacaiuma 
(TCMV) 
BeAn73 - TVP-7995 21/7/2001 SA Mosquito+ 
Culicoides 
1955 
Anopheles B 
(ANBV) 
- Mouse Pass 
179 
- 15/2/1968 SA Mosquito 1940 Anopheles B 
Boraceia 
(BORV) 
SP Ar395 Mouse Pass 
4 
- 6/12/1965 SA Mosquito + 
Culicoides 
1962 
Bakau 
(BAKV) 
MM2322
5 
Mouse Pass 
8 
Vero Pass 1 
- 9/5/1980 Asia Mosquito 1956 Bakau 
Ketapang 
(KETV) 
MM2549 Mouse Pass 
5 
R16179 
 
15/5/1970 Asia Mosquito - 
Bwamba 
(BWAV) 
- Mouse Pass 
86 
Vero Pass 2 
- 3/80 Africa Mosquito - Bwamba 
Pangola 
(PGAV) 
- Mouse Pass 
9 
 
- 17/3/1971 Africa Mosquito - 
Acara 
(ACAV) 
BeAn276
39 
 
Smb Pass 3 - 26/6/1966 SA 
North 
America 
(NA) 
Mosquito 1961 Capim 
Capim 
(CAPV) 
- Mouse Pass 
16 
Vero Pass 1 
- 8/2/1994 SA Mosquito 1958 
Gamboa 
(GAMV) 
GML4385
24 
- TVP2657 18/12/1990 SA Mosquito - Gamboa 
San Juan 
(SJ2441V) 
78V2441 Vero Pass 4 - 4/12/1981 NA Mosquito - 
Bertioga 
(BERV) 
- Mouse Pass 
4 
 
- 4/1/1966 SA Mosquito - Guama 
Guama 
(GMAV) 
BeAn277 Mouse Pass 
5 
Vero Pass 1 
- 13/1/1992 SA 
NA 
Mosquito - 
Koongol 
(KOOV) 
MRM31 
 
Mouse Pass 
1 
- 23/11/1965 Australia Mosquito 1960 Koongol 
Wongal 
(WONV) 
MRM168 Mouse Pass 
9 
- 6/6/1966 Australia Mosquito 1960 
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Minatitlan 
(MNTV) 
70U39 Mouse Pass 
4 
- 25/4/1974 NA Mosquito 1967 Minatitlan 
Palestina 
(PLSV) 
76/V1565 Pass sm 3 
Vero 2 
- 31/8/1982 SA Mosquito 1976 
Eretmapodit
es 
(E147V) 
- Mouse Pass 
7 
- 3/10/1966 Africa Mosquito - Nyando 
Nyando 
(NDV) 
Mp401 Mouse Pass 
7 
 
- 15/3/1971 Africa Mosquito - 
Botambi 
(BOTV) 
BA937 Mouse Pass 
3 
 
- 8/3/1970 Africa Mosquito 1968 Olifantsvlei 
Olifantsvlei 
(OLIV) 
SA 
Ar5133 
Mouse Pass 
5 
- 28/7/1964 Africa Mosquito 1963 
Pahayokee 
(PAHV) 
FE3 52F Mouse Pass 
4 
- 14/9/1968 NA Mosquito 1964 Patois 
Patois 
(PATV) 
63A49 Mouse Pass 
3 
 
- 8/3/70 NA Mosquito 1961 
Batama 
(BMAV) 
DAK 
AnB1292 
Mouse Pass 
8 
- 15/12/1984 Africa Tick 1970 Tete 
Tete 
(TETEV) 
SA 
An3518 
Pass sm 7. 
Vero 1 
- 12/7/1984 Africa Tick 1959 
M’Poko 
(MPOV) 
BA365 Mouse Pass 
11 
- 22/8/1980 Africa Mosquito - Turlock 
Turlock 
(TURV) 
- - MP847-32 9/2/1959 NA,SA Mosquito - 
 
Table 2.2.  Viruses used in this study. The information of passage history was provided 
by Dr. R.E. Shope. Country of origin, year of isolation and vector of these viruses are 
retrieved from International Cataloque of Arboviruses, 1985. 
 
 
 
 
 
 
 
 
 74 
 
for a large flask. One ml of this cell suspension was used to seed a large flask containing 
50 ml growth medium and 0.5 ml for a medium flask containing 25 ml growth medium. 
 
The insect cell line C6/36 was maintained in medium size flasks and split once a week. 
The cells were washed twice with growth medium, then 2 ml of medium was added to the 
flask. The side of the flask was hit vigorously to dislodge the cells. An additional 3 ml of 
the medium was added to the flask to give a final volume of 5 ml. 0.5 ml of the cell 
suspension was seeded in a medium-sized flask containing 25 ml of L-15 growth medium. 
 
2.2.2 Preparation of virus stock 
 
A 70% confluent monolayer of Vero-E6 or BHK-21 cells in a 25 cm2 flask was infected 
with 100 µl of the original virus stock and incubated at 37oC for 1 h with gentle agitation 
every 15 minutes. After the absorption, the medium was discarded and 5 ml of DMEM 
containing 2% FBS was added. The infected cells were further incubated for up to 5 days 
at 33oC until 70% cytopathic effect (cpe) was observed.  The culture supernatants were 
transferred to 15 ml Falcon tubes and cell debris were then removed by centrifuging at 
3,000 rpm for 5 min in a swinging bucket rotor. The supernatant was aliquoted in 1 ml 
volumes and frozen at -70oC.  
 
If no cpe was observed, the culture supernatants were harvested at 7 days post infection 
(pi) and were further passaged until a good cpe was obtained. 
 
2.2.3 Plaque Assay  
 
The titre of the virus stocks was determined by plaque formation. Virus-infected 
supernatant was serially diluted from 10-1 to 10-6 dilution in PBS containing 2% FBS. A 
200 µl volume of each dilution (from dilution 10-2 to 10-6) was inoculated to each well of a 
6-well tissue culture plate containing confluent Vero-E6 or BHK-21 cells. The last well 
was used to inoculate 200 µl PBS supplemented with 2% FBS as a control well. The cells 
were then incubated at 37oC for 1 h with rocking every 15 min. The inoculum was 
removed and the infected cells were then overlaid with 2 ml equal volume of 1.2% agarose 
(pre-warmed at 55oC) and 2x MEM containing 2% FBS (pre-warmed at 45oC). The plates 
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were incubated at 33oC for 4-5 days. After incubation, the plates were fixed with 2 ml of 
4% (v/v) formaldehyde and incubated at room temperature for at least 3 hours. The overlay 
was removed and the cells were then stained with Giemsa’s for 5-10 min. The stained cells 
were then washed with the tap water until the clear plaques were obvious.  
 
2.2.4 Plaque purification of viruses 
 
This assay was conducted as above, except, rather than staining the infected cells with 
Giemsa, monolayers were stained with 1 ml neutral red (diluted 1/20 in PBS) per dish at 
37oC for at least 4 h without prior fixing. The plaques were then picked using 1 ml blue 
micropipette tip, placed into 1 ml growth medium, and vortexed to release the virus 
particle from the agarose. Half was used to inoculate 25 cm2 flasks of Vero-E6 cells. The 
cells were then incubated at 37oC and the virus supernatants were harvested after 70% cpe 
was observed. The harvested supernatants were used as a stock to infect 80 cm2 flask of 
Vero-E6 cells to get a working stock. 
 
2.2.5    Preparation of SDS-PAGE 
 
Ten ml of 15% mini resolving gels were used in this study. The gel was prepared as below;  
 7.2 ml of (30%) acrylamide: bis solution was added with 3 ml RGB, 1.8 ml water, 100 µl 
ammonium persulphate, and 10 µl TEMED. This resolving gel was poured in-between the 
assembled glass plate. A space equivalent to two comb-depths was left for the stacking gel 
and 70% isopropanol was layered onto the resolving gel to create a smooth surface. Once 
the gel had polymerised, the isopropanol was removed and the gel was rinsed twice with 
distilled water.  
 
A 6 ml stacking gel was prepared which containing 1 ml 30% acrylamide:bis solution, 1.5 
ml SGB, 3.5 ml water, 55 µl ammonium persulphate, and 10 µl TEMED. The gel mixture 
was then poured on-top of the resolving gel, the comb of 0.75 mm was inserted and the gel 
was allowed for polymerisation.  
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2.2.6 In vivo protein labelling  
 
A 35 mm-diameter dish of monolayer Vero-E6 cells was infected with 1 PFU/cell of virus 
and incubated at 37oC for 24 h. The cells were then starved of methionine by incubating 
them in 1 ml DMEM without methionine for 30 minutes at 37oC. After labelling the cells 
with 30 µCi [35S] methionine for 2 h at 37oC, the medium was removed, washed once with 
cold PBS and the cells were lysed in 200 µl protein dissociation mix by scraping them 
using a rubber policeman and then passing through a 23g needle several times. Fifteen µl 
of the cell lysate was used to load each well of the mini gel. The gel was run for 1.5 h at 
100 V in 1x Tris-glycine buffer using the Bio-Rad Mini–Protean III apparatus. The gel was 
then fixed with 20% methanol containing 10% acetic acid for 1 h at room temperature and 
transferred to distilled water for about 30 min. The gel was placed onto Whatman filter 
paper, covered with cling film and dried for 50 min at 80oC. The gel was exposed to X-
Omat S x-ray film overnight at room temperature. 
 
2.2.7 Preparation of virions for RNA extraction 
 
A 175 cm2 flask of Vero-E6 cells were infected with 5 PFU/cell virus, incubated for 24-48 
h until 70% cpe was observed. The supernatants were harvested and centrifuged at 3,000 
rpm for 5 min to remove cell debris. The virus particles in the supernatant were collected 
by centrifugation at 26,000 rpm for 2 h in an AH629 rotor at 4oC. The pellet was 
resuspended in 1 ml TRIzol reagent for RNA extraction. 
 
2.2.8 Preparation of viral nucleocapsid 
 
This method was based on Leppet et al. (1979). A 175 cm2 flask of Vero-E6 cells was 
infected with 5 PFU/cell virus, incubated for 24-48 h until 50% of the cpe was observed. 
The cells were then scraped into the tissue culture medium and centrifuged at 3,000 rpm 
for 5 min. The cell pellet was washed with PBS, re-spun for another 5 min and 
resuspended in 2 ml cold lysis buffer. After incubation on ice for 5 min, the suspension 
was vortexed for 2 min and centrifuged at 8,000 rpm for 5 min at 4oC in a refrigerated 
microcentrifuge. The supernatant was transferred to a new tube and 25 µl 0.5 M EDTA 
was added to each 2 ml cell extract. CsCl gradients comprised 6 ml of 20-40% (w/w) CsCl 
in 25 mM Tris-HCl (pH7.5);  2 mM EDTA (TE), overlaid with 2 ml of 5% (w/v) sucrose 
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in 50 mM NaCl; 25 mM Tris-HCl (pH7.5); 2 mM EDTA (NTE). Gradients were overlaid 
with the above cell extract and centrifuged for at least 16 h at 32,000 rpm at 12oC. The 
visible band of the nucleocapsid around the middle of the gradient was harvested with a 
syringe, diluted at least 3-fold with NTE buffer, and the nucleocapsids were pelleted at 
40,000 rpm for 2 h at 4oC in TST rotor. The pellet was dissolved in 1 ml TRIzol and the 
viral RNA was extracted. 
 
 
2.2.9 RNA Extraction 
 
Total RNA was extracted from infected Vero-E6 cells or virions or nucleocapsids using 
TRizol, essentially as described by the manufacturer. Total RNA extracted from infected 
35 mm-diameter dishes of Vero-E6 cells at 24 h p.i. was prepared by first removing the 
culture medium, resuspending the monolayer with 1 ml TRIzol, and transferring to a 1.5 
ml Eppendorf tube. For RNA extracted from virions and nucleocapsids, the pellet was 
resuspended in 1 ml of TRIzol reagent. The TRIzol and the virus mixture was pipetted up 
and down, and incubated at room temperature for 5 min. After the incubation, 200 µl of 
chloroform was added and the tube was inverted a few times, then the mixture was further 
incubated at room temperature for 3 min. After centrifugation at 13,000 rpm for 15 min, 
the upper phase was transferred to a new 1.5 ml tube and 500 µl isopropanol was added. 
The mixture was then incubated at room temperature for 10 min followed by centrifugation 
at 13,000 rpm for 10 min. The supernatant was removed and the pellet was washed with 1 
ml cold 70% ethanol. After centrifugation at 10,000 rpm for 5 min at 4oC, the pellet was 
air-dried and resuspended in 30 µl DEPC-water or nuclease-free water. The extracted RNA 
was stored at -20oC until use. 
 
2.2.10 RNA ligation 
 
Aliquots of 1-5 µg of TRIzol extracted RNA were heated at 75oC for 5 min to remove 
secondary structure, followed by ligation in 25 µl reaction volume containing 2.5 µl 10x 
reaction buffer (500 mM Tris-HCl, pH 7.5; 100 mM MgCl2; 50 mM DTT; 10 mM ATP), 
20 U of RNasin and 20 U of T4 RNA ligase. The reaction mixture was incubated at 37oC 
for 2 h followed by 65oC for 15 min to inactivate the enzyme. Ten µl of the ligated RNA 
was used for cDNA synthesis.  
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2.2.11 Reverse Transcription-Polymerase Chain Reaction (RT-PCR)  
 
The one step Access RT-PCR system from Promega was used for amplification of full and 
partial length S segment cDNA, using primers that correspond to the highly conserved 
termini of the genome RNAs published for Bunyamwera, California, Group C and Simbu 
serogroup viruses. RT-PCR were carried out in a 50 µl reaction mixture containing 1-5 µg 
of viral RNA, 20 pmol of BUN S+ forward primer , 20 pmol of BUN S- reverse primer 
(Dunn et al., 1994),  1x  RT-PCR buffer [20 mM Tris-HCl, pH 8.4; 50 mM KCl; 1 mg/ml 
bovine serum albumin(BSA); 2.5 mM MgCl2], 10 U of RNasin, 0.2 mM of dNTPs, 2 U of  
Thermus flavus (Tfl) DNA polymerase and 5 U AMV reverse transcriptase. RT-PCR was 
performed for 60 min at 45oC, followed by 35 cycles consisting of 94oC for 45 s, 54oC for 
45 s and 68oC for 1.5 min and a final extension at 72oC for 10 min. 
  
For amplification of partial cDNA, RT-PCR was conducted as above but using primers 
S400F (this study) and BUNCAL2 (Bowen et al., 2001).  
 
The PCR products were analysed by agarose gel electrophoresis. Ten µl of PCR product 
was mixed with 2 µl of 6x loading dye and electrophoresed on 1% agarose gel containing 
0.5 µg/ml ethidium bromide prepared in 1x TBE buffer. Electrophoresis was at 100 V for 
30 min. The product was observed and photographed using a UV transluminator at 365nm.  
 
2.2.12 3’/5’ RACE RT-PCR 
 
3’/5’ RACE RT-PCR was conducted using the kit from Roche, following the 
manufacturer’s instruction. In the 5’ RACE, 1-5 µg of virion RNA was reverse-transcribed 
to cDNA in a reaction of 20 µl containing cDNA synthesis buffer, 0.2 mM dNTPs, 12.5 
µM specific primer 1F, 25 U Transcriptor reverse transcriptase and nuclease-free water. 
The cDNA product was further purified using the PCR purification kit from the same 
company and 19 µl of the cDNA was then subjected to oligo(A) tailing in a 25 µl reaction 
containing 2.5 µl 10x  reaction buffer, 2.5 µl 2 mM dATP. After the denaturation at 94oC 
for 3 min and quick chilling on ice for 4 min, 10 U terminal transferase was added to the 
reaction. The reaction was incubated at 37oC for 20 min and stopped by heating at 70oC for 
10 min. Five µl of the tailed cDNA product was used in a first PCR reaction in 50 µl 
reaction containing 1x PCR reaction buffer, 2.5 U Taq DNA polymerase, 12.5 µm second 
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specific primer 2F and 37.5 µm oligo (dT) anchored primer (OAP), 0.2 mM dNTPs, 1.5 
mM MgCl2, and nuclease-free water. The PCR was performed for 2 min at 94oC, followed 
by 35 cycles of 94oC for 15 s, 55oC for 30 s and 72oC for 40 s, followed by incubation at 
72oC for 7 min. 
 
 If no band was observed, one µl of 10-fold diluted first PCR product was then subjected to 
the nested PCR reaction using PCR anchor primer (AP) and third specific primer 3F. 
For the 3’ RACE, the extracted RNA was firstly tailed with A residues using poly (A) 
RNA polymerase (Epicentre) and reverse transcription was conducted using the OAP 
primer at 50oC for 1 h. The cDNA was then treated with 2 U of RNase H at 37oC for 30 
min and further purified using Qiagen PCR purification kit. The first PCR was conducted 
on 5 µl of the purified cDNA using OAP primer and specific primer 1R. If the first PCR 
was not observed, 1 µl of the first PCR was further subjected to nested PCR using AP 
primer and specific primer 2R. The products were examined in 1% agarose gel 
electrophoresis and purified by QIAquick gel purification kit (Qiagen). The products were 
either sequenced directly, or, if the band was weak, it was cloned into pGEMT vector. 
 
2.2.13 Modified 3’/5’ RACE 
 
This method was conducted as described by Li et al. (2005). For 5’ RACE, 1 µg RNA 
extracted from nucleocapsid was incubated at 65oC for 5 min, followed by RT reaction to 
synthesize cDNA. The reaction was conducted in 20 µl volume containing 20 pmol virus 
specific (VSP) forward-1, 5 U AMV reverse transcriptase enzyme, 1x RT buffer (50 mM 
Tris-HCl; 75 mM KCl; 10 mM MgCl2), 20 U of RNasin and 0.2 mM of dNTPs (Promega). 
The reaction mixture was incubated at 42oC for 60 min, followed by inactivation at 85oC 
for 5 min and treatment with 2 U of RNaseH (Invitrogen) at 37oC for 30 min. After 
purification using the QIAquick PCR purification kit (Qiagen), the cDNA was ligated with 
a 3’ end cordecypin-blocked adapter DT88 using T4 RNA ligase (Promega). The resulting 
adapter-ligated cDNA was then amplified using primers DT89, which is complementary to 
primer DT88, and VSP forward-2 primer.  
 
The cDNA amplification was conducted in a 50 µl reaction containing PCR buffer (10 mM 
Tris-HCl; 50 mM KCl; 0.1% Triton X-100), 1.5 mM MgCl2 , 2 U Taq DNA polymerase, 
0.2 mM dNTPs, 20 pmol of each primer and 1 µl of a 1:10 diluted cDNA mix. The PCR 
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was performed for 35 cycles of 94oC for 20 s, 55oC for 20 s and 72oC for 30 s, and a final 7 
min extension at 72oC.  Five µl of the PCR products were electrophoresed on a 1% TBE 
agarose gel. If no band was observed, a secondary PCR was carried out using DT89 and 
VSP forward-3 primer, using essentially similar conditions as the primary PCR, except 
replacing the cDNA template with 1 µl of a 1:100 diluted primary PCR product. 
 
For 3’ RACE, adapter ligation was carried out first before cDNA synthesis as follows: 
1 µg RNA, 20 pmol of DT88, 2 µl of 10x RNA ligase buffer, 20 U of T4 RNA ligase, and 
nuclease-free water to a final volume of 20 µl. The reaction mixtures were mixed and 
incubated at 37oC for 1 h. A 2 µl aliquot was taken out to make cDNA using 20 pmol of 
primer DT89.  RT, PCR and RNase treatment were performed as for 5’ RACE above 
except primer DT89 was used with VSP reverse-1 in primary PCR and VSP reverse-2 in 
secondary PCR.  
 
2.2.14 Rolling circle amplification-RACE (RCA-RACE) 
 
The reaction was conducted as described by Polidoros et al. (2006). Total RNA was 
extracted from nucleocapsids. First strand cDNA was synthesized using 3 µg RNA in a 
reaction containing 20 pmol (VSPF1) for genomic-sense RNA and VSPR1 for 
antigenomic-sense RNA, 0.2 mM dNTPs, 10 mM DTT, 1x RT buffer,  and 200 U Moloney 
murine leukaemia virus (MMLV) reverse transcriptase (Promega). The reaction was 
incubated at 42oC for 1 h, followed by enzyme inactivation at 70oC for 15 min. After the 
RNaseH treatment, the reaction was purified using QIAquick PCR purification kit 
(Qiagen).  
 
Half of the purified cDNA was then circularised using 100 U CircLigase, 1x reaction 
buffer (Epicentre Biotechnologies), and 50 µM ATP at 60oC for 1 h, followed by 
inactivation of the enzyme at 80oC for 10 min and purification using the QIAquick PCR 
purification kit (Qiagen). 
 
RCA reactions were performed in 50 µl volume containing a 10 µl aliquot of the 
circularised cDNA, 1 mM dNTPs, 200 µg/ml BSA, 1x Ф29 DNA polymerase reaction 
buffer (New England Biolabs), 10 U Ф29 DNA polymerase, and 10 µM random hexamers 
modified by the addition of phosphothioate linkages on the 3’ end to make primer resistant 
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to the Ф29 exonuclease activity. Control reaction containing all reagents except Ф29 DNA 
polymerase was also performed. The reaction was incubated at 30oC for 21 h followed by 
heat inactivation at 60oC for 10 min. 
 
 0.5 µl of neat and 10-1 dilution of RCA mixture were then used as a template in inverse 
PCR amplification. The PCR was performed as above but using primers VSPF2 for 
genomic RNA or VSPR2 for antigenomic RNA, and InvR. The cycling parameters for 
PCR were 94oC for 3 min, followed by 35 cycles of 94oC for 30 s, 56oC for 45 s and 72oC 
for 1.5 min, and a final extension step at 72oC for 10 min. 
 
2.2.15 Cloning  
 
2.2.15.1  Ligation 
 
The PCR product was eluted and purified using QIAquick gel extraction kit following the 
procedures recommended by the manufacturer (Qiagen). The DNA was cloned into 
pGEMT easy vector. Ligation was performed in 12 µl reaction mixtures containing 4 µl of 
fresh PCR product (less than 2 days), 6 µl 2x ligation buffer, 1 µl of vector DNA and 1 µl 
(2 U) of T4 DNA ligase. The ligation mixture was incubated at 4oC overnight or 37oC for 1 
h.  
 
2.2.15.2  Preparation of competent E. coli cells 
 
One colony of E.coli JM109 or DH5α was inoculated into 10 ml LB broth without 
ampicillin and incubated overnight at 37oC with shaking. One ml of the culture broth was 
then subcultured into 100 ml LB broth and incubated with shaking for 2 h at 37oC. The 
culture was centrifuged at 3,000 rpm for 5 min and the bacterial pellet was resuspended in 
2 ml TSB with 5% DMSO and was stored at 4oC for up to 2 days. 
 
2.2.15.3  Transformation 
 
The ligation mixtures were briefly spun down and placed on ice. Five µl of ligation 
mixture were added to 200 µl of competent cells and gently mixed by flicking the side of 
the tube. The tube was incubated on ice for 30 min and 800 µl of the TSB glucose with 5% 
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DMSO were added to the tube. The mixture was then incubated at 37oC for 1 h and 
centrifuged for 1 min at 6,000 rpm. Eight hundred µl of the medium were removed and the 
remaining 200 µl were used to resuspend the bacteria pellet. The bacterial suspension was 
then spread onto LB agar plates containing ampicillin (50 µg/ml), IPTG (0.1 mM) and X-
gal (20 µg/ml), and incubated at 37oC overnight. White colonies most probably contain the 
inserts were selected for plasmid preparation. 
 
2.2.15.4  Plasmid preparation 
 
Small scale plasmid preparation was carried out using Qiagen spin miniprep kit according 
to the manufacturer’s protocol. The plasmid DNA was extracted from 3 ml of bacterial 
culture grown overnight in LB broth containing 50 µg/ml ampicillin. 
 
2.2.15.5  Restriction endonuclease digestion of plasmid DNA 
 
Three µl of the small scale plasmid preparation were digested with the restriction enzyme 
in a 10 µl reaction containing 1 µl 10x reaction buffer, 5-10 U restriction enzyme and 
distilled water to a final volume of 10 µl. The reaction was incubated at the appropriate 
temperature for 1-2 h. Two µl of loading dye was added to the digestion mixture and 
electrophoresed on 1% agarose gel containing ethidium bromide. The gel was then 
visualised on a UV transluminator. 
 
2.2.16 Sequences analysis and alignments 
 
Automated DNA sequence determination was performed by University of Dundee. Three 
independent plasmids containing the expected insert were sequenced in both directions 
using M13F and M13R primers.  
 
The sequences were analysed using Bioedit software and Sequence Navigator of the ABI 
system, and aligned using the ClustalX (NCBI) and ClustalW program (EMBL-EBL). 
Phylogenetic analyses were generated by Neighbor-joining (NJ) (Saitou and Nei, 1987) 
and Maximum Parsimony (MP) analysis methods, implemented with the Mega 2.1 
software packages (Kumar et al., 2000). 
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Accession numbers of the S segment sequences used are as follows:  
Bunyamwera serogroup viruses; Maguari (P16606), Cache Valley (CAA51845),  Main 
Drain (CAA51853), Kairi (CAA51849), Batai (CAA51843), Guaroa (CAA51847), 
Bunyamwera (AAL37356). 
 
California serogroup viruses; California encephalitis(AAC54051),  Jameston Canyon 
(AAC54049), Keystone (AAC54053), La Crosse (P04873), Tahyna (CAA92805), 
Trivittatus (U12803), Melao (U12802), Snowshoe hare (J02390), Lumbo (X73468).  
Group C serogroup viruses; Caraparu BeAn3994 (ABA54067), Itaqui BeAn12797 
(ABA54073),Vinces  75V-807(ABA54087), Murutucu BeAn 974(ABA54065), Restan 
TRVL 51144(ABA54083), Marituba BeAn 15 (ABA 54069), Nepuyo TRVL 18462 (ABA 
54071), Gumbo Limbo FE-371H (ABA 54081), Madrid BT 4075 (ABA 54085). 
 
Simbu serogroup viruses; Oropouche (AAU29359), Aino (P12414), Akabane 
(BAE98058), Tinaroo (AB000819), Yaba-7 (AF362392), Douglas (AF362393), 
Sabo(AF362396), Buttonwillow (AF362398), Mermet (AF362399), Peaton (AF362401), 
Sathuperi (AF362403), Shuni (AF362405), Facey’s Paddock (AF362400), Ingwavuma 
(AF362395). 
 
Accession numbers of the M segment sequences used are as follows:  
Bunyamwera virus (NC001926), La Crosse virus (U18979) and Oropouche virus 
(NC005775) 
 
Accession numbers of the L segment sequences used are as follows:  
Bunyamwera virus (NC001925), La Crosse virus (AF525489) and Oropouche virus 
(AF484424) 
 
2.2.17 In vitro Transcription and Translation (TnT) assay 
 
2.2.17.1 Transcription of T7 transcription plasmid 
 
The full length S segment cDNAs from the pGEMT easy vector were amplified using 
forward primer 5’ Xba/BUN S+ and reverse primer 5’Kpn/BUN S-. The PCR products 
were then digested with Kpn I and Xba I, excised from the gel and ligated to the 
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pBluescript2 SK+ vector (previously cut with Xba I and Kpn I, and treated with CIP to 
remove the 5’ phosphate from the vector). The ligation mixture was transformed into 
E.coli JM109. The plasmid was extracted using the miniprep kit column and the insert was 
checked by restriction enzymes, followed by checking the orientation by sequencing. 
Plasmids containing inserts in the correct orientation were then linearised by digestion with 
Kpn I and were used in the TnT reaction. 
 
 
2.2.17.2             Transcription and Translation reaction.  
 
The TnT system was used to express proteins from plasmid in vitro. Reactions were 
performed according to the manufacturer’s condition.  A 25 µl reaction volume was used 
which containing 12.5 µl TnT rabbit reticulocyte lysate or wheat germ lysate; 1 µl TnT 
reaction buffer; 0.5 µl (10 U) T7 RNA polymerase; 0.5 µl (1 µM) amino acid mixture, 
minus methionine; 0.5 µl (10 U) RNAsin; 1 µl (10 µCi) [35S] Methionine; 1 µg plasmid 
with insert, and top up to final volume with nuclease-free water.  
      
The reaction was incubated at 30oC for 90 min and 13 µl of the reaction were analysed by 
electrophoresis in NUPAGE 6-12% gradient Pre-cast polyacrylamide gel. 
 
2.2.18 Interferon assay 
 
2.2.18.1  IFN reporter gene assays 
 
2.2.18.1.1 Dual Renilla luciferase assay system 
 
1 µg of the IFN-ß reporter plasmid pIF∆(-125) lucter and 0.1 µg/µl of control plasmid 
pRL-SV 40 or phRL-CMV diluted with 200 µl OptiMEM were added slowly to 200 µl 
OptiMEM containing 3 µl Lipofectamine 2000 preincubated at room temperature for 5 
min. The mixture was then incubated at room temperature for 20 min and 400 µl of the 
mixtures were added slowly to a confluent monolayer A549 cells. The cells were then 
incubated for at least 4 h at 37oC with gentle shaking for every 30 min. The OptiMEM was 
removed and the cells were infected with 1 PFU/cell virus. After incubating for 1 h at 
37oC, 2 ml of growth medium was added to the cells and further incubated for 18 h at 
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37oC. Luciferase assays were performed using the dual Renilla Luciferase Assay System 
purchased from Promega. Briefly, the cells in 35-mm diameter dishes were lysed by 
removing the culture medium, washing the monolayer once with PBS, adding 200 µl 1x 
Passive lysis buffer (PLB) and incubating on an orbital shaker for 15 min at room 
temperature. The lysate was collected into 1.5 ml tube and cell debris was pelleted by brief 
centrifugation.  20 µl of the cell lysate was added to 100 µl of Luciferase Assay Reagent 
(LAR) 11 solution and the luminosity of the firefly and Renilla luciferase activities in the 
sample was read using a luminometer. One hundred µl of Stop & Glo reagent was added in 
between the two readings. If the reading of luciferase activity was too high (>9999), the 
lysates were further diluted with 1x PLB. The firefly luciferase activities were normalised 
to the corresponding Renilla luciferase activities to determine the level of IFN induction. 
 
2.2.18.1.2 IFN-specific RT-PCR 
 
Confluent 293 cells were infected with 1 PFU/cell virus for 18 h and total infected cell 
RNA was extracted using TRIzol reagent. A two step RT-PCR was used in this 
experiment. Prior to the RT reaction, 1 µg of RNA was first treated with 2 U DNase I 
(Promega) by incubating at 37oC for 30 min, followed by enzyme inactivation at 65oC for 
10 min. The RNA was then reverse-transcribed to cDNA in a 20 µl reaction containing 100 
ng of random hexanucleotides (Amersham), 5 U AMV reverse transcriptase enzyme, RT 
buffer (50 mM Tris-HCl; 75 mM KCl; 10 mM MgCl2), 20 U RNasin and 0.2 mM of 
dNTPs. The mixture was incubated at 42oC for 1 h, followed by 65oC for 10 min. 
 
The resulting cDNA was amplified in 50 µl reaction volume containing PCR buffer (10 
mM Tris-HCl; 50 mM KCl; 0.1% Triton X-100), 1.5 mM MgCl2 , 2 U Taq DNA 
polymerase, 0.2 mM dNTPs and 20 pmol forward and reverse primers. The primers used to 
amplify IFN-β mRNA were IFN-βF and IFN-βR primers, and human γ-actin F and human 
γ-actin R for human γ-actin mRNA (Spiegel et al., 2005). The PCR was performed for 35 
cycles consisting of 94oC for 45 s, 58oC for 45 s and 72o C for 1min. Five µl of the PCR 
products were electrophoresed on a 1% TBE agarose gel. 
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2.2.19 Shutoff of host cell protein synthesis in virus-infected cells  
 
2.2.19.1 In vivo protein labeling at different time points  
 
This experiment was conducted as described previously (Section 2.2.6), except that Vero-
infected cells were labelled with 30 µCi [35S] methionine at 12 and 24 h, and 36 h pi for 
cell-infected with ANAV, TCMV, ANBV, BORV, TETEV and BMAV. After labelling the 
cells for 2 h at 37oC, the medium were removed, washed once with cold PBS and 200 µl 
protein dissociation mix was added. 15 µl of the cell lysate were analysed by SDS-PAGE. 
 
For ANAV, TCMV, ANBV, BORV, TETEV and BMAV infected cells, the cell lysate was 
analysed by electrophoresis in NUPAGE 6-12% gradient pre-cast polyacrylamide gel. 
 
2.2.19.2 Luciferase expressing plasmid based assay 
 
 0.1 µg control plasmid pRL-SV 40 or phRL-CMV was transfected into subconfluent 
BHK-21 or C6/36 cells respectively, using 3 µl of Lipofectamine 2000 diluted in 400 µl of 
OptiMEM. The cells were incubated for at least 5 h at 37oC with gentle shaking every 30 
min. The OptiMEM was removed and the cells were infected with 1 PFU/cell virus, 
incubated for 1 h at 37oC, and then 2 ml of growth medium was added. The cells were 
incubated for another 18 h at 37oC. The cells were then washed once with PBS, 200 µl 1x 
PLB was added to the cells, and further incubated for 15 min at room temperature with 
shaking. Twenty µl of the lysate was added to 100 µl of LAR 11 solution and the 
luminosity of the firefly and Renilla luciferase activities of the sample was then taken 
using the luminometer. 
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3 Characterization of Viral Growth and Protein Profiles 
 
 
3.1 Introduction 
 
Viruses in family Bunyaviridae are divided into genus and serogroup based on their 
serological relationships, and morphological and biochemical characteristics (Elliott, 
1990). Biochemical analyses of representatives of 10 serogroups viruses of genus 
Orthobunyavirus: Anopheles A, Anopheles B, Bunyamwera, California, Capim, Group C, 
Guama, Patois, Simbu and Turlock serogroups revealed that the  molecular weight of their 
proteins are estimated to be 259 kDa for L, 108-120 kDa for Gc, 29-41 kDa for Gn and 15-
18 kDa for NSm, 19-25 kDa for N and 10-13 kDa for NSs (Gentsch et al., 1977; White, 
1975; Klimas et al., 1981; McPhee and Westaway, 1981; Ushijima et al., 1980; Ushijima et 
al., 1981; Short et al., 1982; Elliott, 1985; McPhee and Della-Porta, 1988). To date, no 
biochemical data on Bakau, Bwamba, Koongol, Gamboa, Minatitlan, Nyando, Olifantsvlei 
and Tete serogroup viruses are available.  
 
Shutoff of host cell RNA and protein synthesis during the infection of orthobunyaviruses 
in the mammalian cells have been reported before (Pennington et al., 1977; Lazdins and 
Holmes, 1979; McPhee and Westaway, 1981; Short et al., 1982; McPhee and Della-Porta, 
1988; Frugulhetti and Rebello, 1989; Bridgen et al., 2001; Blakqori et al., 2005). The NSs 
protein of BUNV and LACV were shown to be responsible in causing this shutoff 
(Bridgen et al., 2001; Blakqori et al., 2005). 
 
This study was undertaken with the aims to grow the viruses in different cell culture 
systems (Vero-E6, BHK-21 and LLCMK2), to determine the pattern of viral proteins 
synthesized in infected cells, and to investigate the ability of the virus to cause shutoff of 
host protein synthesis in infected cells.  
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3.2 Results 
 
3.2.1 Virus propagation 
 
Most of the viruses received were as freeze dried, infected mouse brain homogenates 
(Table 2.2). Therefore the viruses had first to be reconstituted and then attempts were made 
to grow them in different cell lines until a good cpe was observed. For some of the viruses 
(BAKV, KETV, ACAV, PGAV, SJ2441V, KOOV, WONV, MNTV, PLSV, OLIV, 
PAHV, PATV, MPOV and TURV), longer adaptation to the cell culture systems (more 
than 5 passages) were needed. These could have been due to the low viability of the frozen 
stock of the viruses. Once they were adapted, growth occurred more rapidly with earlier 
appearance of cpe. Using the cell culture systems (Vero-E6, BHK-21 and LLCMK2), I 
managed to grow 27 of the 28 viruses received. I was unable to grow BOTV from the 
Olifantsvlei serogroup. An attempt to grow this virus in mosquito Aedes albopictus 
(C6/36) cells was also unsuccessful. There were also difficulties in obtaining high virus 
titers (more than 106 PFU/ml) for some viruses (ANAV, ANBV, BORV, TETEV, BMAV, 
SJ2441V, PGAV and KETV). Therefore I decided to use low moi of virus (1 PFU/cell) for 
all my experiments as it was not possible to do high moi (5 PFU/cell) with these stocks to 
allow synchronous infection of all cells. The results of the virus propagation studies are 
summarised in Table 3.1. Some of the viruses were plaque purified in Vero-E6 cells. The 
titers of the virus stocks obtained using Vero-E6 cells are also recorded. 
 
3.2.2 Plaque morphologies produced by the viruses  
 
This assay was performed to examine the size of plaque produced by the different viruses 
in Vero-E6 cells. All the viruses used in this study produced cpe in this cell line (Table 
3.1), thus, plaque production in these cells was also expected. In general, viruses in the 
same serogroup were found to produce almost similar sizes of plaques. Although some of 
the viruses were plaque purified, mixed sizes of plaques were still observed in Vero-E6 
cells. With the exception of TCMV, most of the viruses isolated from human (BWAV, 
PGAV, GMAV and NDV) and primate (BAKV) were found to produce clear plaques that 
were either medium or large in size (Figure 3.1 and Table 3.2).  However some viruses 
such as KOOV, WONV, BERV and KETV, which were isolated from mosquitoes, also 
produced large sized plaques. The plaque assay results are summarised in Table 3.2. 
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CELL 
 
SEROGROUP VIRUS 
Vero-E6 
 
BHK-21 LLCMK2 
VIRUS 
TITER IN 
VERO 
CELLS 
PFU/ml  
Ana A 
(ANAV) 
cpe (P3) cpe (P3) cpe (P3) 1.0 x 106 1. Anopheles A 
Tacauima  
(TCMV) 
cpe (P3) cpe (P3) cpe (P3) 2.0 x 106 
Ana B 
(ANBV) 
cpe (P3) cpe (P3) cpe (P3) 1.0 x 106 2.Anopheles B 
Boraceia 
(BORV) 
cpe (P3) cpe (P3) cpe (P3) 1.0 x 106 
Bakau 
(BAKV) 
cpe (P5) cpe (P5) cpe (P5) 4.5 x 106 3.Bakau 
Ketapang 
(KETV) 
cpe (P5) cpe (P5) cpe (P5) 4.0 x 105 
Bwamba 
(BWAV) 
cpe (P3) cpe (P3) cpe (P3) 1.0 x 107 4.Bwamba 
Pangola 
(PGAV) 
cpe (P7) cpe (P7) cpe (P7) 1.0 x 105 
Acara 
(ACAV) 
cpe (P5) cpe (P5) cpe (P5) 5.0 x 106 5.Capim 
Capim 
(CAPV) 
cpe (P4) cpe (P4) cpe (P4) 3.5 x 106 
Gamboa 
(GAMV) 
cpe (P3) cpe (P3) cpe (P3) 3.0 x 106 6.Gamboa 
San Juan 
(SJ2441V) 
cpe (P5) cpe (P5) cpe (P5) 1.0 x 105 
Bertioga 
(BERV) 
cpe (P3) cpe (P3) cpe (P3) 1.0 x 107 7.Guama 
Guama 
(GMAV) 
cpe (P3) cpe (P3) cpe (P3) 6.5 x 107 
Koongol 
(KOOV)  
cpe (P5) cpe (P5) cpe (P5) 4.0 x 107 8.Koongol 
Wongol 
(WONV) 
cpe (P5) cpe (P5) cpe (P5) 6.0 x 106 
Minatitlan 
(MNTV) 
cpe (P5) cpe (P5) cpe (P5) 2.0 x 106 9. Minatitlan  
Palestina 
(PLSV) 
cpe (P5) cpe (P5) cpe (P5) 1.5 x 107 
Eretmapodites 
(E147V) 
cpe (P3) cpe (P3) cpe (P3) 5.0 x 106 10.Nyando 
Nyando 
(NDVV) 
cpe (P3) cpe (P3) cpe (P3) 2.0 x 107 
Botambi  
(BOTV) 
No cpe 
(>P10) 
No cpe 
(>P10) 
No cpe 
(>P10) 
ND 11. Olifantsvlei 
Olifantsvlei 
(OLIV) 
cpe (P5) cpe (P5) cpe (P5) 7.0 x 107 
Pahayokee  
(PAHV) 
cpe (P5) cpe (P5) cpe (P5) 6.5 x 106 12.Patois 
Patois 
(PATV) 
cpe (P5) cpe (P5) cpe (P5) 6.5 x 106 
Batama     
(BMAV) 
cpe (P3) cpe (P3) cpe (P3) 1.0 x 106 13.Tete 
Tete 
(TETEV) 
cpe (P3) Cpe (P3) cpe (P3) 2.0 x 106 
M’Poko  
(MPOV) 
cpe (P5) cpe (P5) cpe (P5) 2.0 x 107 14.Turlock 
Turlock 
(TURV) 
cpe (P5) cpe (P5) cpe (P5) 1.0 x 107 
Table 3.1 Propagation of the virus in Vero-E6, BHK-21 and LLCMK2 cells. P  indicates 
passage level; cpe indicates cytopathic effect;  ND indicates not done and > indicates more 
than. 
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BUNV      BUNdelNSs    
 
 
 
 
 
ANAV      TCMV 
 
 
Fig.3.1 Plaques formed by the viruses in infected Vero cells after 6 days pi. The 
plaques were fixed for more than 3 h with 4% formaldehyde solution and 
stained with Giemsa solution for 5-10 min. 
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VIRUSES SEROGROUP PLAQUE 
SIZE 
PLAQUE 
TYPE 
HOST 
ASSOCIATION 
PLAQUE  
CLONED 
IN VERO CELLS  
Ana A 
(ANAV) 
Small Turbid NR Yes 1. Anopheles A 
Tacauima  
(TCMV) 
 
Small Turbid Human, 
Primate 
Yes 
Ana B 
(ANBV) 
Small Turbid NR Yes 2.Anopheles B 
Boraceia 
(BORV) 
Small Turbid NR Yes 
Bakau 
(BAKV) 
Medium 
and Large 
Clear Primate No 3.Bakau 
Ketapang 
(KETV) 
Medium Clear NR No 
Bwamba 
(BWAV) 
Small, 
Medium 
and Large 
Clear Human Yes 4.Bwamba 
Pangola 
(PGAV) 
Large Clear Human Yes 
Acara 
(ACAV) 
Medium Clear Rodent No 5.Capim 
Capim 
(CAPV) 
Medium 
and large 
Turbid Rodent No 
Gamboa 
(GAMV) 
Large Turbid NR Yes 6.Gamboa 
San Juan 
(SJ2441V) 
Medium 
and Large 
Turbid NR Yes 
Bertioga 
(BERV) 
Small, 
Medium 
and Large 
Clear NR No 7.Guama 
Guama 
(GMAV) 
Small, 
medium  
and Large 
Clear Human No 
Koongol 
(KOOV) 
Large Clear NR No 8.Koongol 
Wongol 
(WONV) 
Large Clear NR No 
Minatitlan 
(MNT) 
Small and 
medium 
Turbid NR No 9. Minatitlan 
Palestina 
 (PLSV) 
Small and 
Medium 
Turbid NR No 
Eretmapodites 
(E147V) 
Medium Turbid NR Yes 10.Nyando 
Nyando 
(NDVV) 
Medium 
and Large 
Clear Human Yes 
Botambi 
(BOTV) 
ND ND NR ND 11.Olifantsvlei 
Olifantsvlei 
(OLIV) 
Medium Turbid NR No 
Pahayokee 
(PAHV) 
Medium Turbid Rodent Yes 12.Patois 
Patois 
(PATV) 
Medium Turbid Rodent Yes 
Batama     
(BMAV) 
Medium Turbid Bird Yes 13.Tete 
Tete 
(TETE) 
Medium Turbid Bird Yes 
M’Poko 
(MPOV) 
Medium 
and Large 
Clear NR Yes 14. Turlock 
Turlock 
(TURV) 
Medium Clear Bird Yes 
 
Table 3.2 Summary of the plaques produced by the viruses in infected Vero cells. ND 
represents not done; NR represents not reported. Plaque sizes; big (3-5 mm), medium (2-4 
mm) and small (<2 mm). 
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3.2.3 In vivo protein labeling in Vero-E6 cells 
 
To analyse the proteins synthesized by the viruses, Vero-E6 cells were infected with 1 
PFU/cell of each virus, and labeled with [35S] methionine at 12, 24 and up to 36 h pi for 
ANAV, TCMV, ANBV, BORV, TETEV and BMAV. The cell lysates were analysed by 
SDS PAGE.  Analysis of the gels (Figure 3.2) revealed that all the viruses had a typical 
orthobunyavirus protein profile, with L, Gc and N easily identified; the Gn, NSm and NSs 
protein were only clearly observed for some of the viruses. However in cells infected with 
BMAV, TETEV, PLSV, MNTV and PGAV, L and Gc proteins were not clearly observed, 
where lack of shutoff prevented identification of these proteins. The N protein was the 
most abundant protein observed in virus infected cells. Different sizes of N protein were 
observed, for instance, E147V, PGAV, OLIV, KOOV, PATV, PAHV, TURV, KETV, 
GMAV and NDV have N protein similar in size to BUNV (22 kDa), ANAV, TCMV, 
ANBV, BORV, TETEV, BMAV, PLSV, MNTV, ACAV, CAPV, BWAV, MPOV, 
BAKV, BERV, GAMV and SJ2441V were found to have N protein larger than that of 
BUNV, with the largest N protein observed in TETEV and BMAV (26 kDa), while 
WONV has the smallest N protein among the studied viruses (20 kDa) (Table 3.3). Not 
much variation in the size of L protein was seen, Gc protein showed more variation in size 
with the smallest in KOOV, GAMV, SJ2441-infected cells (<110 kDa). The presence of 
different sizes of NSm and NSs were also observed in some of the infected cells profiles. 
The suspected NSs protein bands were only observed in cells infected with ACAV, BERV, 
E147V, WONV, PATV, PAHV, SJ2441V, TURV, NDV, KETV, GAMV, GMAV and 
BUNV with the largest NSs protein observed in GAMV and SJ2441V-infected cells (14 
kDa). A strange protein profile was observed in cells infected with ACAV, this could be 
due to the presence of mixed viruses in this extract since it was not from the plaque 
purified culture. A number of protein bands were also observed in some of the virus 
infected extracts but not in mock-infected cells. It is unclear whether they are virus or host-
coded proteins.  
 
3.2.4 Shutoff of host protein synthesis 
 
Previously, BUNV was shown capable of producing shutoff of host protein synthesis in 
infected Vero cells, but not with its mutant virus that lacks the NSs protein, BUNdelNSs 
(Bridgen et al., 2001). Inspection of the gels in Figure 3.2 show that after 24 h pi, shutoff  
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+  
 
 
 
 
 
       
 
Fig. 3.2 Viral protein synthesis and shutoff of host protein synthesis of the viruses in 
infected Vero-E6 cells. The cells were infected with 1 PFU/cell virus, 
labelled at 12, 24  and up to 36 h pi for ANAV, TCMV, ANBV, BORV, 
TETEV and BMAV using 30 µCi [35S] methionine and analysed by (A) 
NUPAGE 6-12 % gradient gel (Invitrogen) and (B) 15 % polyacrylamide 
gel electrophoresis. Blue arrows indicate unknown protein bands that were 
not observed in mock-infected cells. Position of molecular weight standards 
are indicated at the right. 
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PROTEIN SIZE VIRUSES SEROGROUP 
L 
kDa 
Gc 
kDa 
Gn 
kDa 
N 
kDa 
NSm 
kDa 
NSs 
kDa 
LEVEL OF 
SHUTOFF 
Ana A 
(ANAV) 
259 110 32 24 NO NO ++ 1. Anopheles A 
Tacauima  
(TCMV) 
>259 110 32 23 NO NO ++ 
Ana B 
(ANBV) 
>259 110 32 24 NO NO ++ 2.Anopheles B 
Boraceia 
(BORV) 
259 110 32 24 18 NO ++ 
Bakau 
(BAKV) 
259 110 32 23 18 NO +++ 3.Bakau 
Ketapang 
(KETV) 
259 110 32 22 18 11 - 
Bwamba 
(BWAV) 
259 110 NO 23 18 NO +++ 4.Bwamba 
Pangola 
(PGAV) 
NO NO NO 22 18 NO - 
Acara 
(ACAV) 
259 110 28 23 17 12 ++ 5.Capim 
Capim 
(CAPV) 
259 110 NO 23 18 NO +++ 
Gamboa 
(GAMV) 
259 <110 32 23 18 14 ++ 6.Gamboa 
San Juan 
(SJ2441V) 
259 <110 NO 23 18 14 ++ 
Bertioga 
(BERV) 
259 110 32 23 18 11 ++ 7.Guama 
Guama 
(GMAV) 
259 110 32 22 18 11 ++ 
Koongol 
(KOOV) 
259 <110 NO 22 18 NO ++ 8.Koongol 
Wongol 
(WONV) 
259 110 30 20 17 13  +++ 
Minatitlan 
(MNT) 
NO NO NO 23 17 NO - 9. Minatitlan 
Palestina 
 (PLSV) 
NO NO NO 23 18 NO - 
Eretmapodites 
(E147V) 
259 110 NO 22 18 11 ++ 10.Nyando 
Nyando 
(NDVV) 
259 110 32 22 18 11 ++ 
11.Olifantsvlei Olifantsvlei 
(OLIV) 
259 110 NO 22 17 NO ++ 
Pahayokee 
(PAHV) 
259 110 NO 22 18 11 +++ 12.Patois 
Patois 
(PATV) 
259 110 NO 22 18 11 +++ 
Batama     
(BMAV) 
NO NO NO 26 NO NO - 13.Tete 
Tete 
(TETE) 
NO NO NO 26 NO NO - 
M’Poko 
(MPOV) 
259 110 32 23 18 NO ++ 14. Turlock 
Turlock 
(TURV) 
259 110 32 22 18 11 ++ 
Bunyamwera BUNV 259 110 32 22 18 11 +++ 
Table 3.3 Summary of the estimated size of protein synthesized by the viruses and 
shutoff caused by the viruses in infected Vero cells. NO represents not obvious, +++ 
indicates drastic (same as shutoff caused by BUNV), ++ indicates moderate shutoff (same 
as shutoff caused by BUNdelNSs) and – indicates no shutoff.  
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of almost similar as in BUNV-infected cells was seen in cells infected with CAPV, 
BWAV, WONV, PAHV, PATV and BAKV, whereas lesser shutoff similar to BUNdelNSs 
infected cells was observed in cells infected with ACAV, ANAV, TCMV, ANBV, BORV, 
E147V, NDV, OLIV, KOOV, GAMV, SJ2441V, TURV, MPOV, SJ2441V, BERV and 
GMAV. No shutoff was observed in TETEV, BMAV, PLSV, MNTV, PGAV and KETV-
infected cells (Figure 3.2) 
 
 
3.3 Discussion 
 
3.3.1 Virus propagation 
 
Some of the viruses were received as mouse brain homogenate form and had been kept 
frozen for more than 40 years. Furthermore some had not been passaged in cultured 
mammalian cells before (Table 2.2), therefore a problem was encountered in growing and 
getting a good cpe of the viruses in these cells. Some of them needed more than 5 passages 
in different cell types. Since some of the viruses were isolated from mosquito, I also tried 
to grow OLIV, BOTV, SJ2441V and KETV in Aedes albopictus C6/36 cells for at least 3 
passages before propagating them in mammalian cell cultures. All viruses except BOTV 
generated cpe. Perhaps BOTV was already dead since it has been kept frozen for more than 
40 years, or alternatively, was unable to replicate in mammalian cells used. RT-PCR also 
gave a negative result with this virus and therefore it was excluded from further 
experiments. 
 
It was very difficult to produce high titre stocks of some viruses. This problem delayed me 
to do further experiments. To overcome this problem, a few steps were taken including 
pelleting the virus infected supernatant at high speed (26,000 rpm for 2 h) to concentrate 
the virus. However these attempts were unsuccessful. According to Lazdins and Holmes 
(1979), this could be due to the fragility of bunyaviruses, giving rise to great losses during 
concentration of the virus by centrifugation. The other step is growing the virus from the 
isolated plaques. However, this method was also failed for some of the viruses. The 
production of virus defective interfering particles after repeating passage the virus at high 
multiplicity   might also contributed to this failure (Obijeski et al., 1976). 
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3.3.2 Plaque characteristic of the viruses 
 
The plaque-forming properties are used as a marker to distinguish attenuated and virulent 
strains of some viruses such as Rhinovirus (Dougles et al., 1974), Newcastle disease virus 
(Singh et al., 1970) and Measles virus (Matumoto, 1966). Although mutant virus 
BUNdelNSs that lacking the NSs protein has been shown to exhibit a smaller plaque size, 
and less pathogenic in mice compared to wt BUNV (Bridgen et al., 2001), for the other 
orthobunyaviruses, the presence of NSs protein and the pathogenicity of the virus have 
been shown not to correlate with the plaque size. This was as previously reported in MA-
104 embryonic rhesus monkey kidney cells infected with GROV which encodes NSs 
protein in its S segment, two sizes of plaques were produced in the infected cells and both 
were found to have same pathogenicity in suckling mice (Tauraso, 1969). This confirms 
that the size of the plaque is not always correlated with the presence of NSs protein and the 
virulence of the virus. Mixed sizes of plaques were also observed with some of the viruses 
used in this study.  
 
3.3.3 Protein synthesis in virus infected cells 
 
Analysis of protein profiles revealed that all the viruses used in this study have proteins of 
almost similar migration pattern to those of other viruses in the Orthobunyavirus genus. 
Therefore these results support the serological classifications, which include the viruses in 
Orthobunyavirus genus. In this study, NSs protein was only detected in certain viruses. 
Most probably that these viruses do not have NSs protein in their S segment, the protein is 
too short or too little to be detected by SDS-PAGE.  
 
The results obtained with ANAV, CAPV, and BORV were in agreement with the results 
obtained by Ushijima et al (1980) and Klimas et al (1981), where the N proteins were 
found to be bigger than BUNV N protein. A similar result was obtained by Ushijima et al 
(1981) who found the N protein of PAHV was almost similar in size to that of BUNV. The 
result obtained for TURV in Turlock serogroup was found in contrast with the result of 
Klimas et al. (1981), where bigger N protein size was reported (24 kDa) compared to this 
study (22 kDa). Therefore, sequencing of N protein is needed to confirm this result. 
However my study revealed that MPOV, which is also in the Turlock serogroup possess an 
N protein larger than BUNV N protein (23 kDa). 
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In agreement with the previous result by Ushijima et al. (1980), who found that not all of 
the viruses in the same serogroup have the same size of N protein. For example viruses in 
Bwamba (BWAV and PGAV), Bakau (BAKV and KETV), and Koongol (KOOV and 
WONV) serogroups had different sizes of N protein. Considering these, it is not possible to 
group the viruses to the same serogroup based on their protein profiles alone. Therefore, 
serological and sequencing data are needed to support this classification.  
 
3.3.4 Shutoff of host protein synthesis 
 
BUNV and LACV have been shown to cause a drastic shutoff of host protein synthesis in 
infected BHK and Vero cells (Lazdins and Holmes, 1979; McPhee and Westaway, 1981; 
Short et al., 1982; Bridgen et al., 2001; Blakqori et al., 2004) but it depends on multiplicity 
of infection of the virus (Lazdins and Holmes, 1979). However, no shutoff was observed in 
Vero cells infected with Uukuniemi virus in the Phlebovirus genus (Pattersson, 1974), in 
hantavirus infected cells (Elliott et al., 1984) nor in some nairovirus-infected cells (Watret 
et al., 1985).  My study revealed that no shutoff was observed in cells infected with 
TETEV, BMAV, PLSV, MNTV, PGAV and KETV. It is a possible that these viruses 
replicated more slowly and might need longer time to cause shutoff of host protein 
synthesis. It has been shown previously that a mutant virus of BUNV, BUNdelNSs which 
is lacking the NSs protein, caused shutoff later than BUNV (Bridgen et al., 2001). No NSs 
protein band was observed in the cells infected with TETEV, BMAV, PLSV, MNTV, 
PGAV and KETV, leading to a preliminary conclusion that these viruses are similar to 
BUNdelNSs and do not produce an NSs protein. However these speculations needed to be 
confirmed by the sequencing results. Some shutoff was still observed in cells infected with 
BUNdelNSs, suggesting that beside the presence of NSs protein, other factor such as cap-
snatching process by L protein might also plays a role in causing this shutoff. However the 
shutoff caused by this process is minimal compared to the shutoff caused by NSs protein 
(Hart, 2004). Besides that, shutoff also depends on the multiplicity of infection, where the 
shutoff caused by 10 PFU/cell virus was found to be less than the shutoff caused by 1 
PFU/cell virus due to the presence of autointerference (McPhee and Westaway, 1981). 
 
 
 
 108 
4 Sequence Analysis of the S RNA Segments of 
Orthobunyaviruses 
 
 
4.1.1 Introduction 
 
As discussed in Chapter 1, the genus Orthobunyavirus contains more than 170 viruses that 
are classified serologically into 18 serogroups (Calisher, 1991). To-date, molecular data 
and full length sequences are only available for viruses in 4 serogroups: Bunyamwera, 
California, Group C and Simbu. Thus, sequences of viruses in the other serogroups are 
needed to give us a fuller understanding of their phylogenetic relationships and a greater 
insight into their evolutions. Therefore, in this chapter, I aimed to sequence the S RNA 
segments of representatives of the other 14 serogroups with a view to rationalise their 
classification and to understand their evolutionary relationships.  
 
 
4.2 Results 
 
4.2.1 RT-PCR, cloning and sequencing of the S segments  
 
Twenty seven viruses which represent 14 serogroups viruses were grown up as listed in 
Table 2.2. Due to the unavailability of a viable isolate, BOTV was excluded from this 
study. RT-PCR, 3’/5’ rapid amplification cDNA ends (RACE), modified RACE, Rolling 
Circle cDNA Amplification (RCA)-RACE and cloning were conducted as described in the 
“Materials and Methods” section. The sequences of the primers used are as listed in Table 
2.1. The steps and primers used to get the sequence of each virus S segment are 
summarised in Table 4.1.  
 
To synthesize S segment cDNA, RNA extracted either from virus infected cells or from 
nucleocapsid RNA was used for RACE, and the RNAs extracted from virions were used 
for RT-PCR. Initially, primers BUN S+/S- (Dunn et al., 1994) based on the 15 terminal 
nucleotides of the published S segment sequences of Bunyamwera, California, Group C 
and Simbu serogroups viruses were used to amplify cDNA. These primers were thought to 
be conserved in all orthobunyaviruses. However, only complete S segment sequences of  
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SEROGROUP VIRUS PRIMER PRODUCT 
SIZE  (bp) 
FINAL 
PRODUCT (bp) 
Ana A 
 (ANAV) 
BUN S+/BUNCAL2 
S25F/S13- 
884 
947  
947 
(Complete) 
Anopheles  
 A 
Tacaiuma 
(TCMV) 
BUN S+/BUNCAL2 
S25F /S13- 
910 
960  
960 
(Complete) 
Ana B 
 (ANBV) 
BUN S+/BUNCAL2 
S13+/ORO2S 
884 
991 
991 
(Complete) 
Anopheles  
B 
Boraceia 
(BORV) 
BUN S+/ BUNCAL2 
S13+/ORO2S 
909 
982  
982 
(Complete) 
Bakau 
(BAKV) 
NP NP NP Bakau 
Ketapang 
(KETV) 
NP NP NP 
Bwamba 
(BWAV) 
BUN S+/BUN S- 
BWAPR/ORO2S 
868 
578 
1096 
(Complete) 
Bwamba 
Pangola 
(PGAV) 
NP NP NP 
Acara 
(ACAV) 
NP NP NP Capim 
Capim 
(CAPV) 
S400R/PGTR 
CAPPF/CAPPF 
CAPPF/CAPPR on 
ligated RNA  
357 
545 
235 
991 
(Partial) 
Gamboa 
(GAMV) 
BUN S+/BUNCAL2 
 
1170  1170 
(Partial) 
Gamboa 
San Juan 
(SJ2441V) 
BUN S+/BUNCAL2 
SJPF/S13- 
1179 
498 
1250 
(Complete) 
Bertioga 
(BERV) 
S350F/BUNCAL2 
S400F/BERPF/RACE 
OAP and AP  
632 
420 
695 
(Partial) 
Guama 
Guama 
(GMAV) 
S400F/BUNCAL2 
GMAPF/GMAPR on 
ligated RNA 
510 
427 
621 
(Partial) 
Koongol 
(KOOV) 
NP NP NP Koongol 
Wongol 
(WONV) 
NP NP NP 
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Minatitlan 
(MNTV) 
NP NP NP Minatitlan 
Palestina 
(PLSV) 
NIFFF/PGTR 
PLSPF/NNHR on 
Ligated RNA 
305 
543 
662 
(Partial) 
 
Eretmapodites 
(E147V) 
BUN S+/BUN S- 902 902 
(Complete) 
Nyando 
Nyando 
(NDV) 
BUN S+/BUN S- 941 941 
(Complete) 
Olifantsvlei Olifantsvlei 
(OLIV) 
NP NP NP 
Pahayokee 
(PAHV) 
NP NP NP Patois 
Patois 
(PATV) 
S400F/S13- 
PATPR/PATNNHR 
/RACE OAP and 
RACE AP 
501 
286 
768 
(Partial) 
Tete  
(TETEV) 
BUN S+/BUNCAL2 
BUN S+/S13- 
947 
1022 
1022 
(Complete) 
Tete 
Batama 
(BMAV) 
BUN S+/BUNCAL2 
BUN S+/S13- 
944 
1021 
1021 
(Complete) 
M’Poko 
(MPOV) 
BUN S+/BUN S- 
MPO400PR+S13+ 
951 
578 
1075 
(Complete) 
Turlock 
Turlock 
(TURV) 
NP NP NP 
 
Table 4.1 Primers used in the RT-PCR. The sequences and the location of the primers 
were shown in Table 2.1 and Fig. 2.1. F and + stand for forward ; R and – stand for reverse 
; P for partial; bp for base pair; NP stands for no product obtained, RACE for rapid 
amplification cDNA ends, OAP stands for Oligo (dT) anchor primer and AP stands for 
anchor primer. 
 
 
 
 
 
 
 
 111 
viruses in the Nyando serogroup, NDV and E147V, were obtained with these primers. 
Therefore, combinations of published and designed primers for the partial and complete 
sequences were used for the other viruses. Table 4.1 summarised the primers used and 
PCR products obtained using these primers. Besides NDV and E147V, complete sequences 
of the S segment were also obtained for ANAV, TCMV, ANB, BORV, TETEV, BMAV, 
SJ2441V, NDV, E147V, BWAV and MPOV, while partial sequences of CAPV, GAMV, 
PLSV, PATV, BERV and GMAV were obtained. No products were obtained from ACAV, 
BAKV, KETV, MNTV, OLIV, KOOV, PAHV, PGAV, TURV and WONV RNAs.  The 
3’/5’ RACE, modified 3’/5’ RACE, RCA-RACE and RT-PCR on ligated RNA were 
conducted using internal primers that were designed based on the partial sequences 
obtained initially and RACE primers. Even though I failed to get the 3’ and 5’ end 
sequences using these methods, a product shorter than an expected length was obtained. It 
is likely that annealing of RACE primers to the truncated RNA was greater than annealing 
to complete RNA. 
 
The PCR products were cloned into pGEMT easy vector. All the sequences obtained 
represent the consensus from sequencing three independent plasmids containing the insert 
of each S segment, using M13 forward and reverse primers. For 3’/5’ RACE products only 
two clones were available for some of the viruses. Low numbers of nucleotide variations 
(less than 5 nucleotides) were recorded between clones of the same segment. The 
nucleotide present in the majority of the clones was accepted for compiling the consensus 
sequence. Direct sequencing of PCR product was found to produce unsatisfactory 
sequencing results. 
 
4.2.2 ‘Architecture’ of S segment 
 
The nucleotide sequence data obtained were manipulated and analysed using the Lasergene 
program (DNAStar inc). A summary of the sequences is shown in Table 4.2. Similar to 
those of the published viruses, different lengths of S segment were also observed either 
between viruses within the same serogroup or between different serogroups (Fig. 4.1 & 
Table 4.2). SJ2441V in the Gamboa serogroup was found to have the longest S segment to 
date (1250 nucleotides) while the shortest S segment was noted in E147V (902 
nucleotides). However the shortest S segment to date is reported for OROV in the Simbu 
serogroup (754 nucleotides) (Saeed et al., 2001). Similar to previous reports, the S RNAs  
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A. S sequence with NSs protein 
 
 
(i) SJ2441V-complete sequence 
 
 
1         AGTAGTGTACTCCACAGTAAACTATTCATAAAATCTTACAAATCTTTCAAAGTTTTGCAA 
                                            StartN StartNSs 
61        ACCTGGAGGTGCTTTTTGAGAACGACGAAGCAAGATGTCTAATGATCTTTACGTATTCGA 
                                             M  S  N  D  L  Y  V  F  D  
                                                    M  I  F  T  Y  S  
121       CGATGATACGTCGGCAAGCTCTAGCTCTTATGATCCAAAGAGAGAATATGATAAATTTAT 
           D  D  T  S  A  S  S  S  S  Y  D  P  K  R  E  Y  D  K  F  I  
          T  M  I  R  R  Q  A  L  A  L  M  I  Q  R  E  N  M  I  N  L   
181       TAGTACTTACGGGCAGCAACTTACTCCAGCAAACATTAAATGTTTTCTCTTGCATGCACG 
           S  T  Y  G  Q  Q  L  T  P  A  N  I  K  C  F  L  L  H  A  R  
          L  V  L  T  G  S  N  L  L  Q  Q  T  L  N  V  F  S  C  M  H   
241       CACGGCCAAGGCTCGTCTTTCAAAGGACCCGGCGGAACGCAGAACGCTTACTTTTGGAAC 
           T  A  K  A  R  L  S  K  D  P  A  E  R  R  T  L  T  F  G  T  
          A  R  P  R  L  V  F  Q  R  T  R  R  N  A  E  R  L  L  L  E   
301       TTGGAAGGTTGAGGTTGTTAATAACCATTATCGACGAGCCGCTCCAATTACGGTGCAGGA 
           W  K  V  E  V  V  N  N  H  Y  R  R  A  A  P  I  T  V  Q  D  
          L  G  R  L  R  L  L  I  T  I  I  D  E  P  L  Q  L  R  C  R   
361       CCATGATCTTACCTTGCACCGCCTTTCCGGATATATTGCCTTGTACTGTCTGCAGGCCAG 
           H  D  L  T  L  H  R  L  S  G  Y  I  A  L  Y  C  L  Q  A  S  
          T  M  I  L  P  C  T  A  F  P  D  I  L  P  C  T  V  C  R  P  
421       TGTGGAGAATGCGCAGTCTTTCGAGCGAATCAGATCAACAGTCATCAACCCGATCTCTGA 
           V  E  N  A  Q  S  F  E  R  I  R  S  T  V  I  N  P  I  S  E  
          V  W  R  M  R  S  L  S  S  E  S  D  Q  Q  S  S  T  R  S  L   
                                          StopNSs 
481       GTCCATGGGGATCAACTGGCAGCATGGAGCAATGATGTATCTTTCAACCCTACCTGGTGC 
           S  M  G  I  N  W  Q  H  G  A  M  M  Y  L  S  T  L  P  G  A  
          S  P  W  G  S  T  G  S  M  E  Q  *   
541       AGAAATGTTTCTAACAGAGTTCCAGCTTCTCCCACTAGCATTTGCTGTGGTGAGAGTAAA 
           E  M  F  L  T  E  F  Q  L  L  P  L  A  F  A  V  V  R  V  K  
601       AAAGAACCTGGCGAGCCCAGAAACGGTTAAGAAAGTACTAAGACAGAGATATGAGGGCAG 
           K  N  L  A  S  P  E  T  V  K  K  V  L  R  Q  R  Y  E  G  R  
661       ACTTCCGGGAGAATGGATGAACTCAGAGCTGGAAAAGGTCAAAGCTGCAATCACCAGAGT 
           L  P  G  E  W  M  N  S  E  L  E  K  V  K  A  A  I  T  R  V  
721       GGAGTCGTTGCACAAGACTTTTGTCGGAGTGACTGCAAGAATGATTGAGTTCTTCAGTGC 
           E  S  L  H  K  T  F  V  G  V  T  A  R  M  I  E  F  F  S  A  
                                      StopN 
781       TCTAGGCATTAATCTTGATTTGAGAAGATAAGAACCAGATCATTTTTTGAAATGTTTTAA 
            L  G  I  N  L  D  L  R  R  *   
841       TATTTGACAATTTTTATTACTCTTTTAAAACTTTTTGTATATATACTTTTATATTATATT 
901       TTTATCAATATTTAACCAGTGTAACCATATTATCCAGTTAATCCATATATAGGACATATA 
961       TATATTTTTATTAAGATTATATCAATATATATCATATCCAGTAATATGTAACCCATACTA 
1021      TCCTGATTTATCAATTTTTATTATATTATTCCACATCATTTAGTTTTAGCAAAATTTGGT 
1081      AAGGACTAACAATACTAACAATTTTATAGGTAGTTTTAGTACTAACACATTAGACTAGTT 
1141      AGGACCCAAAAGCAGCTGTCAATGGGTGGGTGGTCGGGGCAACTTTGCCAATTTCTTCAA 
1201      ATCATTTTAGTAGATTAAATCAAACGAATGTTTACGTGGAGCACACTACT 
 
  
 
Fig. 4.1 Nucleotide sequences of positive-sense S segments of the viruses.  
*  indicates stop codon for N protein; * stop codon for NSs protein; red bold 
letters represent N protein and green letters represent NSs protein. The 
nucleotides were translated to amino acid using DNAMAN version 4.0 
program (Lynnon Biosoft) 
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(ii)GAMV-incomplete sequences 
 
 
1         AGTAGTGTACTCCACAGTAAACTATTCTTAAAAATACTACAAAGTTTTGCAAACCTGGAG 
                                    StartN                     StartNSs 
61        ATCCTCTTTGAGTCCGACGAAGCAAGATGTCTGACTCTCTATACGTATTTGACGATGATT 
                                                                 M  I   
                                    M  S  D  S  L  Y  V  F  D  D  D  S 
121       CGACGGCAAGCTCTAGCACTTATGATCCAACGCAGGAATACAATGTCTTTATTAGTACTC 
           R  R  Q  A  L  A  L  M  I  Q  R  R  N  T  M  S  L  L  V  L   
            T  A  S  S  S  T  Y  D  P  T  Q  E  Y  N  V  F  I  S  T  H 
181       ACGGGGACCAGCTTACTCCAGCAAACATTAAATGTTTCTTCCTGCATGCACGTACAGCCA 
           T  G  T  S  L  L  Q  Q  T  L  N  V  S  S  C  M  H  V  Q  P   
            G  D  Q  L  T  P  A  N  I  K  C  F  F  L  H  A  R  T  A  K 
241       AGGCTCGTCTGGCAAAGGACCCGGCGGAACGCAGAACGCTTACTTTTGGATCTTGGAAGG 
           R  L  V  W  Q  R  T  R  R  N  A  E  R  L  L  L  D  L  G  R   
            A  R  L  A  K  D  P  A  E  R  R  T  L  T  F  G  S  W  K  V 
301       TTGAGGTTGTTAATAACCATTACAGAAGAGCCACTCCGGTTACAGTGCAGGACCATGATA 
           L  R  L  L  I  T  I  T  E  E  P  L  R  L  Q  C  R  T  M  I   
            E  V  V  N  N  H  Y  R  R  A  T  P  V  T  V  Q  D  H  D  N 
361       ATACCTTGCACCGCATTTCCGGATATCTTGCCCTGTACTGCTTGCAGACCAGCTCCCAGA 
           I  P  C  T  A  F  P  D  I  L  P  C  T  A  C  R  P  A  P  R   
            T  L  H  R  I  S  G  Y  L  A  L  Y  C  L  Q  T  S  S  Q  N 
421       ATAAGCAGAACTTTGAGCGAATCAAGTCAGTCGTCATCAACCCGATCTCTGAGTCCATGG 
           I  S  R  T  L  S  E  S  S  Q  S  S  S  T  R  S  L  S  P  W   
            K  Q  N  F  E  R  I  K  S  V  V  I  N  P  I  S  E  S  M  G 
                                  StopNSs 
481       GGATCAACTGGCAGCATGGAGCAATGATCTATCTGTCTACGCTTCCCGGAGCAGAAATGT 
           G  S  T  G  S  M  E  Q  *   
            I  N  W  Q  H  G  A  M  I  Y  L  S  T  L  P  G  A  E  M  F 
541       TTCTCACTGAGTTTCAGCTGTTCCCACTTGCATTTGCAGTTGTAAGAGTGAAAAAGAACC 
            L  T  E  F  Q  L  F  P  L  A  F  A  V  V  R  V  K  K  N  L 
601       TGGCAAGCCCTGAGACAGTGAAGAAAGTGCTGAGACAGAGATATGACGGCAGATTGCCTG 
            A  S  P  E  T  V  K  K  V  L  R  Q  R  Y  D  G  R  L  P  G 
661       GAGAATGGATGAATTCAGAACTAGAAAAGGTTAAGACCGCAATCACAAAGGTTGAAGCAC 
            E  W  M  N  S  E  L  E  K  V  K  T  A  I  T  K  V  E  A  L 
721       TTCACAAGACCTTTGTTGGAGTTACTGCCAGAATGATTGAGTTCTTCACTGCTCTTGGAA 
            H  K  T  F  V  G  V  T  A  R  M  I  E  F  F  T  A  L  G  I 
                              StopN 
781       TCAACCTTGACATGAGACGTTAATTCAATTTTGAATTTCCAGTACAATTTTACTTTTATT 
            N  L  D  M  R  R  *   
841       TCCAATTTTTATTTTTGCTTTATATATTTTATTACTTGACTATATTTTATTATATTCTTA 
901       TTTTATCCATATATAACCAATATATAATCTATATATCCCAATATGTAATCCATATACCAA 
961       TTATATATGTATCGATAGTTAATCATTATTATATCCAGTTTATTTAGAAATCCCAGTGTA 
1021      TTCAATTTTGTTTCTATATTTGCAATATTCAATAGAATTATCAAATTTAGATAAGAACTA 
1081      ACAATACTAACATTTTTATATTAAGATTTTACTAACTCACTAGATTAGTTAGGACTCAAA 
1141      AACAGCTGTCAAATGGGTGGGTGGTAGGG 
 
 
 
4.1.1 S segment sequences of Gamboa serogroup viruses. 
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(i)NDV-complete sequence  
 
 
1         AGTAGTGTGCTCCACAATTGAATTCTATCATTCACATAGTTATCACATACAAGTGATCTT 
                    StartN             StartNSs                                                                            
61        CTGACTTGTTATGTCTGAGATCGCTTTTTATGATGTCCAGTCTACTGCCCAAAATGGATT 
                    M  S  E  I  A  F  Y  D  V  Q  S  T  A  Q  N G  F  
                                        M  M  S  S  L  L  P  K  M  D   
121       TGATCCTGATCAACAATACTTGGCATTTAAAGCTGCTGCAGGAGCAGGGCTTAATATTGT 
           D  P  D  Q  Q  Y  L  A  F  K  A  A  A  G  A  G  L  N  I  V  
          L  I  L  I  N  N  T  W  H  L  K  L  L  Q  E  Q  G  L  I  L   
181       TTCCGCTCGGATCTTCTTCCTCAATGCCCGGAAAGCCAAAGATCAACTCTCTCGTAGACC 
           S  A  R  I  F  F  L  N  A  R  K  A  K  D  Q  L  S  R  R  P   
          F  P  L  G  S  S  S  S  M  P  G  K  P  K  I  N  S  L  V  D   
241       AGAGCCAAAGATTAACCTTAAATTTGGCACATGGTCGGTGGAGGTGGTCAATAACCATTT 
           E  P  K  I  N  L  K  F  G  T  W  S  V  E  V  V  N  N  H  F  
          Q  S  Q  R  L  T  L  N  L  A  H  G  R  W  R  W  S  I  T  I   
301       TCAAGGAAACCGGGACAATGTTATCAGCGACACGGATCTTACAATCCACAGACTGTCAGG 
           Q  G  N  R  D  N  V  I  S  D  T  D  L  T  I  H  R  L  S  G  
          F  K  E  T  G  T  M  L  S  A  T  R  I  L  Q  S  T  D  C  Q   
               StopNSs 
361       ATATATAGCCAGATTTATTCTGGACCAATATCTTGCAGGCAATACTGTGGTTCAGTCTGG 
           Y  I  A  R  F  I  L  D  Q  Y  L  A  G  N  T  V  V  Q  S  G  
          D  I  *   
421       GATCCAACTTCAGATTGTTAATCCTATTGCTGAGTCCAATGGAATAAAGTGGAGCGCAGG 
           I  Q  L  Q  I  V  N  P  I  A  E  S  N  G  I  K  W  S  A  G  
481       TGCAGAGATCTACCTGTCCTTTTTCCCAGGAACTGAAATGTTTCTGGAAAAATTCAATTT 
           A  E  I  Y  L  S  F  F  P  G  T  E  M  F  L  E  K  F  N  F  
541       TTATCCATTGGCAATTGGAATCTACCGAGTGAAGAGAGGGATGATGGATGCACAATATCT 
           Y  P  L  A  I  G  I  Y  R  V  K  R  G  M  M  D  A  Q  Y  L  
601       AAAAAAAGCATTGAGACAGAGATACGGAAATCTAACTGCAGACCAGTGGATGCAATCAAA 
           K  K  A  L  R  Q  R  Y  G  N  L  T  A  D  Q  W  M  Q  S  K  
661       ATCAGATGATGTCTTGAGGGCAATAGCAGTATTGGAGAAGTTGCAGTGGGGCAAATCAGG 
           S  D  D  V  L  R  A  I  A  V  L  E  K  L  Q  W  G  K  S  G  
                                                          StopN 
721       CCTGAGCGAAGCAGCTAGGCAGTTCCTGGGAAAGTTTGGTATCTTAATTTAGAAAGCTAT 
           L  S  E  A  A  R  Q  F  L  G  K  F  G  I  L  I  *   
781       TTCAGAATTTAATTGGTTTGTACACGTATTATCAATTGGCTATTTCAAAAGACCTTCGGG 
841       TCACAATATCAGCAGCTGGGTGGGTGGTAGGGGAACACCAAATATCTAATTGAGTCTAGA 
901       TTGTTAAATAAAAATCAATATTCATTGTGGAGCACACTACT 
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(ii)EREV-complete sequence  
 
                                                                       StartN 
1       AGTAGTGTGCTCCACAATTGAATTCTATTTTTGAACTGCTATTAAATGTCGGAACTGGTG 
                                                     M  S  E  L  V   
              StartNSs  
61        TTCTATGATGTCGAGCCAACTGCCCAAAATGGATTTGATCCTGATAAGCAGTATGTGGCA 
          F  Y  D  V  E  P  T  A  Q  N  G  F  D  P  D  K  Q  Y  V  A   
               M  M  S  S  Q  L  P  K  M  D  L  I  L  I  S  S  M  W  H  
121       TTTAAAGCTTCAGCTGGAGCAGGGCTTAACATTGTTTCCGCTAGGATCTTCTTCCTCAAT 
          F  K  A  S  A  G  A  G  L  N  I  V  S  A  R  I  F  F  L  N   
            L  K  L  Q  L  E  Q  G  L  T  L  F  P  L  G  S  S  S  S  M  
181       GCCAGGAAAGCCAAAGATCAACTCGCTCGTAGACCAGAGCCGAAGGTTGGTCTTAAATTT 
          A  R  K  A  K  D  Q  L  A  R  R  P  E  P  K  V  G  L  K  F   
            P  G  K  P  K  I  N  S  L  V  D  Q  S  R  R  L  V  L  N  L  
241       GGAACATGGCAGGTGGAAGTGGTCAATAACCATTTTCAAGGAAACCGGGACAATCCTATC 
          G  T  W  Q  V  E  V  V  N  N  H  F  Q  G  N  R  D  N  P  I   
            E  H  G  R  W  K  W  S  I  T  I  F  K  E  T  G  T  I  L  S  
                                                  StopNSs 
301       GGCGACTCAGATCTCACAATGCATAGACTCTCAGGATATATAGCCCGGTATATCTTAGAT 
          G  D  S  D  L  T  M  H  R  L  S  G  Y  I  A  R  Y  I  L  D   
            A  T  Q  I  S  Q  C  I  D  S  Q  D  I  *   
361       CAATATCTAGCTGGGAATAGTGTTGCACAAGCTGGCATCCAGCTTCAGATCATCAATCCA 
          Q  Y  L  A  G  N  S  V  A  Q  A  G  I  Q  L  Q  I  I  N  P   
421       ATAGCAGAATCAAATGGAATAAAGTGGAGTGCTGGTGCAGAGGTGTACCTATCTTTTTTC 
          I  A  E  S  N  G  I  K  W  S  A  G  A  E  V  Y  L  S  F  F   
481       CCAGGCACAGAAATGTTCTTAGAAAAATTTAATTTTTACCCCTTGGCAATTGGAATATAC 
          P  G  T  E  M  F  L  E  K  F  N  F  Y  P  L  A  I  G  I  Y   
541       AGAGTAAAAAAAGGGATGATGGAAGCCCAATTCTTGAAGAAATCTCTCAGACAAAGATAT 
          R  V  K  K  G  M  M  E  A  Q  F  L  K  K  S  L  R  Q  R  Y   
601       GGCCAAATGACAGCAGATCAATGGATGCAGACAAAATCGGATGATGTGATGAGGGCAGTA 
          G  Q  M  T  A  D  Q  W  M  Q  T  K  S  D  D  V  M  R  A  V   
661       GCAGTTCTTGAAAAATTGAGTTGGGGAAGATCAGGTCTGAGTGAAGCTGCCCGTCAATTC 
          A  V  L  E  K  L  S  W  G  R  S  G  L  S  E  A  A  R  Q  F 
                                  StopN   
721       CTGGGCCGATTCGGGATTGTTATCTAATTCATAAAATATACGCCTATTCGACTCCAAATT 
          L  G  R  F  G  I  V  I  *   
781       CTAAAATATTTAATTTGACACCAAAAGACCTTCGGGTCAAAGCCGACAGCTTAATGGGTG 
841       GGTGGTAGGGGAAACATAGCTTCAAAAGCATTTTTTCAAAATTCATTGTGGAGCACACTA 
901       CT 
 
 
 
4.1.2  S segment sequences of Nyando serogroup viruses.  
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(i)BWAV-complete sequence  
 
 
1         AGTAGTGTACTCCACTTAAGTACTAAAGCTATTAATTGAGGACATCGACTAATAAAAGCA 
                               StartN             StartNSs               
61        ACTTTAAGTAGAGGCACTATTATGTCCGATTTGATCTTCTATGATGTCGACTCGGTTAAT 
                               M  S  D  L  I  F  Y  D  V  D  S  V  N   
                                                   M  M  S  T  R  L  M  
121       GCCAATGAGTTTGACCCTGATACAGGATACCTGGATTTTAAAAATAACTATCCAGGGGCA 
          A  N  E  F  D  P  D  T  G  Y  L  D  F  K  N  N  Y  P  G  A   
            P  M  S  L  T  L  I  Q  D  T  W  I  L  K  I  T  I  Q  G  H  
181       CTCAATACAAATACCGCTAGGACATTCTTCCTCAATGCCGCAAAGGCCAAGAATGTGCTC 
          L  N  T  N  T  A  R  T  F  F  L  N  A  A  K  A  K  N  V  L   
            S  I  Q  I  P  L  G  H  S  S  S  M  P  Q  R  P  R  M  C  S  
241       CGCAATAAACCTGACAAGAAGGTCAATCCTAAATTTGGAAACTGGGAGGTGGAGGTTGTC 
          R  N  K  P  D  K  K  V  N  P  K  F  G  N  W  E  V  E  V  V   
            A  I  N  L  T  R  R  S  I  L  N  L  E  T  G  R  W  R  L  S  
301       AATAATCATTTTCCTGGAAACAGGAACAACCCAATTGGTAAAGATGATCTTACCCTCCAC 
          N  N  H  F  P  G  N  R  N  N  P  I  G  K  D  D  L  T  L  H   
            I  I  I  F  L  E  T  G  T  T  Q  L  V  K  M  I  L  P  S  T 
                         StopNSs  
361       AGAATTTCAGGATATTTAGCAAGATGGATTTTGGAGGAATATAAGAGAGATGATGAATCA 
          R  I  S  G  Y  L  A  R  W  I  L  E  E  Y  K  R  D  D  E  S   
            E  F  Q  D  I  *   
421       GAAAAGGAAATCATTGAAAGCACAGTTATTAATCCAATAGCTGAATCAAATGGGATTAGA 
          E  K  E  I  I  E  S  T  V  I  N  P  I  A  E  S  N  G  I  R   
481       TGGAGTGATGGAGCAGAGATATATCTATCATTTTTCCCTGGCACAGAGATGTTTTTGGAA 
          W  S  D  G  A  E  I  Y  L  S  F  F  P  G  T  E  M  F  L  E   
541       CCATTCAAATTCTATCCACTAGCAATTGGCATATACAGAGTCAAACATAAGATGATGGAT 
          P  F  K  F  Y  P  L  A  I  G  I  Y  R  V  K  H  K  M  M  D   
601       GCACAGTTCCTGAAAAAAGCCTTGCGGCAGAGATATGGGAAAATGACAGCTGAAAAATGG 
          A  Q  F  L  K  K  A  L  R  Q  R  Y  G  K  M  T  A  E  K  W   
661       ATGTCAACAAAAGTGAAGACTATAGGTGAGGCTGTTAGAAATGTAGAAAAGCTAAAGTGG 
          M  S  T  K  V  K  T  I  G  E  A  V  R  N  V  E  K  L  K  W   
721       GGCAAGGGTGGTTTGAGCGATGCTGCAAGAAACTTCCTAAAGAAGTTTGACATTGCAATG 
          G  K  G  G  L  S  D  A  A  R  N  F  L  K  K  F  D  I  A  M 
             StopN   
781       ATATAACCAGCCATATGCAAATATTTAGCTATCACTAAAACATATAACCAATATCAATAA 
          I  * 
841       CCATAGGACATATATAAAATAAAATATAAAATACAAAAAAACAAATAAAACATATATAAA 
901       AATAATAAAAAATATAGGGTTAGGGTAAAAACAAAAACAAAAAACACAAAAAAACACACA 
961       AAAACACAAAAAAACAAAAAAACACACAACACACACAACAGCAATAAAGAAAGTAGTGAA 
1021      CAGTGTTCTCATGGCCGATATTAATCTTTGCTTGGCTAATGGAAATAATTAAAGGTACTT 
1081      AGTGGAGCACACTACT 
 
 
4.1.3 S sequence of Bwamba serogroup virus.  
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(i)MPOV-complete sequence  
 
 
1         AGTAGTGTACTCCACGTGTCTACTTTGGTAAAGTCTTGCTAAAATCTTGCAAATAAAAACTA 
                                                                 StartN 
61        GCTATCAAATTAAACTGTCAATCGCAATTCTGGGGAGCTTTGAACAATATCCAGGATGTC 
                                          StartNSs               M  S  
121       AGACCTTGTGCTCACATTTTCAGACTCCGACGATGTCAGTCGAAGTACTTATAACCCAGG 
           D  L  V  L  T  F  S  D  S  D  D  V  S  R  S  T  Y  N  P  G  
                                           M  S  V  E  V  L  I  T  Q  E 
181       AGAGGAATACGATACGTTTGTGGATACATACCGAGAACATCTCACAGTGGATAACATTAG 
           E  E  Y  D  T  F  V  D  T  Y  R  E  H  L  T  V  D  N  I  R  
             R  N  T  I  R  L  W  I  H  T  E  N  I  S  Q  W  I  T  L  E 
241       AATCTTCTTCCTCAAGGCTGCAGAGGCCAAAGCTCACATGGCGAAGGTTAACAACGAGGT 
           I  F  F  L  K  A  A  E  A  K  A  H  M  A  K  V  N  N  E  V  
             S  S  S  S  R  L  Q  R  P  K  L  T  W  R  R  L  T  T  R  S 
301       CGTTGAAGTTCATTTTGGAACACTCGTCCTCCCGTTGGTTAATAACCATAAGCCTGGTAG 
           V  E  V  H  F  G  T  L  V  L  P  L  V  N  N  H  K  P  G  R  
             L  K  F  I  L  E  H  S  S  S  R  W  L  I  T  I  S  L  V  E 
                                       StopNSs 
361       AGCCCAGCGTGAGGTTGCGGACTCTGACTTAACTCTCCACAGAGTCTCTGGATACTTAGC 
           A  Q  R  E  V  A  D  S  D  L  T  L  H  R  V  S  G  Y  L  A  
             P  S  V  R  L  R  T  L  T  *   
421       TAAGTTTGTGTTGGAATTGTACAAAAAGCTAAGAAAATCTTCCGAGAGAGAGGCTATTAC 
           K  F  V  L  E  L  Y  K  K  L  R  K  S  S  E  R  E  A  I  T  
481       AAGCAGAATCATCAACCCAATTTCTGCTAAGATGGGCTTCCAATGGAGTGTTGGGCCAGA 
           S  R  I  I  N  P  I  S  A  K  M  G  F  Q  W  S  V  G  P  E  
541       GATTTACCTTTCTACTCTGCCTGGAACTGAAATGTTTCTGGATGCATTCAAAATGTATCC 
           I  Y  L  S  T  L  P  G  T  E  M  F  L  D  A  F  K  M  Y  P  
601       TTTAGCATTCATCCTGCTTAGAGTAAAGAGGGGTGAAATCAAGATTGACATGGCAAAAAA 
           L  A  F  I  L  L  R  V  K  R  G  E  I  K  I  D  M  A  K  K  
661       AGCTATGCGTCAGAGGTATGGTGACAAAGAGGCTTCAACCTGGCTTGAGGAAGAGGTCGA 
           A  M  R  Q  R  Y  G  D  K  E  A  S  T  W  L  E  E  E  V  D  
721       CACTGTAAAAAGTGCAATCAAGACAGTTGAGAAGCTGAAGCCTACTCTCACTGGACTTGC 
           T  V  K  S  A  I  K  T  V  E  K  L  K  P  T  L  T  G  L  A 
                                                     StopN  
781       TGCAAGCATGACCAAGTTCCTCCAGGAGCTTGGTATTTCTAAATAAATTTCATATTCCAA 
           A  S  M  T  K  F  L  Q  E  L  G  I  S  K  *   
841       ATTAATATTTCATGTGTTATCTCCTATTATATCCAATATATTATCCAATTTATCCATATA 
901       TAACCAATTTATAATCTTTTAGTTATCTTAAGTTTATTAATCATACTAATAATTTAGTTT 
961       TAAGTTTTCATCTAATCTTCATCTAATCATCCCCCATCCCCATCCAATAACAGCGCAATA 
1021      AATCAATGTATTCAAGTTTGCATTAATTAATAGTAGTCGTGGAGCACACTACT 
 
 
 
4.1.4  S segment sequence of Turlock serogroup virus.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 118 
 
B S sequence without NSs protein 
 
 
(i)ANAV-complete sequence 
                                                                                                                        
                                                               StartN 
1         AGTAGTGTACTCCACATAAAGTCAAACTATCGCTTGTTGTAAAAACATTCAAAATGTCAT 
                                                               M  S  S 
61        CCATGGATTATATGTTTGACGATCCTGGTCATATCCAGATCATCAACTATATACCAGAGG 
            M  D  Y  M  F  D  D  P  G  H  I  Q  I  I  N  Y  I  P  E  E 
121       AGGAATATATGGCATTTTGTGCAAAATATCAAGATCAACTGACAGTAGAGAACATTAGGA 
            E  Y  M  A  F  C  A  K  Y  Q  D  Q  L  T  V  E  N  I  R  I 
181       TTTTCTTCCTTAATGCAGGCAAATTCAAGAAAATGTTGAGGACAAATCCAAAATTGAAAG 
            F  F  L  N  A  G  K  F  K  K  M  L  R  T  N  P  K  L  K  V 
241       TTCAAGTCAAATTTGGCACGCTTCAACTTGAGATCATCAATACTCACAATCCAGCAAATC 
            Q  V  K  F  G  T  L  Q  L  E  I  I  N  T  H  N  P  A  N  R 
301       GTGAAATTCAATTGTCATCAAGTGACCTAACATTACATAGAGTCTCTGCCTATTTGGCTA 
            E  I  Q  L  S  S  S  D  L  T  L  H  R  V  S  A  Y  L  A  R 
361       GAAAATCCCTTCGACTTTGGGAAGCCCTAACATTGGATCAAAAAGAAGAATTCAAGCTAA 
            K  S  L  R  L  W  E  A  L  T  L  D  Q  K  E  E  F  K  L  K 
421       AGATCATCATGCCATTAGCAGAAAAAGCTGGAGTCACTTGGGATAATGCCGGATCTGTTG 
            I  I  M  P  L  A  E  K  A  G  V  T  W  D  N  A  G  S  V  E 
481       AGATGTACCTAGGTTTTGCTCCAGGTGCTGAGTTCTTCTTAAAAGATTTCAAATTTTATC 
            M  Y  L  G  F  A  P  G  A  E  F  F  L  K  D  F  K  F  Y  P 
541       CACTTGCAATTGGCATTGCTAGAGTTAAGAAAGGACTGATGAGCCCTGATTTCTTATCAA 
            L  A  I  G  I  A  R  V  K  K  G  L  M  S  P  D  F  L  S  K 
601       AAACTCTGAGACAGAGATATGGAGGAATACCACCAGCTGACTGGATGGCTATTCACAAAT 
            T  L  R  Q  R  Y  G  G  I  P  P  A  D  W  M  A  I  H  K  S 
661       CAGCCGTGAGGACCGCCGTTGAATTTGTTGACAAATTCCCACTAATGAGATCCAATGCTT 
            A  V  R  T  A  V  E  F  V  D  K  F  P  L  M  R  S  N  A  S 
721       CATCGCATGTTGAGCAATTTTTGGTTGATTTGGGTCTGAGTCGGGCAACTGTTGCCTCAA 
            S  H  V  E  Q  F  L  V  D  L  G  L  S  R  A  T  V  A  S  M 
                  StopN 
781       TGAAGCGTTAATTCATGATTACAATCAATTTTATCCAAGTTAATCGCATATAATCACAAA 
            K  R  *    
841       TATTAATCACTAACATTTATAATTTTGGGGGTGGGTGGTTGGGGACAGCATCTAAGTAAT 
901       CAGTTGAATATTCTAAAATTATGTACTTTATGTGGAGCACACTACT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 119 
(ii)TCMV-complete sequence  
 
 
                                                    StartN 
1         AGTAGTGTACTCCACTAGAAGCAAAGTTTGTAAAAGTTTAAAATGTCAGGAATAGATTTC 
                                                    M  S  G  I  D  F   
61        ATCTACGATGATCCTGGTAGGATCCAGCAATCAGACTTTGTTCCTAGAGAGGAGTATGCT 
          I  Y  D  D  P  G  R  I  Q  Q  S  D  F  V  P  R  E  E  Y  A   
121       GTTTTCTGCTCAAAGTTTGCACTTGTCTTAATATTGCAAAACATACGGATTTTTTTTCTC 
          V  F  C  S  K  F  A  L  V  L  I  L  Q  N  I  R  I  F  F  L   
181       AATGCAGGGAAACTAAAAGCTGCACTTAAATTATCTCCTAAAAGGAAAGTAAAGGCAAAA 
          N  A  G  K  L  K  A  A  L  K  L  S  P  K  R  K  V  K  A  K   
241       TTTGGAACTCTGGAAGTGGAGATTACAAATACGCATAACAGGGCATTTGCTGACTCAAAA 
          F  G  T  L  E  V  E  I  T  N  T  H  N  R  A  F  A  D  S  K   
301       TTGGAAAAAGGTGACATCACACTTCACAGACTTTCAGGATTTCTTGCAAAAAAGATTTTG 
          L  E  K  G  D  I  T  L  H  R  L  S  G  F  L  A  K  K  I  L   
361       GATATATACAATGCTGGCTCGTTTGATCTTCAAACACAGATTAAGGCTGAAATCATCATC 
          D  I  Y  N  A  G  S  F  D  L  Q  T  Q  I  K  A  E  I  I  I   
421       CCATTAGCTGAGGTTGCTGGTGTCTCATGGGCTAATTCTACGCCAGAAATTTACCTAAGC 
          P  L  A  E  V  A  G  V  S  W  A  N  S  T  P  E  I  Y  L  S   
481       TTTTGCCCAGGTTCAGAATTCTTTCTAGCAGATTTCAAATTTTATCCACTAGCAATTGGC 
          F  C  P  G  S  E  F  F  L  A  D  F  K  F  Y  P  L  A  I  G   
541       ATAGCTAGGGTGAAAAAGGATCTAATGAAGCCAGAGTTTCTGGCAAAATTACTGAGGCAA 
          I  A  R  V  K  K  D  L  M  K  P  E  F  L  A  K  L  L  R  Q   
601       AGATATGGCAATATGACACCTGGAGAATGGATGAAAACACATTCCGTCTCAGTGCAGTCT 
          R  Y  G  N  M  T  P  G  E  W  M  K  T  H  S  V  S  V  Q  S   
661       GCTATTTCTGAAATAGAGAAATACCCACTCATGAAGGTGAATTCCCGTCCTCATGTTGAG 
          A  I  S  E  I  E  K  Y  P  L  M  K  V  N  S  R  P  H  V  E   
721       GAGTTCCTAAAGTCTCTAGGTCTATCTGCCCACTATATAAATGGGGCTCTAAGAGGGTAA 
          E  F  L  K  S  L  G  L  S  A  H  Y  I  N  G  A  L  R  G  *   
781       GCATAGCAAATACAGTCTGAATATCTAACACTAACATTAAATCACATATACTATAAACAC 
841       TAACATTAAATCACATACACTATAAGCACTACATACACTAAAATACTAACACAAGGGTGG 
901       GTGGTTGGGGACTGCATCTTATTAGCTGTTAGTTTTTGTCTTGATGTGGAGTACACTACT 
 
 
 
 
 
4.1.5  S segment sequence of Anopheles A serogroup viruses. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 120 
(i)ANBV-complete sequence 
 
 
                                             StartN 
1         AGTAGTGTACTCCACATTATAGTAATAAAGTCAAGATGGCGTCTCAAGTTGATTTTGCTT 
                                             M  A  S  Q  V  D  F  A F 
61        TTGAAGACACAGGAAATATCACTCAGTCTGACTTTATTCCTGATGTGGGGTATACTGCAT 
            E  D  T  G  N  I  T  Q  S  D  F  I  P  D  V  G  Y  T  A  F 
121       TCTGCCTGGGCAAGACAGCACATCTGTCTCTTGAGAATATCAAGATATTCTTCCTAAATG 
            C  L  G  K  T  A  H  L  S  L  E  N  I  K  I  F  F  L  N  A 
181       CTGGCAAATTAAAGCAGCAGATGAAAACGTGCTCAAAAACTAAAATAAAAGCAAAGTTTG 
            G  K  L  K  Q  Q  M  K  T  C  S  K  T  K  I  K  A  K  F  G 
241       GCACGTTAGAAATTGAACTAGTAAATACATTGAATCGAAGCTTAGGACAAGTCTCACTTC 
            T  L  E  I  E  L  V  N  T  L  N  R  S  L  G  Q  V  S  L  Q 
301       AGCCGAATGATGTGACACTCCACAGGGCATCCGCATATTTGGCAAGAAAAGCTCTTGAAC 
            P  N  D  V  T  L  H  R  A  S  A  Y  L  A  R  K  A  L  E  L 
361       TTTACCGGGAGGGCCAAGCTGATTTCCAAGCAGCCATGAGAGATCAATTTGTTATGCCTC 
            Y  R  E  G  Q  A  D  F  Q  A  A  M  R  D  Q  F  V  M  P  L 
421       TTGCTGAGGTTGCTGGTGTTCAATTCAAGCCGGAAGTGCCACCAGAGCTTTATATTGGTT 
            A  E  V  A  G  V  Q  F  K  P  E  V  P  P  E  L  Y  I  G  F 
481       TTGCCCCTGGTGCGGAATTCTTCATGAAGCTCTTCAAGTGCTACCCGCTAGCAATTGCAG 
            A  P  G  A  E  F  F  M  K  L  F  K  C  Y  P  L  A  I  A  V 
541       TTGTTCGTGTAAAGAAAGGGCAAATGCAGCCTGAATTCCTAGCTAAGAGCCTACGTCAAC 
            V  R  V  K  K  G  Q  M  Q  P  E  F  L  A  K  S  L  R  Q  R 
601       GTTATGCTGGGGCTCCACCAGCAGAGTGGATGTCCACAAATGCTGCAGCAATTAAGGCAG 
            Y  A  G  A  P  P  A  E  W  M  S  T  N  A  A  A  I  K  A  A 
661       CCACTGCAATGGTGGAGAAATACCCTATGATGAAGGTTGCGTCTAGGCCTCACATTGAAA 
            T  A  M  V  E  K  Y  P  M  M  K  V  A  S  R  P  H  I  E  K 
                                                                  StopN 
721       AGCTTCTGTCCGAACTTGGACTATCAGCTCCCACTATCCAGCAGGCTTTAACCAAGTGAG 
            L  L  S  E  L  G  L  S  A  P  T  I  Q  Q  A  L  T  K  *   
781       CCACAGTGCTTCATCTCATACTGTAAATAGATATCCATATTAATCGGAACCATATATAGT 
841       CAATATATAACCATATATATATATAATAGGGGGTGGTGGTGGGGCTTCAAACAGCATAAC 
901       ATATGGGTGGGTGGTTGGGGACAGCAACTGTTATATTCAAAATTGACATATGCTTCGCTG 
961       TAATATAATCTTTTATGTGGAGCACACTACT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 121 
 
(ii)BORV-complete sequence 
 
 
                                             StartN 
1         AGTAGTGTGCTCCACATCAAAGTAATAAAGTCACAATGTCGTCTACTGTGGATTTCGCAT 
                                             M  S  S  T  V  D  F  A F 
61        TTGAAGACACAGGGAATGTCACTCAGTCTGACTTTGTTCCAGATGTGGGGTATACTACCT 
            L  K  T  Q  G  M  S  L  S  L  T  L  F  Q  M  W  G  I  L  P   
121       TCTGCATTGGGAGGTCCAATCAACTGTCACTGGAGAATATCAAAATATTCTTCGTCAATG 
            C  I  G  R  S  N  Q  L  S  L  E  N  I  K  I  F  F  V  N  A 
181       CTGGAAAGCTAAAAATGCAAATGAAAAGCAGTCTTAAACCAAGAATCAAAGCTAAATTTG 
            G  K  L  K  M  Q  M  K  S  S  L  K  P  R  I  K  A  K  F  G 
241       GAACATTAGAAATTGAAATGGTAAACACATTAAATAAGGCTTTGGGCCAAATAAGCCTGC 
            T  L  E  I  E  M  V  N  T  L  N  K  A  L  G  Q  I  S  L  Q 
301       AGCCTACTGACCTTACTCTGCATAGGGCATCTGCATTTTTGGCTAGAAGAGCTCTGGAGA 
            P  T  D  L  T  L  H  R  A  S  A  F  L  A  R  R  A  L  E  M 
361       TGTACCATGGGGGAGCTGCAGATTTCCAGGCAGCTATGAGGGACCAATTTGTGATGCCTC 
            Y  H  G  G  A  A  D  F  Q  A  A  M  R  D  Q  F  V  M  P  L 
421       TAGCTGAAGTTTCCGGCGTCCAATTCAAGCCTGAGGTTCCTCCAGAGCTTTACATCGGAT 
            A  E  V  S  G  V  Q  F  K  P  E  V  P  P  E  L  Y  I  G  F 
481       TTGCTCCCGGAGCAGAATTCTTCATGAAGCTATTCAAATGCTACCCTCTTGCCATTGCTG 
            A  P  G  A  E  F  F  M  K  L  F  K  C  Y  P  L  A  I  A  V 
541       TGGTTAGAGTGAAAAAAGGGCAGATGCAACCCGAATTCTCAGCTAAGTGCCTAAGGCAGC 
            V  R  V  K  K  G  Q  M  Q  P  E  F  S  A  K  C  L  R  Q  R 
601       GGTTTGGTGGAGCACCTCCAGCTGAATGGATGACCACTAATGCTCCTGCAATCAAGATTG 
            F  G  G  A  P  P  A  E  W  M  T  T  N  A  P  A  I  K  I  A 
661       CAACTGCAATGGTAGAGAAGTTCCCAATGATGAGAACTGCATCCAGGCCTCATGTTGAGA 
            T  A  M  V  E  K  F  P  M  M  R  T  A  S  R  P  H  V  E  K 
                                                                  StopN 
721       AGCTTCTCTCAGAGCTGGGCCTTTCTACTCCAACTATTCAGAGAGCTCTTACCAAGTAAG 
            L  L  S  E  L  G  L  S  T  P  T  I  Q  R  A  L  T  K  *   
781       CATAACCTTCACATATATCTAGCAGTTAGTCTATATAACCATTATAATCCATATTTAGAG 
841       GTTTTGGGTAGATATTAGGGGTCAGGGGGGTGGGACTGGGCAGCAAGAGATATGGGTGGG 
901       TGGTTGGGGACAGCATTCAAAACTACTGCAAATATACATATGAGATGCAGAAAATACAAT 
961       CTATAAAGTGGAGTACACTACT 
 
 
 
4.1.6  S segment sequence of Anopheles B serogroup viruses.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 122 
(i)TETEV-complete sequence 
 
 
1         AGTAGTGTACTCCACTGGATACAAAATCGTTAATACTGAGAATTTATAGATTGCCAATAG 
                       StartN 
61        CAAATCATACAAAATGCCCAAAGGAGGAAAAAGCGATCCTGAACCATCCATCAACGTTGT 
                       M  P  K  G  G  K  S  D  P  E  P  S  I  N  V  V  
121       TGCCAGTGCCGCATTCGAAGATGATGAGATCGATTATCATTTTACAGCAGGGGATGATGG 
           A  S  A  A  F  E  D  D  E  I  D  Y  H  F  T  A  G  D  D  G  
181       AGGTGCTCCATTCAATCCCATGACTGCTTATAAAAGGTTCATGGAAGTCCATGGCAAGGA 
           G  A  P  F  N  P  M  T  A  Y  K  R  F  M  E  V  H  G  K  E  
241       ACTAAACCTGCCCAATATCAAGGTCTTTTTCTTGAAGGCTCGCCAGGCAAAGGAGATAAT 
           L  N  L  P  N  I  K  V  F  F  L  K  A  R  Q  A  K  E  I  M  
301       GCGGTCCAAGGCAAAGTCAGAAATGACTTTTACTTTCGGATCTCTGACTCTGACCTTCAA 
           R  S  K  A  K  S  E  M  T  F  T  F  G  S  L  T  L  T  F  K  
361       GAACACCCATCATCCATCTAATCGTCACCTGGCTGTTGAGCAGGACGACTTGACTATCAA 
            N  T  H  H  P  S  N  R  H  L  A  V  E  Q  D  D  L  T  I  N  
421       CAGAGTCACCGGATTTATGGCTCATGCTATTTTGCTGACTCATAGAGACCCAAAGCATAA 
            R  V  T  G  F  M  A  H  A  I  L  L  T  H  R  D  P  K  H  K  
481       GGATGCAGTTGAAAAAACTATCATTAATCCAATTGCGGATTCAAAAGGTGTGACCTGGAA 
            D  A  V  E  K  T  I  I  N  P  I  A  D  S  K  G  V  T  W  K  
541       AGAAAGGGGCAAATGTATATCTTGTTTCTTCCCTGGAACTGAGATGTTCATGCTCGAGTT 
            E  R  G  K  C  I  S  C  F  F  P  G  T  E  M  F  M  L  E  F  
601       CAAGTTCTTCCCGCTTGCAGTTGGATTAGCTCGCTGCCATAAGGAAAAAATGGACACCGA 
            K  F  F  P  L  A  V  G  L  A  R  C  H  K  E  K  M  D  T  E  
661       ATACTTGAAGAAGCCAATGCGCCAGATGCTCACTGATGGAACAAAGGCACAGGTTTGGCT 
            Y  L  K  K  P  M  R  Q  M  L  T  D  G  T  K  A  Q  V  W  L  
721       AGGTGCTAAGATTGAAGAGATCAGGAAGGCCTACAAGGTTTGCATGAACCTTAAATTTGT 
            G  A  K  I  E  E  I  R  K  A  Y  K  V  C  M  N  L  K  F  V  
781       CAAGGCTGGGTTCTCTGAGGCTGCAAGAGAGTTCCTAAAGGAATTTGGATTGGACCAGGA 
            K  A  G  F  S  E  A  A  R  E  F  L  K  E  F  G  L  D  Q  D  
                 StopN 
841       TAAGAACTAAACAATTCTCTTTTAAGAGATAGGGGTTGGTATTTATATACCAACTCCGAC 
            K  N *   
901       ATGTAAACAGCTTAAGTAAGCTGTAATATGAGGTGGGTGGTTGGGGCAAGGTTCAGATCA 
961       ACTCATTGCAATCTTATTCTTCATTATTCTTTCTGTTCTTATATAAAGTGGAGTACACTA 
1021      CT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 123 
 
(ii) BMAV-complete sequence 
 
 
1         AGTAGTGTACTCCACAAAATACAAAATCGTTAATACTGAGAATTTATAGATTGCATATAG 
                       StartN 
61        CAAACCATACAAAATGTCCAAAGTAAAAAGAGGTGAGTCAGAACCATCAATCAGCGTTGC 
                       M  S  K  V  K  R  G  E  S  E  P  S  I  S  V  A  
121       AGCTAGTGCCGCATTTGCTGAAGATGAGATTGATTACCATTTCTCAGCAGGGGATGATGG 
           A  S  A  A  F  A  E  D  E  I  D  Y  H  F  S  A  G  D  D  G  
181       AGGTGCTCCATTCAACCCTATGGCTGCATACAAAGAGTTCATGGAAACTCATGGCAAGGA 
           G  A  P  F  N  P  M  A  A  Y  K  E  F  M  E  T  H  G  K  D  
241       TTTAACTGTCACCAACATAAGAGTCTTTTTCTTGAAGGCTCGCCAGGCTAAAGAAATTAT 
           L  T  V  T  N  I  R  V  F  F  L  K  A  R  Q  A  K  E  I  M  
301       GAGGTCTAAAGCCAAATCTGAAATGACTTTCACTTTTGGCAGCCTAACCCTGACCTTCAA 
           R  S  K  A  K  S  E  M  T  F  T  F  G  S  L  T  L  T  F  K  
361       GAACACTCATCACCCATCTAATCGGCATTTGACCGTTGACCAGGATGATTTGACTATCAA 
            N  T  H  H  P  S  N  R  H  L  T  V  D  Q  D  D  L  T  I  N  
421       TAGGGCCACTGGGTTTATGGCCTACGCAATCCTCCTGACTCATAGGGAGCCTAAAAGCAA 
           R  A  T  G  F  M  A  Y  A  I  L  L  T  H  R  E  P  K  S  K  
481       GGATGCAGTTGAAAAGACCATCATCAATCCTATTGCAGAATCAAAGGGTGTTACCTGGAA 
           D  A  V  E  K  T  I  I  N  P  I  A  E  S  K  G  V  T  W  K  
541       GGAGGGAGCAAATATCTATCTGAGCTTCTTCCCTGGGACTGAAATGTTCATGCTTGAATT 
           E  G  A  N  I  Y  L  S  F  F  P  G  T  E  M  F  M  L  E  F  
601       CAGGTTCTTTCCACTAGCTGTTGGTCTGGCTAGATGCCACAAAGAAAAGATGGACACTGA 
           R  F  F  P  L  A  V  G  L  A  R  C  H  K  E  K  M  D  T  E  
661       ATACCTGAAGAAGCCCATGCGTCAAATGTTGACTGATGGAACAAAGGCTCAAGTCTGGCT 
           Y  L  K  K  P  M  R  Q  M  L  T  D  G  T  K  A  Q  V  W  L  
721       CGGTGCCAAGATTGAAGAGATCAGGAAGGCATATAAGGTTTGTATGAACCTTAAATTTGT 
           G  A  K  I  E  E  I  R  K  A  Y  K  V  C  M  N  L  K  F  V  
781       TAAAGCTGGTTTCTCTGAGGCTGCTAGGGAGTTCCTTAAAGAATTCGGATTAGACCAGGA 
           K  A  G  F  S  E  A  A  R  E  F  L  K  E  F  G  L  D  Q  D 
                StopN 
841       CAGAAACTAAATAATTCTCTTTTAAGAGATAGGGGTTGGTATATTTACCAACCCCGACAT 
           R  N *   
901       GTAAACAGCTAAATTAAGCTGCAATATGTGGTGGGTGGTTGGGGCAAGATTCAGATCAAC 
961       TCATTACAATCTTTTTCCTCATCATTAGTTCTATTCTTATGTATCCAGTGGAGCACACTA 
1021      CT 
 
 
 
4.1.7  S segment sequence of Tete serogroup viruses.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 124 
 
(i)CAPV-incomplete sequence 
 
 
                                                         StartN     
1 AGTAGTGAACTTCGTAGGAAGTTAAAATCATTCCAGAGAATAAATCAATATGGGAGAAGT 
                                                          M  G  E  V  
61        TGCTAATTTTGAATTTGGTGAGCGTTTGATAGCAGAAGGGAGGAACCCTTTTGTACCTGA 
            A  N  F  E  F  G  E  R  L  I  A  E  G  R  N  P  F  V  P  D  
121       TGTAGCCTATGCTCGGTTCATCAGAGAGCACGTACCTATGCTTACGCCTGGGAATATCAG 
            V  A  Y  A  R  F  I  R  E  H  V  P  M  L  T  P  G  N  I  R  
181       GATCTTTTTCCTGCGTGCATATGATGCAAAGCAGAAACTTAAGACCACAACAGCTCGGAC 
            I  F  F  L  R  A  Y  D  A  K  Q  K  L  K  T  T  T  A  R  T  
241       TGCCAACCTTAAATTTGGCACTGCTACGTTCACTGTGAAAAATAACCACAATGAGCGAAA 
            A  N  L  K  F  G  T  A  T  F  T  V  K  N  N  H  N  E  R  N  
301       CGCCAATATTGAGGTTGAAGCTGAAGACCTGACTTTGCATCGGATCTCTGGATTCCTTGC 
            A  N  I  E  V  E  A  E  D  L  T  L  H  R  I  S  G  F  L  A  
361       AAAGTTCGTGAGAGAGTCTATGGTGGACGAGACTGCATCTAAGATGATCAGGGACACAAT 
            K  F  V  R  E  S  M  V  D  E  T  A  S  K  M  I  R  D  T  I  
421       CGTGAACCCGATTGCTGAAAGTCTAGGTATAACCTGGGAAAATGGGGATGATGTATATCT 
            V  N  P  I  A  E  S  L  G  I  T  W  E  N  G  D  D  V  Y  L  
481       CTCATTCTTCCCTGGCACAGAGATGTTCTTGGACACCTTCCACATGCTACCTCTGGCTAT 
            S  F  F  P  G  T  E  M  F  L  D  T  F  H  M  L  P  L  A  I  
541       TGGAATCTACAGAGTCCAGCAAAAGCAGATGAAGGCTGAGTTCCTGAAGAAGCACCTGCG 
            G  I  Y  R  V  Q  Q  K  Q  M  K  A  E  F  L  K  K  H  L  R  
601       CCAACAATATGGAGGACTTGCTGCTTCCCAGTGGATGTCAGAAAGGAAAGAAGATGTCAA 
            Q  Q  Y  G  G  L  A  A  S  Q  W  M  S  E  R  K  E  D  V  K  
661       GCTTGCCTTAACATTAATTTCCAGGCTGCCCTGGGGAAAAGCTGGGCTCTCTGCTGCAGC 
            L  A  L  T  L  I  S  R  L  P  W  G  K  A  G  L  S  A  A  A 
                                            StopN  
721       TAGAAATTTCCTAGCTGACTTCGGTATAACCTTTTAATATCTCCCAGCTTTTTGTCTTGT 
            R  N  F  L  A  D  F  G  I  T  F  *   
781       CCCCCAAATCCATTTTAATCAAAATTTAAAACCGAAATTAATGATCCAATGGTAAGTTCA 
841       AATGGTAAGTTCTAATGGTAAGTCAATGGTAAGTTTCAAAACCTAAAATTCAAAATTTTG 
901       AAATTAAAATAAGTAAATAATTCGCCAAATGGCAAAACAATAACAGCAAAAGGGGTGGCG 
961       ATAAGGGGGAACACTGTCACAGTAGGGTACT 
 
 
 
4.1.8  S segment sequence of Capim serogroup virus.  
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(i)PLSV-incomplete sequence 
 
 
             StartN 
1         ATGAATGACCCGATGCCCTCTTTTGAGTTTAAGGAGGAGTCCGCTGCAGTAGGGAGTAAT 
          M  N  D  P  M  P  S  F  E  F  K  E  E  S  A  A  V  G  S  N   
61        CCTTTTATTCCGGATGAAGCCTATGGAGTTTTCGTTAACGAAAACCAGGCCCAATTGACC 
          P  F  I  P  D  E  A  Y  G  V  F  V  N  E  N  Q  A  Q  L  T   
121       ATCCCGAATATTAGGATTTTCTTCCTGCGAGCGTATGACGCCAAACTTAAACTCAAGAGA 
          I  P  N  I  R  I  F  F  L  R  A  Y  D  A  K  L  K  L  K  R   
181       ACGGAAGCAAGGTCTGCGAATCTCACATTTGGAACTATGAAGCTGCATATAATGAATAAC  
          T  E  A  R  S  A  N  L  T  F  G  T  M  K  L  H  I  M  N  N   
241       CACAACAACAAGTTTGCAAACACTGAACTCGAACCCCATGATCTGACCCTCCACAGAGTG 
          H  N  N  K  F  A  N  T  E  L  E  P  H  D  L  T  L  H  R  V   
301       TCTGGCTTTTTGGCAAGATTCCTGAAAGAGGCTATGGCTAACACTGCAACCCGCATGGAC 
          S  G  F  L  A  R  F  L  K  E  A  M  A  N  T  A  T  R  M  D   
361       ATCCACAAGAACATCATAAACCCGATTGCAGCAGCTCTGAAACTGGAATGGACAGTTGGA 
          I  H  K  N  I  I  N  P  I  A  A  A  L  K  L  E  W  T  V  G   
421       GACGACATCTATCTCTCATTCTTCCCTGGCGCTGAGATGTTCATGGACAGATTCAAAATG 
          D  D  I  Y  L  S  F  F  P  G  A  E  M  F  M  D  R  F  K  M   
481       TTCCCCCTGGCCATTGCAATCTTCAGAGTCCAACAGAAGCAGATGGACCCAGAGTTTCTA 
          F  P  L  A  I  A  I  F  R  V  Q  Q  K  Q  M  D  P  E  F  L   
541       AAGAAACACCTGCGCCAGTACTGCGGAGCCATCCCATCCTCTCAGTGGATGCTGACTACG 
          K  K  H  L  R  Q  Y  C  G  A  I  P  S  S  Q  W  M  L  T  T   
601       AATTGCTTACTGAGCGAATATTTCAAACACTACATTGCATTACATTGCTTTAATTGGTCA 
          N  C  L  L  S  E  Y  F  K  H  Y  I  A  L  H  C  F  N  W  S   
661       AA 
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Patois serogroup 
 
(i)PATV-incomplete 
 
 
1         AAGCACCAAGAGCTACATTGCGCTTTCGTGATTGGAGAGTTGAGGTTGTCAACAACCATA 
            A  P  R  A  T  L  R  F  R  D  W  R  V  E  V  V  N  N  H  N 
61        ACCCAAGACTGGGTCAAGTTGAAGTTCTACCGACAGAACTTACTCTACATCGCATATCAG 
            P  R  L  G  Q  V  E  V  L  P  T  E  L  T  L  H  R  I  S  G 
121       GTTTCATTGCAAGACACCTTCTTGAAATTGCCAATGGAGTTGACCAGGCCCGCATAATTG 
            F  I  A  R  H  L  L  E  I  A  N  G  V  D  Q  A  R  I  I  D 
181       ATATGCAAGAGCAGATTGCTAATCCATTGGCACTCAGCAAGGGAATCACCTGGAGTGATG 
            M  Q  E  Q  I  A  N  P  L  A  L  S  K  G  I  T  W  S  D  G 
241       GAGCAACCATATACTTGTCATTCTTCCCAGGAACAGAAATGTTTCTAGATCTGTTCAAGT 
            A  T  I  Y  L  S  F  F  P  G  T  E  M  F  L  D  L  F  K  F 
301       TCTACCCACTTGCCATCGGGATCTACAGAGTTCAGATCGGAGACATGGATGCTGAATATC 
            Y  P  L  A  I  G  I  Y  R  V  Q  I  G  D  M  D  A  E  Y  L 
361       TAAAGAAAGCTTTAAGACAACAATATGGTGCTCTGAAACCAAATGAATGGGCAATCCTGA 
            K  K  A  L  R  Q  Q  Y  G  A  L  K  P  N  E  W  A  I  L  K 
421       AAAAAGATGCAGTCAAAACAGCTGTATCTCATGTGGCAGCACTCAAATGGGGATCCAAAG 
            K  D  A  V  K  T  A  V  S  H  V  A  A  L  K  W  G  S  K  G 
                                                            StopN 
481       GTTTCTCTCAGGCTGCACAAGACCTTCTCAAAGAATTTGGGATTAAGGTCTAATTTTGTA 
            F  S  Q  A  A  Q  D  L  L  K  E  F  G  I  K  V  *   
541       AATATTTCACGTAGGAAACATAGGTTAATTTAGGTTTAAGTTAATGGTAAGTCAATGGTA 
601       GGTTTAAATCAATTGTAAATATTAAATTAGGGTAATTTTAATTAGGGTTAGGGCAAAAAC 
661       AGCATCAGTTATTTTAGCAGTTAATGGGGTGGGTGGTAGGGGAACAAAACTAATCTGATT 
721       TATTTTCAATATAGACTACATTATATAATTCTTACGGGGTACACTACT 
 
 
 
 
 
 
 
4.1.10  S segment sequence of Patois serogroup virus. 
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(i)BERV-incomplete sequence 
 
 
1         TCATCAACCCAATTGCTCAGTCAGTAGGGATAACATGGGAAAACGGTGATGATGTCTACC 
            I  N  P  I  A  Q  S  V  G  I  T  W  E  N  G  D  D  V  Y  L 
61        TTTCCTTTTTCCCAGGAACAGAAATGTTTCTGGAAAAATTCAAGCTGTTGCCTCTGGCAA 
            S  F  F  P  G  T  E  M  F  L  E  K  F  K  L  L  P  L  A  R   
121       TCGGAATCTATCGTGTTCAGCAAAAACACATGGATGCTGACTTCCTTAAAAAACACCTCC 
            I  G  I  Y  R  V  Q  Q  K  H  M  D  A  D  F  L  K  K  H  L  
181       GTCAGCAATATGGGGACATACCTGCTTCACAGTGGATGCTGACAATGAAAGAAGATGTCA 
            Q  Q  Y  G  D  I  P  A  S  Q  W  M  L  T  M  K  E  D  V  K 
241       AAAGTGCACTGACTTTGATTTCCAAGCTACCTTGGGGCAAAGCAGGCATGTCTGCTGCAG 
            S  A  L  T  L  I  S  K  L  P  W  G  K  A  G  M  S  A  A  A 
                                             StopN 
301       CCAGAGCCTTCCTTGCTGACTTTGGAATCAGAATGTAAAAACCCACCCTATTTGTAAGTA 
            R  A  F  L  A  D  F  G  I  R  M  *   
361       GATTAGATTCTATAATTTAGTTTATGAAATAACCATAGGATTTACAGTTTAGTTTGTAAG 
421       GTAACTATAGTATAGGATAAGTGATAAATAATGGTAAGAAAATGATACAAAATGGTATTA 
481       ATGGTAAGGTTTTTATTTTTTTACCTTAAATTACAAATTAATTGATTCCCCCCCTACCCA 
541       TATTTTAATTAAAATCCGCTCCCACCGCTCCCTCCCCAAATACCCACATCCCAAATTCTG 
601       AAGCAGTCCATAAAAGGGTTGGGTGGTTGGGGAACGAGACAAACGAATTTGTTGTGTTAT 
661       AATCTTTACATTCTTTAACAACTTAAAAGGGTCTG 
 
 
 
 
 
 
 
(ii)GMAV-incomplete sequence 
 
 
1         CCAGGAACAGAAATGTTTTTGGAAGACTTCAGAATGATCCCGTTGGCAATTGGAATTT 
          P  G  T  E  M  F  L  E  D  F  R  M  I  P  L  A  I  G  I  Y 
61        ACAGAGTTCAACAGAAGCAGATGAAAGCAGAATTCCTCAAAAAGCACATGCGCCAGCAAT 
            R  V  Q  Q  K  Q  M  K  A  E  F  L  K  K  H  M  R  Q  Q  Y   
121       ATGGAGACATGCCTGCAAGCCAGTGGATGACTCTAAAAAAAGCAGATGTTCAGAATGCTT 
            G  D  M  P  A  S  Q  W  M  T  L  K  K  A  D  V  Q  N  A  L   
181       TGACATTAGTGTCTAAGCTTCCCTGGACAAGAGCTGGATTGTCTGCTGCAGCCAGAAACT 
            T  L  V  S  K  L  P  W  T  R  A  G  L  S  A  A  A  R  N  F 
                                    StopN 
241       TCTTGGCAGAATTTGGCATCACCTTGTAATCTCACTCCCCTTTGCTGATAGGTAAGAGTT 
            L  A  E  F  G  I  T  L  *   
301       TCCGATAATATTAACCCATAGGACCCAATGGTAAGTTTAAATGATAAGTTTTAAATGGTA 
361       AGTCTCAATGGTAAGCTCTAATGGTAAGTTTTAAATCAAAGTGTACACTAAAATTTCTAA 
421       ATTCTAAATTCCAAAAATTAAATTCGATTTAAATTAGCCTTGATTGGCACAAACATAAAA 
481       CAGCTTAAAAAATGGGTTGGGTGGTTGGGGAACATAAAAGGTGCAGCCATTAATCTTCTA 
541       GTTCATATGTTTAAAGATCGCGTAACTGCATATTATATTCTGTATTCTTCATATTTTATG 
601       TAACTTGCTACGAAGAACACT 
 
 
4.1.11  S segment sequence of Guama serogroup virus. 
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NUCLEOTIDE SEROGROUP VIRUS 
Total 5’NCR 3’NCR A + U 
(%) 
AMINO ACID 
 
N                 NSs 
REFERENCE 
Ana A 
 (ANAV) 
947 53 156 63 245 No NSs This study Anopheles  
 A 
Tacaiuma 
(TCMV) 
960 42 181 62 245 No NSs This study 
Ana B 
 (ANBV) 
991 35 213 57 247 No NSs This study Anopheles  
B 
Boraceia 
(BORV) 
982 35 203 56 247 No NSs This study 
Bwamba Bwamba 
(BWAV) 
1096 81 310 65 234 92 This study 
Capim Capim 
(CAPV) 
991 
(P) 
ICS ICS ICS 235 No NSs This study 
Gamboa 
(GAMV) 
1170 
(P) 
86 ICS 62 238 130 This study Gamboa 
San Juan 
(SJ2441V) 
1250 94 439 62 238 137 This study 
Bertioga 
(BERV) 
695 
(P) 
ICS ICS ICS 111 (P) ICS This study Guama 
Guama 
(GMAV) 
621 
(P)  
ICS ICS ICS 88 (P) ICS This study 
Minatitlan Palestina 
(PLSV) 
662 
(P) 
ICS ICS ICS 220 (P) ICS This study 
Eretmapodites 
(E147V) 
902 45 155 58 233 92 This study Nyando 
Nyando 
(NDV) 
941 70 170 58 233 92 This study 
Patois Pahayokee 
(PAHV) 
768 
(P) 
ICS ICS ICS 176 (P) ICS This study 
Tete  
(TETEV) 
1022 73 172 58 258 No NSs This study Tete 
Batama 
(BMAV) 
1021 73 171 58 258 No NSs This study 
Turlock M’poko 
(MPOV) 
1075 117 247 61 236 79 This study 
Bunyamwera 
 
BUNV 961 85 174 58 233 101 Elliott et al., 
1989 
 129 
California  California  
Encephalitis 
(CEV) 
978 78 192 58 235 97 Bowen et 
al.,1995 
Group C 
 
Itaqui 
 (ITQV) 
920 76 139 54 234 98 Nunes et al., 
2005 
Simbu Oropouche 
(OROV) 
754 44 14 53 231 91 Saeed et al., 
2000 
 
Table 4.2 Summary of the positive-sense RNA sequences obtained from this study 
and also from the prototype virus for each published serogroups; Bunyamwera (BUNV), 
California (CEV), Group C (ITQV) and Simbu (OROV). P indicates partial; ICS –
incomplete sequences; NCR-non coding region; REF represents reference; F and + 
represent forward; A-adenine and U-Uridine 
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of these viruses were also found to have more A and U residues (more than 55%) 
compared to G and C residues.  
 
The S segments of viruses in Bunyamwera, California, Group C and Simbu serogroups 
encode N and NSs proteins in overlapping reading frames. Similar organisation was 
observed in NDV, E147V, BWAV, MPOV, SJ2441V and GAMV S sequences (Figure 4.1 
and Table 4.2), whereas, no potential NSs ORF was detected in ANAV, TCMV, ANBV, 
BORV, BMAV, TETEV and CAPV. Except for CAPV, all these viruses were found to 
have longer N proteins compared to those viruses that encode an NSs protein (Table 4.2). 
 
4.2.3 Identification of potential NSs ORF in the S segments  
 
The S segments of Bunyamwera, California, Group C and Simbu serogroup viruses encode 
the NSs protein in the +1 frame with respect to N. There are 16 nucleotides difference 
between the N and NSs initiation codons of Bunyamwera and California serogroup viruses, 
and 19 nucleotides different for viruses in Group C and Simbu serogroups. This study 
detected the NSs ORF only in Bwamba, Turlock, Nyando and Gamboa serogroup viruses 
but not in Anopheles A, Anopheles B and Tete serogroup viruses. To determine the 
possible initiation codon of NSs protein, the initiation codons for N and NSs were aligned 
without gap using ClustalW program (Figure 4.2). The alignment showed that only the 
NSs initiation codons of NDV, E147V and BWAV had similar spacing as BUNV and 
CEV, whereas the spacing between the ATG of N and NSs protein of SJ2441V, GAMV 
and MPOV were found to be 4, 25 and 34 nucleotides respectively. The complete 
sequences of the S segments were subjected to analysis by the FRAMES program using 
DNAMAN software (Figure 4.3). From this analysis, a short ORF was detected in BORV, 
CAPV and TCMV. However they were considered too short to encode for NSs protein due 
to the presence of multiple stop codons in the frames. Different initiation codons were 
present at the same relative spacing as BUNV and CEV in BMAV (GTG) and CAPV 
(TTG), and at the same relative spacing as OROV and ITQV in ANAV (TTG), TCMV 
(ACG), ANBV (TTG) and BORV (TTG), and TETEV (ATC). 
 
Previously, it has been shown the presence of six conserved nucleotides between the N and 
NSs initiation codon of viruses in Bunyamwera and California serogroups (Figure 4.2) 
(Dunn et al, 1994). However, only five of these nucleotides were present in OROV and  
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MPOV            ---ATGTCAGACCTTGTGCTCACATTTTCAGACTCCGACGATGTCAGTCGAAGTACTTA---56 
SJ2441V         ---ATGTCTAATGATCTTTACGTATTCGACGATGATACGTCGGCAAGCTCTAGCTCTTA---56 
GAMV            ---ATGTCTGACTCTCTATACGTATTTGACGATGATTCGACGGCAAGCTCTAGCACTTA---56 
OROV            ---ATGTCAGAGTTCATTTTCAACGATGTACCACAACGGACTACATCTACATT---------50 
ITQV            ---ATGTCAGAGTTCATTTTCAACGATGTACCCTCATTCACAGACAATACATT---------50 
CEV             ---ATGTCGGACTTGGTTTTCTATGATGTCGCATCCACAGGTGCAAATGGATT---------50 
BUNV            ---ATGATTGAGTTGGAATTTCATGATGTCGCTGCTAACACCAGCAGTACTTT---------50 
NDVV            ---ATGTCGGAACTGGTGTTCTATGATGTCGAGCCAACTGCCCAAAATGGATT---------50 
E147V           ---ATGTCTGAGATCGCTTTTTATGATGTCCAGTCTACTGCCCAAAATGGATT---------50 
BWAV            ---ATGTCCGATTTGATCTTCTATGATGTCGACTCGGTTAATGCCAATGAGTT---------50 
ANAV            ---ATGTCATCCATGGATTATATGTTTGACGATCCTGGTCATATCCAGATCATCAACTA---56 
TCMV            ---ATGTCAGGAATAGATTTCATCTACGATGATCCTGGTAGGATCCAGCAATCAGACTTTG-56 
ANBV            ATGGCGTCTCAAGTTGATTTTGCTTTTGAAGACACAGGAAATATCACTCAGTCTGACTT---59 
BORV            ATGTCGTCTACTGTGGATTTCGCATTTGAAGACACAGGGAATGTCACTCAGTCTGACTT---59 
TETEV           ---ATGCCCAAAGGAGGAAAAAGCGATCCTGAACCATCCATCAACGTTGTTGC---------50 
BMAV            ---ATGTCCAAAGTAAAAAGAGGTGAGTCAGAACCATCAATCAGCGTTGCAGC---------50 
CAPV            ---ATGGGAGAAGTTGCTAATTTTGAATTTGGTGAGCGTTTGATAGCAGAAGG---------50 
                                                                            
 
 
Fig. 4.2 Alignment of initiation codon of  N and NSs proteins of the 5’region of positive 
sense S segment to indicate their spacing. Red bold letters denote the initiation codon of N 
protein; blue bold letters denote initiation codon of NSs protein; brown bold letter denotes 
possible initiation codon of NSs protein; green bold letters indicates conserved nucleotide 
in-between the spacing relative to BUNV and CEV and dotted lines indicate gaps inserted 
to maximize identity. 
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A.ANAV 
 
 
 
 
 
 
B.TCMV 
 
 
 
 
Fig. 4.3   Open reading frames of ANAV, ANBV, BORV, BMAV, CAPV, TCMV, 
TETEV and control virus BUNV using the DNAMAN programme (Lynnon biosoftware). 
The red boxes represent the N protein ORF, blue boxes represent the NSs protein ORF and 
green boxes represent the potential NSs protein ORF. The upper vertical lines indicate the 
start codons and lower vertical lines are for stop codons. 
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ITQV. In this study, only viruses in NDV serogroup (E147V and NDV) have all the six 
conserved nucleotides; BWAV has five, MPOV has 4, GAMV has three and SJ2441V has 
any of them. However, some of these conserved nucleotides were also present in the NSs 
minus viruses, for example; ANBV and TCMV has five, while other viruses (ANAV, 
BORV, TETEV, BMAV and CAPV) have four or less of these nucleotides. Therefore, it is 
very difficult to relate the presence of these conserved nucleotides with the present of NSs 
protein. Most of the viruses in Bunyamwera and California serogroup start their NSs 
protein with double methionine. However in this study, only BWAV, E147V and NDV 
followed this pattern.  
 
4.2.4 Sequences analysis of 3’/5’ NCR  
 
In agreement to previous findings with viruses in Bunyamwera, California, Group C and 
Simbu serogroups, alignments of 5’ and 3’ NCR of the positive-sense RNA of the viruses 
used in this study revealed that the 3’ NCR is longer than 5’NCR. The longest 3’ NCR was 
observed in SJ2441V (439 nucleotides), while the longest 5’NCR was detected in MPOV 
(117 nucleotides). These regions were found richer in A and U compared to C and G. The 
nucleotide sequences of 3’/5’ NCR were largely non-conserved between the serogroup 
viruses, except in the first 15 nucleotides of the terminal sequences (Figure 4.4). This is as 
expected since these are the primer sequences used to obtain the products. However, some 
conserved nucleotide sequences were observed within the viruses in the same serogroup. 
As reported in Bunyamwera and California serogroup viruses, the non-canonical 
nucleotide pairing (G and U) at position 9 of the 3’/5’ terminal sequences was also 
observed in ANAV, ANBV, BMAV, BWAV, BORV and MPOV. However, some of the 
viruses such as TCMV, TETEV, SJ2441V, E147V and NDV were found to have the same 
nucleotide sequence at these positions (either both A or G), suggesting that the same 
primers had annealed to their both ends. As observed in OROV (Figure 4.4), the CA-rich 
motif in the 5’ NCR of virus-sense S segments downstream of the predicted mRNA 
termination site was also not observed in BWAV and MPOV. However ANBV and BORV 
were found to have two copies of this motif that are separated by 19 nucleotides. An 
extensive GAU/AU/GU-rich motif was observed in the 5’NCR of most of the studied 
viruses especially in BWAV, MPOV and SJ2441V with more than 74% of A and U 
residues. Using the DNAMAN software, repeated sequences as observed in LUMV (Dunn 
et al., 1994) were also detected in BWAV and TCMV (Figure 4.5). 
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OROV            ------------------------------------------------------------ 
MPOV            ------------------------------------------------------------ 
CEV             ------------------------------------------------------------ 
E147V           ------------------------------------------------------------ 
NDVV            ------------------------------------------------------------ 
ITQV            ------------------------------------------------------------ 
TETEV           ------------------------------------------------------------ 
BMAV            ------------------------------------------------------------ 
SJ2441V         CUUGGUCUAGUAAAAAACUUUACAAAAUUAUAAACUGUUAAAAAUAAUGAGAAAAUUUUG 60 
BUNV            ------------------------------------------------------------ 
ANBV            ------------------------------------------------------------ 
BORV            ------------------------------------------------------------ 
ANAV            ------------------------------------------------------------ 
BWAV            ------------------------------------------------------------ 
TCMV            ------------------------------------------------------------ 
                                                                             
 
OROV            ------------------------------------------------------------ 
MPOV            ------------------------------------------------------------ 
CEV             ------------------------------------------------------------ 
E147V           ------------------------------------------------------------ 
NDVV            ------------------------------------------------------------ 
ITQV            ------------------------------------------------------------ 
TETEV           ------------------------------------------------------------ 
BMAV            ------------------------------------------------------------ 
SJ2441V         AAAAACAUAUAUAUGAAAAUAUAAUAUAAAAAUAGUUAUAAAUUGGUCACAUUGGUAUAA 120 
BUNV            ------------------------------------------------------------ 
ANBV            ------------------------------------------------------------ 
BORV            ------------------------------------------------------------ 
ANAV            ------------------------------------------------------------ 
BWAV            ------------------------------------------------------------ 
TCMV            ------------------------------------------------------------ 
                                                                             
 
OROV            ------------------------------------------------------------ 
MPOV            ------------------------------------------------------------ 
CEV             ------------------------------------------------------------ 
E147V           ------------------------------------------------------------ 
NDVV            ------------------------------------------------------------ 
ITQV            ------------------------------------------------------------ 
TETEV           ------------------------------------------------------------ 
BMAV            ------------------------------------------------------------ 
SJ2441V         UAGGUCAAUUAGGUAUAUAUCCUGUAUAUAUAUAAAAAUAAUUCUAAUAUAGUUAUAUAU 180 
BUNV            ------------------------------------------------------------ 
ANBV            ------------------------------------------------------------ 
BORV            ------------------------------------------------------------ 
ANAV            ------------------------------------------------------------ 
BWAV            ------------GGUCGGUAUACGUUUAUAAAUCGAUAGUGAUUUUGUAUAUUGGUUAUA 48 
TCMV            ------------------------------------------------------------ 
                                                                             
 
OROV            ------------------------------------------------------------ 
MPOV            ----------------------------UAAAGUAUAAGGUUUAAUUAUAAAGUACACAA 32 
CEV             ------------------------------------------------------------ 
E147V           ------------------------------------------------------------ 
NDVV            ------------------------------------------------------------ 
ITQV            ------------------------------------------------------------ 
TETEV           ------------------------------------------------------------ 
BMAV            ------------------------------------------------------------ 
SJ2441V         AGUAUAGGUCAUUAUACAUUGGGUAUGAUAGGACUAAAUAGUUAAAAAUAAUAUAAUAAG 240 
BUNV            ------------------------------------------------------------ 
ANBV            ---------------------------------------------GGUGUCACGAAGUAG 15 
BORV            ----------------------------------------------GUAUUG-GAAGU-- 11 
ANAV            ------------------------------------------------------------ 
BWAV            GUUAUUGGUAUCCUGUAUAUAUUUUAUUUUAUAUUUUAUGUUUUUUUGUUUAUUUUGUAU 108 
TCMV            -------------------------------------------------------CGUAU 5 
                                                                             
 
OROV            ------------------------------------------------------------ 
MPOV            UAGAGGAUAAUAUAGGUUAUAUAAUAGGUUAAAUAGGUAUAUAUUGGUUAAAUAUUAGAA 92 
CEV             --CGAGGCCGUCCGUUUAACAAAUCCUGAUUUAAAAUUUUAUUAACCUAUAAAGUUUUAA 58 
E147V           ----------------------CUUUCGAUAAAGUCUUAAAUUAACCAAACAUGUGCAUA 38 
NDVV            -------------------AAGUAUUUUAUAUGCGGAUAAGCUGAGGUUUAAGAU-UUUA 40 
ITQV            -------------------------------GGUAAUCGUGCUAACUUUAAAAAUCUCGA 29 
TETEV           ----------------------------------UGUUAAGAGAAAAUUCUCUAUCCCCA 26 
BMAV            ---------------------------------UUAUUAAGAGAAAAUUCUCUAUCCCCA 27 
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SJ2441V         GUGUAGUAAAUCAAAAUCGUUUUAAACCAUUCCUGAUUGUUAUGAUUGUUAAAAUAUCCA 300 
BUNV            ---------------------------CGUCCCUACGUAAAAAUUAGCCCGAUUUCAGUA 33 
ANBV            AGUAUGACAUUUAUCUAU-AGGUAUAAUUAG CCUUGGUAUAUAUCAGUUAUAUAUUGGUA 74 
BORV            -GUAUAUAGAUCGUCAAUCAGAUAUA-------UUGGUA-AUAUUAGGUAUAAAUCUCCA 62 
ANAV            -------------------------------AAGUACUA-AUGUUAGUUA-AAAUAGGUU 27 
BWAV            AUAUUUUUAUUAUUUUU-UAUAUCCCAAUCCCAUUUU--UGUUUUUGUUUUUUGUGUUUU 165 
TCMV            -CGUUUAUGUCAGACUUAUAGAUUGUGAUUGUAAUUUAGUGUAUAUGAUAUUUGUGAUUG 64 
                                                                             
 
OROV            ------------------------------------------------------------ 
MPOV            --AAUCAAUAGAAUUCAAAUAAUUAGUAUGAUUAUUAAAUCAAAAUUCAAAAGUAGAUUA 150 
CEV             UCAAUUAACCGAUUGAUUUUCCCAAGGAUCCCCGGGUGUUGGUAUCGUCGAUUUAC-CCA 117 
E147V           AUAGUUAACCGAUAAAGUUUUCUGGAAGCCC---AGUGUUAUAGUCGUCGACCCAC-CCA 94 
NDVV            UAAAUUAAACUGU--GGUUUUCUGGAAGCCC-----AGUUUCGGCUGUCGAAUUAC-CCA 92 
ITQV            AGAGUUCUUCGGU--UAUGUUCUGGG--------------------GUCGUAUUGC-CCA 66 
TETEV           ACCAUAAAUAUAUGGUUGAGGCUGUACAUUUG—UCGAAUUCAUUCGACAUUAUACUCCA 84 
BMAV            ACCAUA—UAAAUGGUUGGGGCUGUACAUUUG—UCGAUUUAAUUCGACGUUAUACACCA 83 
SJ2441V         UCAAAAUCAUGAUUGUGUAAUCUGAUCAAUCC--UGGGUUUUCGUCGACAGU-UAC-CCA 356 
BUNV            GACAAAAUUAAACCGAUUUUCCCAACAAAGUU—GGGUGUUUUAUUGUCGACGAAC-CCA 90 
ANBV            -UA-UAUAUAUAUUAUCCCCCACCACCACCCC—GAAGUUUGUCGUAUUGUA-UAC-CCA 128 
BORV            -AAACCCAUCUAUAAUCCCCAGUCCCCCCACC—CUGACCCGUCGUUCUCUA-UAC-CCA 117 
ANAV            -CAAUUAGCGUAUAUUAGU--GUUUAUAAUUA—GUGAUUGUAAAUAUUAAAACCC-CCA 81 
BWAV            UUUGUGUGUUUUUGUGUUUUUUUGUUUUUUUG--UGUGUUGUGUGUGUUGUCGUUA--UU 221 
TCMV            UAAUUUAGUGUAUGUGAUAUUCGUGAUGUAUG--UG-AUUUUAUG-AUUGUGUUCC--CA 118 
                                                                             
 
OROV            ------------------------------------------------------------ 
MPOV            GAAGUAGAUUAGUAGGGGGUAGGGGUAGGUUAUUGUCGCGUUAUUUAGUUACAUAAGUUC 210 
CEV             CCCACCAUCCCCUGUCGUU—UUAUUAUCUUCGAUUUA-GUAAUUAAA-------UUAUU 167 
E147V           CCAUCCCCUUGUGGUUUAU—AGAUUAACUCAGAUCUA-ACAAUUUA--------UUUUU 143 
NDVV            CCCACCAUCCCCUUUGUAU—CGA-------AGUUUUC-GUAAAAAA------------- 129 
ITQV            CCCACCAGCCCCUGUGCUU—GUAAUAAU CCACACUAAAGUGAUUAA----------UUU 114 
TETEV           CCCACCAACCCCGUUCCAAGUCUAGUUGAGUAACGUUAGAAUAAGAAGUAAU---AAGAA 141 
BMAV            CCCACCAACCCCGUUCUAAGUCUAGUUGAGUAAUGUUAGAAAAAGGAGUAGU---AAUCA 140 
SJ2441V         CCCACCAGCCCCGUUGAAA---CGGUUAAAGAAGUUUAGUAAAAUCAUCUA----AUUUA 409 
BUNV            CCCACCAACCCCUGUCU---UUCUGUCGCCCGAUUUAGUUGUAAUA—UAAC---AAUUA 142 
ANBV            CCCACCAACCCCUGUCGUU—GACAAU-AUAAGUUUUAACUGUAUACGAAGC---GACAU 182 
BORV            CCCACCAACCCCUGUCGUA—AGUUUUGAUGACGUUUAUAUGUAUACUCUAC---GUCUU 172 
ANAV            CCCACCAACCCCUGUCGUA--GAUUC--AUUAG—UCAACU-UAUAA--------GAUUU 126 
BWAV            UCUUUCAUCACUUGUCACAAGAGUACCGGCUAUAAUUAGAAACGAACCGAUU---ACCUU 278 
TCMV            CCCACCAACCCCUGACGUAGAAUAAUCGAC---AAUCAAAAACAGAACUAC----ACCUC 171 
                                                                             
 
OROV            -----------------------ACCUCGUGUGAUGA 14 
MPOV            AAACGUAAUUAAUUAUCAUCAGCACCUCGUGUGAUGA 247 
CEV             UUCCAUAAGU------------CACCUCGUGUGAUGA 192 
E147V           AGUUAUAAGUAA----------CACCUCGUGUGAUGA 170 
NDVV            -GUUUUAAGUAA----------CACCUCGUGUGAUGA 155 
ITQV            AGAUCUUAAC------------CACCUCGUGUGAUGA 139 
TETEV           AGACAAGAAUAUAUU------UCACCUCAUGUGAUGA 172 
BMAV            AGAUAAGAAUACAUAGG----UCACCUCGUGUGAUGA 173 
SJ2441V         GUUUGCUUACAAAUG-------CACCUCGUGUGAUGA 439 
BUNV            CCAUAA-AAUUCAAAAU----CCACCUCGUGUGAUGA 174 
ANBV            U-AUAUUAGAAAAUA-------CACCUCGUGUGAUGA 211 
BORV            UUAUGUUAGAUAUUU-------CACCUCAUGUGAUGA 202 
ANAV            UAAUACAUGAAA-UA-------CACCUCGUGUGAUGA 155 
BWAV            UAUUAAUUUCCAUGAAU-----CACCUCGUGAGAUGA 310 
TCMV            AUGUGAUGA---------------------------- 180 
 
 
Fig. 4.4 Alignment of complete 5’ NCR of virus-sense S RNA segments. Dotted lines 
indicate gaps inserted to maximize identity, green letters represent the CA-rich region 
RNA, blue bold letters represent GU rich motif and red bold letter represent the G/A/U-
rich region. 
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BWAV 
  
61  CUGUAUAUAUUUUAUUUUAUAUUUUAU 87 
103 UUGUAUAUAUUUUUAUUAUUUUUUAUA 129  
  
 
151 UGUUUUUUGUGUUUUUUGU 170 
171 GUGUUUUUGUGUUUUUUUG 189 
 
 
TCMV 
                             
27 UUGUGAUUGUAAUUUAGUGUAUAUGAUAU 56 
57 UUGUGAUUGUAAUUUAGUGUAUGUGAUAU 85  
 
 
Fig. 4.5  Presence of repeated sequences in 5’ NCR of virus-sense RNA. Red letters 
indicate the duplicated sequences 
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4.2.5 N nucleotide and protein comparison 
 
Viruses in the Bunyamwera, California, Group C and Simbu serogroups were reported to 
have the same length of N protein, 233, 235, 234 and 233 amino acids respectively. As 
seen in Table 4.2, the same number of amino acids was also observed in the N proteins of 
viruses within the same serogroup; ANAV and TCMV (245), ANBV and BORV (247), 
GAMV and SJ2441 (238), NDV and E147V (233), and TETEV and BMAV (258). The N 
protein of Tete serogroup viruses was the longest reported to date among 
orthobunyaviruses. Amino acid sequence alignment of the N proteins of these viruses 
(Figures 4.6) revealed that the extensions of the N protein sequence of BMAV and TETEV 
were at the amino terminus. However truncation of the N protein at the carboxyl terminus 
was also observed for these viruses. Furthermore, 8 amino acids were apparently inserted 
after amino acid 23 of their amino terminus. In agreement with previous reports, amino 
acid sequence alignments of this study also revealed the presence of some conserved 
motifs in the N protein of these viruses.  
 
The nucleotide and predicted amino acid sequences of the N protein coding region of 
complete and partial S sequences of the viruses obtained in this study, together with the 
published sequences for representatives of other serogroups, (BUNV, CEV, ITQV and 
OROV) were compared (Table 4.3). Except for ANAV and TCMV in the Anopheles A 
serogroup, whose S segments have only 59% nucleotide sequence identity and 53% amino 
acid identity between the N proteins, the S segments and encoded N protein of the viruses 
within the same serogroup were found to have nucleotide and amino acid sequence identity 
greater than 70%. N sequence identity between viruses in different serogroups was as low 
as 24% for amino acid sequences and 5% for nucleotide sequences, which were observed 
between TCMV with TETEV and BMAV, and between ANBV with GAMV and OROV 
(Table 4.3). This low value could be due to the more serogroups (12 serogroups) used in 
these comparisons compared to only four in the previous comparisons. However, greater 
sequence identity was also observed between CAPV with viruses in Guama serogroup 
(BERV and GMAV), with 80% and 77%, and 73% and 74% for amino acid and nucleotide 
identity respectively, while BERV and GMAV exhibited 73% identity for both nucleotide 
and amino acid sequences, indicating that BERV and GMAV are closer to CAPV than to 
each other. BWAV was found to exhibit high sequence identity with CEV with nucleotide 
and amino acid sequence identity of 70% and 68% respectively.  
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Caraparu_BeAn3994            ---------------MIELIFKD--------VASFTDNTFDPEAAFLRFE 27 
Itaqui_BeAn12797             ---------------MIELIFKD--------VPSFTDNTFDPEAAFLRFE 27 
Vinces                       ---------------MIELIFKD--------EPSFTDNTFDPEAAFLRFE 27 
Murutucu_BeAn974             ---------------MIELIFKD--------VASFTDNTFDPEAAYLRFE 27 
Restan_TRVL51144             ---------------MIELIFKD--------VASFTDNTFDPEAAYLRFE 27 
Marituba_BeAn                ---------------MIELVFKD--------VASFTDNTFDPEAAYVRFK 27 
Nepuyo_TRVL18462             ---------------MIELVFKD--------EASFTDNTFDPEAAYVRFK 27 
Gumbo_LimboFE-371H           ---------------MIELVFKD--------ETSFADNTFNPEAAFVAFK 27 
Madrid_BT4075                ---------------MSELEFKD--------VPSFADNTFNPEAQYVTFI 27 
Aino                         --------------MANQFIFQD--------VPQRNLATFNPEVGYVAFI 28 
Akabane                      --------------MANQFIFND--------VPQRNAATFNPDAGYVAFI 28 
Oropouche                    ---------------MSEFLFND--------VPQRTTSTFDPEAAYVAFE 27 
Maguari                      ---------------MIELEFND--------VAANTSSTFDPEIAYVNFK 27 
Cache_Valley                 ---------------MIELEFND--------VAANTSSTFDPEIAYVNFK 27 
Batai                        ---------------MIELEFND--------VAANTSSTFDPEVAYINFK 27 
Bunyamwera                   ---------------MIELEFND--------VAANTSSTFDPEVAYINFK 27 
Main_Drain                   ---------------MIELEFHD--------VAANSSSTFDPEVAYASFK 27 
Kairi                        ---------------MSEIEFHD--------VTANTSSTFDPEAGYAAFK 27 
California_encephalitis      ---------------MSDLVFYD--------VASTGANGFDPDAGYVDFC 27 
Tahyna                       ---------------MSDLVFYD--------VASTGANGFDPDAGYVDFC 27 
La_Crosse                    ---------------MSDLVFYD--------VASTGANGFDPDAGYMDFC 27 
Jameston_Canyon              ---------------MGDLVFYD--------VASTGANGFDPDAGFVAFM 27 
Keystone                     ---------------MGDLVFYD--------VASTGANGFDPDAGYVAFM 27 
BWAV                         ---------------MSDLIFYD--------VDSVNANEFDPDTGYLDFK 27 
E147V                        ---------------MSEIAFYD--------VQSTAQNGFDPDQQYLAFK 27 
NDV                          ---------------MSELVFYD--------VEPTAQNGFDPDKQYVAFK 27 
CAPV                         ------------MGEVANFEFGER-------LIAEGRNPFVPDVAYARFI 31 
ANA_BV                       ------------MASQVDFAFED--------TGNITQSDFIPDVGYTAFC 30 
BORV                         ------------MSSTVDFAFED--------TGNVTQSDFVPDVGYTTFC 30 
TCMV                         -------------MSGIDFIYDD--------PGRIQQSDFVPREEYAVFC 29 
Anopheles_A                  -------------MSSMDYMFDD--------PGHIQIINYIPEEEYMAFC 29 
GAMV                         -------------MSDSLYVFDD--------DSTASSSTYDPTQEYNVFI 29 
SJ2441V                      -------------MSNDLYVFDD--------DTSASSSSYDPKREYDKFI 29 
MPOV                         -------------MSDLVLTFSD--------SDDVSRSTYNPGEEYDTFV 29 
TETEV                        MPKGGKSDPEPSINVVASAAFEDDEIDYHFTAGDDGGAPFNPMTAYKRFM 50 
BMAV                         MSKVKRGESEPSISVAASAAFAEDEIDYHFSAGDDGGAPFNPMAAYKEFM 50 
                                                 : :                : *   :  *  
 
 
Caraparu_BeAn3994            SAYGSQLVSAVVRVFYINAAKVKAYLSRSSELLVFLTLGGVNLAVLNTHF 77 
Itaqui_BeAn12797             SAYGRQLVSAVVRVFYINAAKVKAYLSRSSELLVFLTLGGVNLAVLNTHF 77 
Vinces                       SVYGQQLVAAVVRVFYINAAKVKAYLRRSRELLVFLTLGGVNLAVLNTHF 77 
Murutucu_BeAn974             SDYGSQLESAIVRVFYINAAKVKAYLRRSSELLVSLTLGGVNLAVLNTHF 77 
Restan_TRVL51144             SAYGSQLESAIVRVFYINAAKVKAYLRRSSELLVSLTLGGVNLAVLNTHF 77 
Marituba_BeAn                PAYGSELESSIVRVFYINAAKVKAYLRRSSELLVLLTLGGVNLAVLNTHF 77 
Nepuyo_TRVL18462             PAYGSELESAIVRVFYINAAKVKAYLRRSSELLVSLTLGGVNLAVLNTHF 77 
Gumbo_LimboFE-371H           PTHGSELESSTVRIFYINAAKVKAYLRRSAEQLVSLTLGGVNLAVLNTHF 77 
Madrid_BT4075                PRNGRVLEATIVRIFYINAAKVKAYLHRSSEQLVLLTLGGVNLAVLNTHF 77 
Aino                         AKHGAQLNFDTVRFFFLNQKKAKMVLSKTAQPSVDLTFGGIKFTLVNNHF 78 
Akabane                      SKYGQQLNFTVARVFFLNQKKAKMVLHKTPQPSVDLTFAGVKFTVVNNHF 78 
Oropouche                    ARYGQVLNAGVVRVFFLNQKKAKDVLRKTSRPMVDLTFGGVQFAMVNNHF 77 
Maguari                      RIHTTGLSYDHIRVLYIKGREIKTSLTKRSEWEVTLNLGGWKVAVFNTNF 77 
Cache_Valley                 RIHTTGLSYDHIRIFYIKGREIKTSLTKRSEWEVTLNLGGWKVTVFNTNF 77 
Batai                        RIYTTGLSYDNIRIFYIKGREIKTSLSKRSEWEVTLNLGGWKVTVFNTNF 77 
Bunyamwera                   RLYTTGLSYDHIRIFYIKGREIKTSLAKRSEWEVTLNLGGWKVTVFNTNF 77 
Main_Drain                   RVHTTGLSYDHIRIFYIKGREIKTSLSKRSEWEVTLNLGGWKVAVFNTNF 77 
Kairi                        RRHTTGLNYDHIRIFFLNGKKAKDTLSKRSETTITLNFGGWKIPVVNTHF 77 
California_encephalitis      AKHGESINLAAVRIFFLNAAKAKAALSRKPERKANPKFGEWQVEVVNNHF 77 
Tahyna                       IKHGEAINLHSVRIFFLNAAKAKAALARKPERKASPKFGEWQVEVVNYHF 77 
La_Crosse                    VKNAESLNLAAVRIFFLNAAKAKAALSRKPERKANPKFGEWQVEVINNHF 77 
Jameston_Canyon              ADHGESINLSAVRIFFLNAAKAKAALARKPERKATPKFGEWQVEIVNNHF 77 
Keystone                     ANHGESISLSTVRIFFLNAAKAKAALTRKPERKATPKFGEWQVEIVNNHF 77 
BWAV                         NNYPGALNTNTARTFFLNAAKAKNVLRNKPDKKVNPKFGNWEVEVVNNHF 77 
E147V                        AAAGAGLNIVSARIFFLNARKAKDQLSRRPEPKINLKFGTWSVEVVNNHF 77 
NDV                          ASAGAGLNIVSARIFFLNARKAKDQLARRPEPKVGLKFGTWQVEVVNNHF 77 
CAPV                         REHVPMLTPGNIRIFFLRAYDAKQKLKTTTARTANLKFGTATFTVKNNHN 81 
ANA_BV                       LGKTAHLSLENIKIFFLNAGKLKQQMKTCSKTKIKAKFGTLEIELVNTLN 80 
BORV                         IGRSNQLSLENIKIFFVNAGKLKMQMKSSLKPRIKAKFGTLEIEMVNTLN 80 
TCMV                         SKFALVLILQNIRIFFLNAGKLKAALKLSPKRKVKAKFGTLEVEITNTHN 79 
Anopheles_A                  AKYQDQLTVENIRIFFLNAGKFKKMLRTNPKLKVQVKFGTLQLEIINTHN 79 
GAMV                         STHGDQLTPANIKCFFLHARTAKARLAKDPAERRTLTFGSWKVEVVNNHY 79 
SJ2441V                      STYGQQLTPANIKCFLLHARTAKARLSKDPAERRTLTFGTWKVEVVNNHY 79 
MPOV                         DTYREHLTVDNIRIFFLKAAEAKAHMAKVNNEVVEVHFGTLVLPLVNNHK 79 
TETEV                        EVHGKELNLPNIKVFFLKARQAKEIMRSKAKSEMTFTFGSLTLTFKNTHH 100 
BMAV                         ETHGKDLTVTNIRVFFLKARQAKEIMRSKAKSEMTFTFGSLTLTFKNTHH 100 
                                   :     : : :.    *  :           :.   . . *    
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Caraparu_BeAn3994            PGTQSIPLPDYGLTLHRISGYLARWALYLIRTNPESDIAL-VRSTFVVPL 126 
Itaqui_BeAn12797             PGTQSIPLPDYGLTLHRISGYLTRWALYLIKTNPESDIAL-VRSTFVVPL 126 
Vinces                       PGTQSIPLPDYGLTIHRISGYFSRWALYLIATNPESDIAL-VRSTFVVPL 126 
Murutucu_BeAn974             PGTQSIPLPDYGLTIHRLSGYLSRWALYLIRPSPESEIGL-VRSTFIVPL 126 
Restan_TRVL51144             PGTQSIPLPDYGLTLHRLSGYLARWALYLIRPSPESDIGL-VRSTFIVPL 126 
Marituba_BeAn                PGTQSIPLPDYGLTIHRLSGYLSRWALYLIYIIPESEIDL-VRTTFIVPL 126 
Nepuyo_TRVL18462             PGTQSIPLPDYGLTIHRLSGYLARWALYLICPIPDSDIDL-VRTTFIVPL 126 
Gumbo_LimboFE-371H           PGTQSIPLPDYGLTIHRLSGYLARWALYLICPSPDSSIGL-VRATFVVPL 126 
Madrid_BT4075                PGNQSIPLPDYGLTIHRVSGYLARWALYLIAPSPYSDRDI-VRTTFIVPI 126 
Aino                         PQYTANPVPDTALTLHRLSGYLAKWVADQCKTN-QIKLAE-AMEKIVMPL 126 
Akabane                      PQYTANPVSDTAFTLHRISGYLARWVAEQCKAN-QIKFAE-AAATIVMPL 126 
Oropouche                    PQFQSNPVPDNGLTLHRLSGYLARWAFTQMRS--PIKQAE-FRATVVVPL 124 
Maguari                      PGNRNSPVPDDGLTLHRLSGFLARYLLEKILKVSDPEKLI-IKSKIINPL 126 
Cache_Valley                 PGNRNSPVPDDGLTLHRLSGYLARYLLEKILKVSDPEKVI-IKSKIINPL 126 
Batai                        PGNRNSPVPDDGLTLHRLSGFLARYLLEKILKVSDPEKLI-IKSKIVNPL 126 
Bunyamwera                   PGNRNSPVPDDGLTLHRLSGYLARYLLEKILKVSDPEKLI-IKSKIINPL 126 
Main_Drain                   PGNRNSPVPDDGLTLHRLSGFLARYLLEKILKVSEPEKLL-IKSKIINPL 126 
Kairi                        LENRNMSVPDDGLTLHRVSGYLARYLLDRVYSAGEPEKLK-IKTTIINPI 126 
California_encephalitis      PANRNNPIGNNDLTIHRISGYLARWVLEQYKENEDESQRELVKTTVINPI 127 
Tahyna                       PGNRNNPIDNNDLTIHRLYGYLARWVLEQFKENEDAAQRELIKTTVINPI 127 
La_Crosse                    PGNRNNPIGNNDLTIHRLSGYLARWVLDQYNENDDESQHELIRTTIINPI 127 
Jameston_Canyon              SGNRNNPIGNNDLTIHRLSGYLARWVLEHFNSDDDESQRELIRSTIINPI 127 
Keystone                     PGNRNNPIGNNDLTLHRISGYLARWVLEHFGEGEDESQKELIKSTVINPI 127 
BWAV                         PGNRNNPIGKDDLTLHRISGYLARWILEEYKR-DDESEKEIIESTVINPI 126 
E147V                        QGNRDNVISDTDLTIHRLSGYIARFILDQYLAGNTVVQSG-IQLQIVNPI 126 
NDV                          QGNRDNPIGDSDLTMHRLSGYIARYILDQYLAGNSVAQAG-IQLQIINPI 126 
CAPV                         ERNANIEVEAEDLTLHRISGFLAKFVRESMVDETASKMIR---DTIVNPI 128 
ANA_BV                       RSLGQVSLQPNDVTLHRASAYLARKALELYREGQADFQAA-MRDQFVMPL 129 
BORV                         KALGQISLQPTDLTLHRASAFLARRALEMYHGGAADFQAA-MRDQFVMPL 129 
TCMV                         RAFADSKLEKGDITLHRLSGFLAKKILDIYNAGSFDLQTQ-IKAEIIIPL 128 
Anopheles_A                  PANREIQLSSSDLTLHRVSAYLARKSLRLWEALTLDQKEE-FKLKIIMPL 128 
GAMV                         RRATPVTVQDHDNTLHRISGYLALYCLQTSSQNKQNFER--IKSVVINPI 127 
SJ2441V                      RRAAPITVQDHDLTLHRLSGYIALYCLQASVENAQSFER--IRSTVINPI 129 
MPOV                         PGRAQREVADSDLTLHRVSGYLAKFVLELYKKLRKSSEREAITSRIINPI 129 
TETEV                        PSNRHLAVEQDDLTINRVTGFMAHAILLTHRDPKHKDAVE---KTIINPI 147 
BMAV                         PSNRHLTVDQDDLTINRATGFMAYAILLTHREPKSKDAVE---KTIINPI 147 
                                    :    :*::*  .:::                      .: *: 
 
 
Caraparu_BeAn3994            AEENGITWR--DGVEMYLAFLPGAEMFMSTFEFYPLTIGMYRVRRWSMDP 174 
Itaqui_BeAn12797             AEENGITWR--DGVEMYLAFLPGAEMFMSTFEFYPLTIGMYRVRRWSMDP 174 
Vinces                       AEENGITWR--DGVEMYLAFLPGAEMFMSTFEFYPLTIGMYRVRRWSMDP 174 
Murutucu_BeAn974             AEENGITWS--DGVGMYLAFLPGAEMFMSTFTFYPLTIGMYRVRRWSMDP 174 
Restan_TRVL51144             AEENGITWS--DGVGMYLAFLPGAEMFMSTFAFYPLTIGMYRVRRWSMDP 174 
Marituba_BeAn                AEENGITWT--DGVAMYLAFLPGAEMFMSTFKFFPLTIGMYRVRRWSMDP 174 
Nepuyo_TRVL18462             AEENGITWT--DGVAMYLAFLPGAEMFMSTFTFFPLTIGMYRVRRWSMDP 174 
Gumbo_LimboFE-371H           AEENGITWC--DGVAMYLAFLPGAEMFMSTFAFFPLTIGMYRVRRWTMDP 174 
Madrid_BT4075                AEKNGITWC--DGVTMYLAFLPGSEMFMSTFRFFPLTIGMYKVQRWGMDP 174 
Aino                         AEVKGCTWT--EGLTMYLGFAPGAEMFLETFEFYPLVIDMHRVLKDGMDV 174 
Akabane                      AEVKGCTWS--DGYAMYLGFAPGAEMFLETFEFYPLVIDMHRVIKDGMDV 174 
Oropouche                    AEVKGCTWN--DGDAMYLGFAAGAEMFLQTFTFFPLVIEMHRVLKDGMDV 172 
Maguari                      AEKNGITWA--DGEEVYLSFFPGSEMFLGTFKFYPLAIGIYKVQKKEMEP 174 
Cache_Valley                 AEKNGITWS--DGEEVYLSFFPGSEMFLGTFKFYPLAIGIYKVQRKEMEP 174 
Batai                        AEKNGITWA--DGEEVYLSFFPGSEMFLGTFRFYPLAIGIYKVQRKEMEP 174 
Bunyamwera                   AEKNGITWS--DGEEVYLSFFPGSEMFLGTFRFYPLAIGIYKVQRKEMEP 174 
Main_Drain                   AEKNGITWA--DGEEVYLSFFPGSEMFLGIFKFYPLAIGIYKVQRKEMEP 174 
Kairi                        AASHGITWD--DGEEVYLSFFPGSEMYLTTFKFYPLAIGIYKVQRKLMDP 174 
California_encephalitis      AESNGIRWE--NGAEIYLAFFPGTEMFLETFKFYPLTIGIYRVKNGMMDS 175 
Tahyna                       AESNGIRWD--NGAEIYLAFFPGTEMFLETFNFYPLTIGIYRVKQGMMDP 175 
La_Crosse                    AESNGVGWD--SGPEIYLSFFPGTEMFLETFKFYPLTIGIHRVKQGMMDP 175 
Jameston_Canyon              AESNGIHWN--NGPEIYLSFFPGTEMFLEIFKFYPLTIGIYRVKHGMMDP 175 
Keystone                     AESNGIRWG--NGVEIYLSFFPGTEMFLELFKFYPLTIGIYRVKHGMMDA 175 
BWAV                         AESNGIRWS--DGAEIYLSFFPGTEMFLEPFKFYPLAIGIYRVKHKMMDA 174 
E147V                        AESNGIKWS--AGAEIYLSFFPGTEMFLEKFNFYPLAIGIYRVKRGMMDA 174 
NDV                          AESNGIKWS--AGAEVYLSFFPGTEMFLEKFNFYPLAIGIYRVKKGMMEA 174 
CAPV                         AESLGITWE--NGDDVYLSFFPGTEMFLDTFHMLPLAIGIYRVQQKQMKA 176 
ANA_BV                       AEVAGVQFKPEVPPELYIGFAPGAEFFMKLFKCYPLAIAVVRVKKGQMQP 179 
BORV                         AEVSGVQFKPEVPPELYIGFAPGAEFFMKLFKCYPLAIAVVRVKKGQMQP 179 
TCMV                         AEVAGVSWANSTP-EIYLSFCPGSEFFLADFKFYPLAIGIARVKKDLMKP 177 
Anopheles_A                  AEKAGVTWDNAGSVEMYLGFAPGAEFFLKDFKFYPLAIGIARVKKGLMSP 178 
GAMV                         SESMGINWQ--HGAMIYLSTLPGAEMFLTEFQLFPLAFAVVRVKKNLASP 175 
SJ2441V                      SESMGINWQ--HGAMMYLSTLPGAEMFLTEFQLLPLAFAVVRVKKNLASP 175 
MPOV                         SAKMGFQWS--VGPEIYLSTLPGTEMFLDAFKMYPLAFILLRVKRGEIKI 177 
TETEV                        ADSKGVTWK--ERGKCISCFFPGTEMFMLEFKFFPLAVGLARCHKEKMDT 195 
BMAV                         AESKGVTWK--EGANIYLSFFPGTEMFMLEFRFFPLAVGLARCHKEKMDT 195 
                             :   *  :             :*:*:::  *   **.. : :  .   .  
Caraparu_BeAn3994            NCLEKAIWQRYM-GIGADQWITKETVAILTRFEDVEKLDWARTAFTSAARE 224 
Itaqui_BeAn12797             NCLEKAIWQRYM-GIGADQWITKETVAILTRFEDVEKLDWARTAFTSAARE 224 
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Vinces                       NCLEKAIWQRYM-GIGADQWITKETVAILTRFDAVEKLDWARTAFTSAARE 224 
Murutucu_BeAn974             NCLEKAIWQRYM-GIGADQWITKETVAILTRFEDVEKLDWAKTAFTSSARE 224 
Restan_TRVL51144             NCLEKAIWQRYM-GIGADQWITKETLAILTRFEDVEKLDWAKTAFTSAARE 224 
Marituba_BeAn                NCLEKAIWQRYM-GIGADDWITKETVTILARFEDVEKLDWARTAFTSSARE 224 
Nepuyo_TRVL18462             NCLEKAIWQRYM-GIGADDWITKETVTILARFEDVEKLDWARTAFTSSARE 224 
Gumbo_LimboFE-371H           QCLEKAIWQRYM-GIGADEWITKETVSILARFEDVEKLDWAKTAFTSAARE 224 
Madrid_BT4075                KCLEKAIWQRYA-GIGADTWIQKEYADINARFSVVESLDWARTAFTSTARE 224 
Aino                         NFMRKVLRQRYG-TLTAEQWMTQKIDAVRAAFNAVGQLSWAKSGFSPAARA 224 
Akabane                      NFMRKVLRQRYG-QLTAEEWMTSKLDAVKAAFSSVAQISWAKSGFSPAARA 224 
Oropouche                    NFMKKVLRQRYG-QKTAEQWMREEIVAVRAAFEAVGTLAWARTGFSPAGRD 222 
Maguari                      KYLEKTMRQRYM-GLEAATWTVSKVNEVQAALTVVSGLGWKKTNVSAAARE 224 
Cache_Valley                 KYLEKTMRQRYM-GLEASTWTISKVNEVQAALTVVSGLGWKKTNVSAAARE 224 
Batai                        KYLEKTMRQRYM-GLEASTWTVSKLNEVQSALTVVSGLGWKKTNVSSAARE 224 
Bunyamwera                   KYLEKTMRQRYM-GLEASTWTVSKLNEVQSALTVVSGLGWKKTNVSSAARE 224 
Main_Drain                   KYLEKTMRQKYM-NMDAATWTVTQVSEVQAALTVVSGLGWKKTNVSAAARE 224 
Kairi                        KYLEKTMRQRYM-NLDASQWTQKHFSDVNSALTVVAGLGWKKANVSIAAKD 224 
California_encephalitis      QYLKKALRQRYG-SLTAEKWMSQKTGMIAKSLKEVEQLKWGRGGLSDTART 225 
Tahyna                       QYLKKALRQRYG-SLTADKWMSQKTTAIAKSLKDVEQLKWGRGGLSDTART 225 
La_Crosse                    QYLKKALRQRYG-TLTADKWMSQKVAAIAKSLKDVEQLKWGKGGLSDTAKT 225 
Jameston_Canyon              QYLKKALRQRYG-TLTAEKWMAQKTVLIAKSLKDVEQLKWGRGGLSDAART 225 
Keystone                     QYLKKALRQRYG-TLTADKWMAQKTSMITKSLKDVEQLKWGKGGLSDTARA 225 
BWAV                         QFLKKALRQRYG-KMTAEKWMSTKVKTIGEAVRNVEKLKWGKGGLSDAARN 224 
E147V                        QYLKKALRQRYG-NLTADQWMQSKSDDVLRAIAVLEKLQWGKSGLSEAARQ 224 
NDV                          QFLKKSLRQRYG-QMTADQWMQTKSDDVMRAVAVLEKLSWGRSGLSEAARQ 224 
CAPV                         EFLKKHLRQQYG-GLAASQWMSERKEDVKLALTLISRLPWGKAGLSAAARN 226 
ANA_BV                       EFLAKSLRQRYA-GAPPAEWMSTNAAAIKAATAMVEKYPMMKVASRPHIEK 229 
BORV                         EFSAKCLRQRFG-GAPPAEWMTTNAPAIKIATAMVEKFPMMRTASRPHVEK 229 
TCMV                         EFLAKLLRQRYG-NMTPGEWMKTHSVSVQSAISEIEKYPLMKVNSRPHVEE 227 
Anopheles_A                  DFLSKTLRQRYG-GIPPADWMAIHKSAVRTAVEFVDKFPLMRSNASSHVEQ 228 
GAMV                         ETVKKVLRQRYD-GRLPGEWMNSELEKVKTAITKVEALHKTFVGVTARMIE 225 
SJ2441V                      ETVKKVLRQRYE-GRLPGEWMNSELEKVKAAITRVESLHKTFVGVTARMIE 225 
MPOV                         DMAKKAMRQRYG-DKEASTWLEEEVDTVKSAIKTVEKLKPTLTGLAASMTK 227 
TETEV                        EYLKKPMRQMLTDGTKAQVWLGAKIEEIRKAYKVCMNLKFVKAGFSEAARE 246 
BMAV                         EYLKKPMRQMLTDGTKAQVWLGAKIEEIRKAYKVCMNLKFVKAGFSEAARE 246 
                             .   *  :*::     .  *   .   :                      .                                       
 
 
Caraparu_BeAn3994            FVSRFGIRLA-------- 234 
Itaqui_BeAn12797             FVSRFGIRLA-------- 234 
Vinces                       FVIQFGIRLA-------- 234 
Murutucu_BeAn974             FVSRFGIRLA-------- 234 
Restan_TRVL51144             FVSSFGIRLA-------- 234 
Marituba_BeAn                FVSQFGIKLA-------- 234 
Nepuyo_TRVL18462             FVSQFGIKLA-------- 234 
Gumbo_LimboFE-371H           FVSKFGIRLA-------- 234 
Madrid_BT4075                FVAQFGIKLA-------- 234 
Aino                         FLAQFGINI--------- 233 
Akabane                      FLAQFGIQI--------- 233 
Oropouche                    FLRQFGIGI--------- 231 
Maguari                      FLAKFGINM--------- 233 
Cache_Valley                 FLAKFGISM--------- 233 
Batai                        FLAKFGISM--------- 233 
Bunyamwera                   FLAKFGISM--------- 233 
Main_Drain                   FLAKFGINM--------- 233 
Kairi                        FLNKFGINI--------- 233 
California_encephalitis      FLQKFGIKLP-------- 235 
Tahyna                       FLQKFGIRLP-------- 235 
La_Crosse                    FLQKFGIRLP-------- 235 
Jameston_Canyon              FLIKFGVKLP-------- 235 
Keystone                     FLAKFGVRLP-------- 235 
BWAV                         FLKKFDIAMI-------- 234 
E147V                        FLGKFGILI--------- 233 
NDV                          FLGRFGIVI--------- 233 
CAPV                         FLADFGITF--------- 235 
ANA_BV                       LLSELGLSAPTIQQALTK 247 
BORV                         LLSELGLSTPTIQRALTK 247 
TCMV                         FLKSLGLSAHYINGALRG 245 
Anopheles_A                  FLVDLGLSRATVASMKR- 245 
GAMV                         FFTALGINLDMRR----- 238 
SJ2441V                      FFSALGINLDLRR----- 238 
MPOV                         FLQELGISK--------- 236 
TETEV                        FLKEFGLDQDKN------ 258 
BMAV                         FLKEFGLDQDKN------ 258 
                             :   :*       
Fig. 4.6  Alignment of complete N protein of the viruses. * indicate 100% conserved; brown letters indicate 
conserved motif; dotted lines indicate gaps inserted to maximize identity; : denotes more than 90% 
conserved; . denotes more than 50% conserved. 
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4.2.6 NSs protein comparison 
 
NSs amino acid sequences of NDV, E147V, BWAV, GAMV, SJ4441V and MPOV were 
aligned with the published NSs sequences of BUNV, CEV, ITQV and OROV (Fig. 4.7). 
This alignment showed that the NSs proteins vary in size especially at the carboxy 
terminus. The largest NSs protein was observed in SJ2441V (137 amino acids) in Gamboa 
serogroup and the smallest (79 amino acids) in MPOV in Turlock serogroup. These are the 
largest and the smallest NSs protein reported to date. As observed with GROV NSs 
protein, the relative truncation of MPOV was at both termini. In agreement with previous 
results (Dunn et al., 1994; Bowen et al., 1995), NSs proteins reported in this study were 
more divergent than the corresponding N proteins with no conserved amino acid motif 
observed. The conserved LPS motif at the carboxy terminus in most of NSs protein of 
Bunyamwera and California serogroup viruses was only observed in BWAV NSs protein. 
This motif was also absent in ITQV, OROV and GROV NSs proteins (Figure 4.7). The 
sequence identity of the NSs protein among viruses within the same serogroup was more 
than 80% and between serogroups were as low as 4% (between ITQV and BWAV) (Table 
4.4). In contrast to viruses in Bunyamwera, California, Group C and Simbu serogroup, 
only viruses in Gamboa serogroup were found to have two lengths of NSs protein; 130 
(GAMV) and 137 (SJ2441V) amino acids respectively. This could be due to the limited 
number of viruses used for each serogroup in this study.  
 
4.2.7 Phylogenetic analysis of S segments 
 
To establish genetic relationships among the studied viruses with other orthobunyaviruses, 
phylogenetic trees were constructed from the alignments of complete N amino acid 
sequences of ANAV, ANBV, BMAV, BORV, BWAV, CAPV, E147V, GAMV, MPOV, 
TCMV, NDV, TETEV and SJ2441V (Figure 4.8A) using NJ analysis, and partial N ORF 
of ANAV, ANBV, BMAV, BORV, BWAV, CAPV, E147V, GAMV, MPOV, TCMV, 
NDV, TETEV and SJ2441V, BERV, GMAV, PLSV and PATV using NJ and MP analysis 
methods (Figure 4.8B and 4.8C). For NJ analysis, a distance matrix was calculated from 
the aligned sequences using the Kimura two parameter formulas (Kimura, 1980) and NJ 
tree was computed. The reliability of the inferred tree was tested by bootstrap analyses 
using 100 replicates data sets generated from the original sequence alignment (Felsenstein, 
1993) and a bootstrap consensus tree was generated. For MP analysis, phylogenetic tree  
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NDVNSs          ------MMSSQLPKMDLILISSMWHLKLQLEQGLTLFPLGSSSSMPGKPKINSLVDQSRRLVLNLE 60 
E147VNSs        ------MMSSLLPKMDLILINNTWHLKLLQEQGLILFPLGSSSSMPGKPKINSLVDQSQRLTLNLA 60 
BWANSs          ------MMSTRLMPMSLTLIQDTWILKITIQGHSIQIPLGHSSSMPQRPRMCSAINLTRRSILNLE 60 
CEVNSs          ------MMSHPQVQMDLILMQGMWTSVLNMENQLTLLQLGSSSSMPQRPRLLSRVSQRGKLILNLA 60 
BUNVNSs         ------MMSLLTPAVLLTQRSHTLTLSVSTPLGLVMTTYESSTLKDARLKLVSQKEVNGKLHLTLG 60 
GAMVNSs         -------MIRRQALALMIQRRNTMSLLVLTGTSLLQQTLNVSSCMHVQPRLVWQRTRRNAERLLLD 59 
SJ2441VNSs      MIFTYSTMIRRQALALMIQRENMINLLVLTGSNLLQQTLNVFSCMHARPRLVFQRTRRNAERLLLE 66 
OROVNSs         -------MYHNGLHLHLIRRQHMWHLKLDTDKCSMLVLLESSSSTKRRPKMSYVRHRGPWLTLLLV 59 
ITQVNSs         -------MYPHSQTIHLTLKLLSLDSKVHTAGNWFPPSYESSTSTRRRSKLTSVGQVNSLFFLLLV 59 
MPOVNSs         ----------MSVEVLITQERNTIRLWIHTENISQWITLESSSSRLQRPKLTWRRLTTRSLKFILE 56 
                       ::       :          :              :    : ::           : *  
 
NDVNSs          HGRWKWSITIFKETGTILSATQISQCIDSQDI---------------------------------- 92 
E147VNSs        HGRWRWSITIFKETGTMLSATRILQSTDCQDI---------------------------------- 92 
BWANSs          TGRWRLSIIIFLETGTTQLVKMILPSTEFQDI---------------------------------- 92 
CEVNSs          SGRWRLSIIIFQQTGTIQLVTTILPSTASQDTLPDGS----------------------------- 97 
BUNVNSs         AGRLLYIIRIFLATGTTQFLTMVLPSTASVDSLPGTYLRRC------------------------- 101 
GAMVNSs         LGRLRLLITITEEPLRLQCRTMIIPCTAFPDILPCTACRPAPRISRTLSESSQSSSTRSLSPWGST 125 
SJ2441VNSs      LGRLRLLITIIDEPLQLRCRTMILPCTAFPDILPCTVCRPVWRMRSLSSESDQQSSTRSLSPWGST 125 
OROVNSs         GSNLQWLITISHSSSRIQCRTTVLPCTVCQDT---------------------------------- 91 
ITQVNSs         VLTLPYLTHISQEPSPFHCLTTDSRCTAYRVTSPDGPCI--------------------------- 98 
MPOVNSs         HSSSRWLITISLVEPSVRLRTLT--------------------------------------------79 
                         *          
 
NDVNSs          ----- 
E147VNSs        ----- 
BWANSs          ----- 
CEVNSs          ----- 
BUNVNSs         ----- 
GAMVNSs         GSMEQ 130 
SJ2441VNSs      GSMEQ 130 
OROVNSs         ----- 
ITQVNSs         ----- 
MPOVNSs         ----- 
 
 
Fig. 4.7  Alignment of NSs protein. * indicate 100% conserved; dotted lines indicate gaps 
inserted to maximize identity; red bold letters indicate LPS conserved motif : denotes more 
than 90% conserved. 
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A. Phylogenetic tree using Neighbor-joining based on complete amino acid N sequence 
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B. . Phylogenetic tree using Neighbor-joining based on partial amino acid N sequence. 
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C. Phylogenetic tree using Maximum Parsimony method (Mega 2.1 software) based on 
partial amino acid N sequence.  
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Fig. 4.8 Phylogeny of the studied viruses based on complete N ORF amino acid sequence of ANAV, ANBV, 
BWAV, BORV, E147V, GAMV, MBOV, NDV, SJ2441V and TETEV, and partial N ORF of BERV, 
GMAV and PLSV. Viruses in the Bunyamwera, California, Group C and Simbu serogroups were used as a 
control group. The sequences were aligned using the ClustalX (NCBI) and ClustalW program (EMBL-EBL). 
Phylogenetic analyses were generated by Neighbor-joining (NJ) based on complete N amino acid sequences 
(A) and partial N sequences (B) and Maximum Parsimony (MP) based on partial N sequences (C). Numbers 
adjacent to each branch represent the percentage bootstrap support calculated for 100 replicates. All the trees 
yielding almost identical topologies, except with TCMV. Blue letters indicate the phylogeny results that not 
correlated with serological grouping and red letters indicate serogroups used in this study. Scale bar represent 
10% amino acid sequence divergence. Accession numbers of the control viruses are listed in 2.2.11. 
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was obtained by the heuristic search using equal weighting of all changes.Weighting 
schemes of 3:1 and 10:1 were used and gaps were treated alternatively as missing data. The 
reliability of the inferred tree was tested by bootstrap test performed on 100 replicates data 
sets generated using heuristic search option and a bootstrap consensus tree was computed. 
Representative members of Bunyamwera, California, Group C and Simbu serogroups were 
included in this analysis to root the trees. The results indicated that the overall 
phylogenetic relationships determined using NJ and MP methods were similar except with 
one difference: the NJ plot based on complete N sequence and MP plot based on partial 
sequence predict TCMV in the same clade as ANAV, while the NJ plot based on partial 
sequence, separated these viruses into different clades. Previous serological classification 
grouped BERV and GMAV in the Guama serogroup and CAPV in Capim serogroup. 
However, phylogenetic analysis based on partial amino acid sequence of CAPV, BERV 
and GMAV N proteins grouped BERV in the same clade as CAPV but separate from 
GMAV, indicating that BERV was closer to CAPV than GMAV. With the exception of 
BERV and TCMV viruses, all viruses from the same serogroup were placed in the same 
clade in NJ and MP derived trees.  
 
4.2.8 Partial M and L sequences 
 
During the attempts to get the reverse-transcription PCR product for S segments, primers 
S13+ and S13- were also used, which were designed based on conserved sequences of 13 
terminal nucleotides of the S, M and L segments of the published sequences of 
Bunyamwera, California, Group C and Simbu serogroups viruses. Partial sequences of the 
L and M segments of PATV, and of the L segment of CAPV were obtained (Figure. 4.9). 
For PATV L segment, both primers were found to hybridise at the internal sequences. Only 
the forward primer hybridised at the 3’ end of virus-sense M RNA segment of PATV and 
L segment of CAPV, while the reverse primer hybridised at internal sequences (Figure 
4.10). The lengths of M and L segments obtained for PATV were 505 nucleotides 
(representing 151 amino acids) and 922 nucleotides (representing 307 amino acids) 
respectively. For CAPV L segment, a sequence of 742 nucleotides (representing 237 amino 
acids) was obtained. The sequences were put in the BLAST program (NCBI) and 
compared with the published sequences of representative virus of each serogroup; BUNV 
for Bunyamwera, LACV for California, ITQV for Group C and OROV for Simbu. 
However the comparisons were very limited due to the limited sequences of M and L  
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A. PATV M sequence 
 
1         AGTAGTGTGCTCCACAATAAAGATTTCAAAGGAAATATCAAAAAGATACACCATGTTAAC 
                                                               M  L  T  
 
61        TAAAATGCTGCTGTTTGCACTGCTTACAGTATGTGCATCAGTACCCTTGGATAAGTGCTT 
            K  M  L  L  F  A  L  L  T  V  C  A  S  V  P  L  D  K  C  F  
 
121       CAGTGGAGGCATAGTTATAAAAAAGCTTCAAACTGATTATGGCCTCCCCCATATGTGTCT 
            S  G  G  I  V  I  K  K  L  Q  T  D  Y  G  L  P  H  M  C  L  
 
181       AAGAGACGATATAAGCATGATAAAAACTGATTCGGTTGCAGTTCAAGGTACTTCAAATGA 
            R  D  D  I  S  M  I  K  T  D  S  V  A  V  Q  G  T  S  N  D  
 
241       TGAGAAGACAATATTCACATCAAGTATCACAAGGAAATTGCTTGTGACGGATTGGAAAAA 
            E  K  T  I  F  T  S  S  I  T  R  K  L  L  V  T  D  W  K  N  
 
301       CTGTAGGCCTGAAAAAATGATAGGTGGTCCTATCATGTTGCTATCTGTAGATGACAGAGG 
            C  R  P  E  K  M  I  G  G  P  I  M  L  L  S  V  D  D  R  G  
 
361       TCACTTGAAATCAGAAGAGTATGTGTGTCAAAATGATTGTGAGATAAAATTGGAGAAAGA 
            H  L  K  S  E  E  Y  V  C  Q  N  D  C  E  I  K  L  E  K  E  
 
421       ATCAGGATTGATAATATTTGAAACAGCATCACTAAATTACTATCAAGTGAGTGGTACCAC 
            S  G  L  I  I  F  E  T  A  S  L  N  Y  Y  Q  V  S  G  T  T  
 
481       CATCAGTTCTGGCTGGTTTAAATCA 
            I  S  S  G  W  F  K  S   
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B. PATV L sequence 
 
1         AGTAGTGTGCCCCTCAGCAAGTATTCAATCTAAGAAATCAACTGTGGTGTTTTCAACAAT 
            V  V  C  P  S  A  S  I  Q  S  K  K  S  T  V  V  F  S  T  I  
 
61        TTGTCTACATAAGGATTCAAAGGATGTATTGAAATGCGGGGCATTGTATAAAACATACAA 
            C  L  H  K  D  S  K  D  V  L  K  C  G  A  L  Y  K  T  Y  K  
 
121       AATAGGAGACCAATACATATCTATATCTAAAGCTATTCGTTTAGATAAAGAGAGATGCCA 
            I  G  D  Q  Y  I  S  I  S  K  A  I  R  L  D  K  E  R  C  Q  
 
181       GAGGTTAGTCACAGCTCCTGGAATTTTCATGTTAACCACACTATTGTTGAAAGGGGATAC 
            R  L  V  T  A  P  G  I  F  M  L  T  T  L  L  L  K  G  D  T  
 
241       AGAAATAGACTTAGATGAGATCATGGCTTTCTCATTTTTCACCTCACTATCTATAACAAA 
            E  I  D  L  D  E  I  M  A  F  S  F  F  T  S  L  S  I  T  K  
 
301       AAGTATGCTCTCACTAACAGAGCCATCTAGGTATATGATAATGAACTCGTTGGCAGTGAG 
            S  M  L  S  L  T  E  P  S  R  Y  M  I  M  N  S  L  A  V  S  
 
361       CAGCCATGTCCGAGAATATATAGCCGAAAAGTTTTCTCCATATACAAAAACCTTATTCTC 
            S  H  V  R  E  Y  I  A  E  K  F  S  P  Y  T  K  T  L  F  S  
 
421       AGTTTATATGACAGAATTGATCCACAAAGGCTGCATGTCAGCAAACAACCAACGGTCTAA 
            V  Y  M  T  E  L  I  H  K  G  C  M  S  A  N  N  Q  R  S  K  
 
481       GATATCTGTGAAAAATGTTTTCCTCAATGAATATGAAATAACTCAAAAAGGGGTTTCAGA 
            I  S  V  K  N  V  F  L  N  E  Y  E  I  T  Q  K  G  V  S  E  
 
541       AGATCGCGATCTAGAATCAATCTGGTTTCCAGGACATGTAAATCTCAAGGAATATATCAA 
            D  R  D  L  E  S  I  W  F  P  G  H  V  N  L  K  E  Y  I  N  
 
601       TCAAGTGTATCTCCCCTTTTACTTCAATGCTAAAGGGTTACATAATAAGCATCATGTTAT 
            Q  V  Y  L  P  F  Y  F  N  A  K  G  L  H  N  K  H  H  V  M  
 
661       GATAGACTTAGCTAAGACAGTTTTAGAAATTGAACTAGAACAAAGAGAGCAACTGCCCAA 
            I  D  L  A  K  T  V  L  E  I  E  L  E  Q  R  E  Q  L  P  N  
 
721       CCCATGGGGCAAAGATTTCCAGAAACAATCTGTGAACCTAGAAATATTGATCTATTCGAT 
            P  W  G  K  D  F  Q  K  Q  S  V  N  L  E  I  L  I  Y  S  I  
 
781       AGCAAAGATGCTGAACAATGATACATCTAAGCATAATCATCTAAGAAGCAGGATTGAGAA 
            A  K  M  L  N  N  D  T  S  K  H  N  H  L  R  S  R  I  E  N  
 
841       TAGGAACAACTTCAAGAGGTCACTGGCAAGCATATCGACATTCACTAGCTCGAAGTCATG 
            R  N  N  F  K  R  S  L  A  S  I  S  T  F  T  S  S  K  S  C  
 
901       CATAAAAGTGGGGGATTTCTCG 
            I  K  V  G  D  F  S  
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C. CAPV L sequence  
 
1         AGTAGTGTACCCTGACATAGTATTTAGCTATTTAGAAGGGTACACTCAAAAATGGCAACG 
                                                              M  A  T   
 
61        CAAATTGGAGAATTAGTTAGGCAGTTTGCTGCAAGAGTTAGGGCATTAAACCCAAATCAA 
           Q  I  G  E  L  V  R  Q  F  A  A  R  V  R  A  L  N  P  N  Q   
 
121       CCAGAGTTAGGGAGAGATCTTCTGTCTGAAATAACTGTAGCTCGACATAATTATTTTGCC 
           P  E  L  G  R  D  L  L  S  E  I  T  V  A  R  H  N  Y  F  A   
 
181       CAAGAGTTTTGCGAGAGCATCGGATTAGAATATAGAAACGATGTACCAGCTCTGAATATA 
           Q  E  F  C  E  S  I  G  L  E  Y  R  N  D  V  P  A  L  N  I   
 
241       GTAATGGAGATGAGACCGGACTTCGATCCTATGACAATTAAGGTGCCGGAAATCACACCA 
           V  M  E  M  R  P  D  F  D  P  M  T  I  K  V  P  E  I  T  P   
 
301       GACAACTATTACAGAGACGGGGACAAGATCTATATTATAGATTTTAAAGTATCGGTTAGT 
           D  N  Y  Y  R  D  G  D  K  I  Y  I  I  D  F  K  V  S  V  S   
 
361       GACGAATCTGCTAATCATACATTCAAGAAATACAATACTTTGTTCGGCGATGTCTTTGAT 
           D  E  S  A  N  H  T  F  K  K  Y  N  T  L  F  G  D  V  F  D   
 
421       AAGTTAGGGATTGAATTCGAGGTAGTCATTATTAGGATGGACCCCACAAGAGGAGAGATA 
           K  L  G  I  E  F  E  V  V  I  I  R  M  D  P  T  R  G  E  I   
 
481       TTGAAGGGTTGGGACAAAATGGTCGAAAGAGTCTCAGAAACTAGAGAGATAACCAGAGAT 
           L  K  G  W  D  K  M  V  E  R  V  S  E  T  R  E  I  T  R  D   
 
541       GTGACCAAGCAGAAGCCAAGTATACATTTCATATGGTCTGGGCACAATTCAAAAGAAGTT 
           V  T  K  Q  K  P  S  I  H  F  I  W  S  G  H  N  S  K  E  V   
 
601       ACAGGCAACACTCAGAAAATATTGAGGCTCTCAAAATGTCTACAAAGAATAAAGGACACC 
           T  G  N  T  Q  K  I  L  R  L  S  K  C  L  Q  R  I  K  D  T   
 
661       GACCAATTCAGCACAGCTTTTAGGAAAATAGGTGCACTAATGGATTTCAGTGAAAACATA 
           D  Q  F  S  T  A  F  R  K  I  G  A  L  M  D  F  S  E  N  I   
 
721       GCAGGCTACGAGAATTTTTGCCTGAAGCTAAAAGCAGACGCG  
           A  G  Y  E  N  F  C  L  K  L  K  A  D  A   
 
 
Fig. 4.9 Nucleotide and amino acid sequences of  positive-sense of partial M (A) 
and L segments (B) of PATV and partial L of CAPV (C). The nucleotides were translated 
to amino acid using DNAMAN version 4.0 program (Lynnon Biosoft) 
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Figure 4.10 Position of L sequence obtained for CAPV and PATV (A), and M sequence 
obtained for PATV (B). Red letters indicate position relative to BUN sequences 
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available. For instance, there are no sequences of L and only partial sequences of M 
segment available for Group C virus and this M sequence was found to be outside the 
comparison area of PATV. In comparison with L sequences of BUNV, LACV and OROV, 
the identities of PATV are 65%, 62% and 64% respectively for nucleotides, and 64%, 60% 
and 61% respectively for amino acids, while for CAPV, the identity values are 43%, 46% 
and 47% respectively for nucleotides, and 28%, 26% and 30% respectively for amino 
acids. The nucleotide and amino acid sequence identity of PATV M segment compared to 
BUNV, LACV and OROV is 30%, 43% and 24% respectively for nucleotides, and 37%, 
36% and 33% respectively for amino acids. The L protein sequences alignment of PATV 
revealed 20 deletion of amino acid at the position of amino acid 664 relative to BUNV. 
 
 
4.3 Discussion 
 
Even though Dunn et al. (1994), who designed BUN S+/S- successfully obtained the 
complete sequences of the S segment of seven viruses in Bunyamwera serogroup and 
Nunes et al. (2005) managed to get complete sequences of 13 S segments of viruses in the 
Group C serogroup, other researchers like Bowen et al. (1995) failed to use these primers 
to amplify six of the viruses in California serogroup [CEV, JCV,  Jerry Slough (JSV), 
Melao (MELV), Keystone (KEYV) and TVTV]. An attempt to get  complete S segment 
sequences for Garissa virus with these primers during the hemorrhagic fever outbreak in 
Kenya and Somalia (Bowen et al., 2001) also failed although partial S segment sequences 
obtained using BUNCAL1 and BUNCAL2 primers revealed its closeness to BUNV (>98% 
identity). From the sequences obtained from G-tailed cDNAs of California serogroup 
viruses, variations in the terminal sequences of 3’ and 5’end were detected. In this study, 
repeated attempts to amplify the complete S segment of some viruses using primers BUN 
S+/S- were also unsuccessful except with the viruses in Nyando serogroup, although 
different sources of RNA such as virus infected cell, virion RNA and nucleocapsid RNA 
were used as a template for cDNA synthesis. Variable annealing temperatures were also 
applied but yet failed to get the expected products. Perhaps some viruses do not share the 
same consensus 3’/5’termini sequences of the published orthobunyaviruses. This is further 
suggested by the data of Ushijima et al. (1981), who showed by direct RNA sequencing 
that the terminal RNA sequences of Pahayokee virus were different to those of published 
orthobunyaviruses (UCAUCAAAUGAAGAU). Sequence analysis of partial S sequences 
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of PATV, which were obtained using designed internal primer S400F and terminal primer 
S13-, revealed that nucleotides 14 and 15 of the 3’ end of the positive-sense RNA were 
different to the published S sequences (CA instead of AG- refer to Figure 4.1). This could 
explain why I could not get any product with some of the studied viruses using primers 
BUN S+/S-.  
 
Attempts to get the product using 3’/5’ RACE and RCA-RACE, modified 3’/5’ RACE and 
reverse-transcription PCR on ligated RNA using the internal primers that were designed 
based on the partial sequences obtained also failed. One possible explanation would be that 
ribonucleases present in some of the preparation could have degraded the RNA. Although 
ribonuclease inhibitor was added to the reaction during the reverse-transcription process, 
degradation could occur during the RNA extraction process. Polidoros et al. (2006) 
suggested that the failure to get the product with 3’/5’ RACE could be due to the use of a 
universal primer corresponding to the anchor sequence was present in all cDNAs and the 
presence of many truncated RNAs. Combination of internal primers that were designed 
based on some conserved motifs of the published sequences also did not yield any product 
with some of the viruses, suggesting that not all the viruses contain these motifs.  
 
The other major task in this study was to design the universal primers that are conserved 
for all the viruses and could be used to amplify the S segment of viruses in all 18 
serogroups of Orthobunyavirus genus. Besides that, cross-contamination of the preparation 
with nucleic acid of other viruses especially BUNV was also one of the major problems in 
this study since all the experiments such as RNA extraction, reagent preparation and gel 
running were conducted in the same laboratory. Therefore, beside separating the place for 
RNA extraction, reagent preparation and running gel, filtered tip and pipettors treated with 
RNase AWAY (Molecular BioProducts, Inc) were also used during some of the 
preparations to prevent this contamination.  
 
This study represents the first report on the complete S segment sequences of viruses in 
Anopheles A, Anopheles B, Nyando, Bwamba, Turlock, Tete and Gamboa serogroups, 
partial S sequences of viruses in Patois, Guama, Capim and Minatitlan serogroups, partial 
L sequences of PATV and CAPV, and partial M sequences of PATV. These partial 
sequences will be useful as a template to obtain a complete sequence in the future. 
Analysis for AUG-initiated ORFs (FRAMES analysis) and alignment of N with NSs 
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initiation codon revealed that some viruses lacked on NSs protein initiation codon. This is 
the first report on the presence of naturally occurring orthobunyaviruses that do not have 
NSs ORF, i.e. those in Anopheles A, Anopheles B, Tete and Capim serogroups. Whether 
the NSs function has been replaced by the N protein or by proteins encoded on the other 
segments is not known and therefore needs to be further investigated. It is interesting that 
most of these viruses were found to have longer N proteins compared to viruses with an 
NSs ORF. Similar to GROV NSs protein, a shortening of NSs protein of MPOV was also 
observed at both ends. It is possible that this is a homoplastic event in the evolution of 
orthobunyavirus that by having short or without NSs protein, to free the S segment from 
the constraints involved in encoding N and NSs proteins in the same sequence. 
 
Analysis of the second ORF potentially to encode NSs protein using FRAMES programme 
of the DNAMAN software has detected the presence of different initiation codons at the 
same relative spacing as BUNV and CEV in BMA and CAPV, and at the same relative 
spacing as OROV and ITQV in ANAV, TCMV, ANBV, BORV and TETEV, but they 
were considered too short to encode for NSs protein. In TCMV, an ORF starts with TTG 
(Figure 4.3) with the length of 61 amino acids was observed. Whether they are the ORFs 
for NSs protein need to be further investigated. It is possible that ATG initiation codon of 
these viruses had been lost or mutated over time due to certain selective pressures. 
 
Sequence alignments of the nucleotide and amino acid sequences of N protein obtained 
here with the published sequences of viruses in Bunyamwera, California, Group C and 
Simbu serogroups have identified some conserved regions. These regions might contain 
possible functional domains which might play a role in N protein interaction with L protein 
and virus RNA or epitopes for CF antibodies to react.  
 
Previous serological classification has placed TCMV in the same serogroup as ANAV 
from the Anopheles A serogroup and phylogenetic analysis using NJ plot based on 
complete S sequence and MP plot based on partial N sequence supported this 
classification. However based on published data, their nucleotide and amino acid sequence 
identities were found outside the range to be placed in the same serogroup, and 
phylogenetic analysis using NJ method based on partial N sequence have placed this virus 
in different clade from ANAV. However a similar result has been reported before with the 
viruses in the Simbu serogroup, where the N amino acid sequence identity between 
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Mermet virus (MERV) and Douglas virus (DOUV), and between Buttonwillow virus 
(BUTV) and AKAV were as low as 59%, suggesting that greater sequence divergence was 
observed in Simbu serogroup viruses (Saeed et al., 2001). Serological classification has 
placed BERV in the same serogroup as GMAV in Guama serogroup. Based on the 
comparison of partial amino acid sequences of the N protein and phylogenetic analysis 
using NJ and MP methods, BERV was found to be closer to CAPV compared to GMAV. 
However sequence identities between these three viruses were found to be more than 70%, 
suggesting that these viruses originated from the same ancestor; therefore, it is 
recommended that they be placed into one group. However, comparison of complete N 
sequences of BERV, CAPV and GMAV are needed to confirm this.  It is also possible that 
TCMV and BERV are reassortant viruses that have different S segment but similar M 
segment as ANAV and GMAV respectively, and were placed in their current serogroups 
based on PRNT or HI assays which recognise epitopes encoded by M RNA gene products. 
Therefore, sequence analyses of M segment of ANAV, TCMV, BERV, CAPV and GMAV 
are necessary to confirm this speculation. The sequence comparison result of BWAV was 
in agreement with previous serology classification, which also identified BWAV as 
‘bridging’ virus between California and Bwamba serogroups (Calisher, 1988). Previously, 
GAMV has been identified as a bridging virus between Gamboa and Capim serogroup 
(Calisher, 1988). However, sequence comparison result has showed that the sequence 
identity for GAMV and CAPV was only 35%. Based on the published data, this value was 
too low to place this virus as a bridging virus between these two serogroups.  
  
The last ten amino acid residues including the LPS motif at the carboxy terminal of NSs 
protein, which were conserved in Bunyamwera and California serogroup viruses was  only 
detected in BWAV. However this motif was also absent in GROV, Group C and Simbu 
serogroup viruses (Fig. 4.5). This domain is reported to be involved in the inhibition of 
cellular RNA polymerase II-driven transcription through the interaction with MED8 
component of mediator, a protein complex that is necessary for the host mRNA production 
(Leonard et al., 2006). Absence of the domain was shown to reduce the ability of the virus 
to inhibit host protein expression and the interferon response. This suggests that this motif 
is not conserved in all orthobunyaviruses and it is possible that these LPS minus viruses 
use a different binding motif or interact with a different cellular partner to inhibit host 
protein expression and interferon response. 
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5 Interferon response and Shutoff of Host Protein Synthesis 
caused  by NSs Minus Orthobunyaviruses  
 
 
5.1 Introduction 
 
Sequencing data in Chapter 4 revealed that viruses in 3 serogroups (Anopheles A, 
Anoheles B and Tete) as well as CAPV do not show any evidence of having an NSs ORF. 
As mentioned in Chapter 1, the NSs proteins of BUNV in Bunyamwera serogroup and 
LACV in California serogroup are necessary to cause the shutoff of host protein synthesis 
in mammalian cells and also act as interferon antagonists (Bridgen et al., 2001; Weber et 
al., 2002; Blakqori and Weber, 2005). In this chapter, I analysed the proteins expressed by 
the S segments of these NSs-minus viruses, and studied the shutoff of host protein 
metabolism and induction of the interferon response in infected cells. CAPV was omitted 
in this study because its S sequence was only obtained after these experiments had been 
conducted.  
 
 
5.2 Results 
 
5.2.1 In vitro transcription and translation (TnT) 
 
This TnT system allows coupled in vitro transcription and translation of protein coding 
regions cloned downstream of the T7, SP6 or T3 RNA polymerase promoter in a 
eukaryotic environment. The S segment cDNAs of the viruses were cloned into 
pBluescript2 KS plus plasmid (Strategene) under the control of a T7 RNA polymerase 
promoter. The constructs were used to program protein synthesis in TnT systems 
(Promega) using wheat or rabbit reticulocyte lysates in the presence of [35S] methionine. 
The products were then separated by SDS-PAGE. Plasmid without an insert was used as a 
control.  
 
In vitro TnT reactions using both rabbit reticulocyte and wheat germ lysate systems 
showed that only N protein was expressed from the S segment of these viruses; in the 
control BUNV S segment, both N and NSs were translated (Figure 5.1). The N protein 
bands of these NSs minus viruses were shown to be larger than BUNV and BUNdelNSs N  
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Fig. 5.1 Proteins expressed from orthobunyavirus S segments in the in vitro TnT system 
using wheat germ lysate and rabbit reticulocyte lysate system. The products were 
fractionated by polyacrylamide gel electrophoresis [NUPAGE 6-12 % gradient gel 
(Invitrogen)]. 
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protein bands. In the rabbit retyculocyte lysate protein gel, smaller products less abundant 
than BUNV NSs band were detected. However, they were not obviously seen in the other 
gel using wheat germ lysate system. Globin bands of 15–16 kDa were also observed in 
some of the lanes using this system but not in the wheat germ system. In the wheat germ 
system, a band of 16 kDa was observed in the BUNdelNSs lane but not in the other 
system. A non-specific band of more than 26 kDa was seen in the control plasmid of both 
gels, which was clearly observed in wheat germ system. How this band appeared is 
unknown.    
 
5.2.2 Shutoff of host protein synthesis 
 
Two assay systems, direct protein radio-labelling of infected cells and a luciferase 
expressing plasmid based assay were used in this study to examine the shutoff caused by 
the different viruses. 
 
5.2.2.1 Shutoff in A549 infected cells  
 
In these cells, a drastic shutoff was only observed in cells infected with TCMV and 
BUNV, but the level of shutoff caused by TCMV was slightly slower compared to BUNV, 
where the shutoff was almost complete at 24 h pi.  In comparison to shutoff in mock 
infected cells, a slight shutoff was observed in cell infected with ANAV, ANBV, BORV, 
TETEV, BMAV and BUNdelNSs virus (Figure 5.2).  
 
5.2.2.2 Shutoff in Hep2 infected cells 
 
No shutoff was observed in Hep2 cells infected with any of the virus including BUNV 
(Fig. 5.3). The N protein bands were only observed in TCMV, BORV, BUNV and 
BUNdelNSs-infected cells with the highest amount in BUNV-infected cells. No obvious 
viral protein bands were observed in ANAV, ANBV, TETEV and BMAV-infected cells.  
 
5.2.2.3 Shutoff in Hep2/V cells infected with the viruses 
 
In these infected cells, similar result was observed as in infected Hep2 cells where no 
shutoff was observed. Unlike in Hep2-infected cells, the N proteins expressed by TCMV,  
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Fig. 5.2 Shutoff of host protein synthesis in infected A549 cells at 18 h pi. The cells were 
infected with 1 PFU/cell virus and labeled for 2 h with 30 µCi [35S]methionine. Infected 
cell lysates were harvested and analysed by 15% SDS-PAGE gel. 
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Fig. 5.3 Shutoff of host protein synthesis in infected Hep2 cells at 18 h pi. The cells were 
infected with 1 PFU/cell virus and labeled for 2 h with 30 µCi [35S]methionine. Infected 
cell lysates were harvested and analysed by 15% SDS-PAGE gel. 
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BORV and BUNdelNSs in Hep2/V-infected cells were almost similar in amount to that in 
BUNV-infected cells (Fig. 5.4). Similar to Hep2-infected cells, no viral protein bands were 
observed in cells infected with ANAV, ANBV, TETEV and BMAV. Thus, the growth of 
these viruses was either inhibited or delayed in these cells. 
 
5.2.3 Shutoff of protein synthesis using a luciferase reporter based assay 
 
5.2.3.1 Shutoff in infected BHK-21 cells  
 
Transfection of cells with plasmids expressing luciferase gene has been used to investigate 
the role of influenza A NS1 and rotavirus NSP3 proteins in shutoff of host protein 
synthesis (Salvatore et al., 2002; Vende et al., 2000). A similar assay to examine the 
shutoff caused by BUNV using a luciferase reporter plasmid (pRL-SV40 or phRL-CMV) 
to investigate the effect of NSs on host protein synthesis in infected BHK-21 cells was first 
established by Hart (2004). These two plasmids contain the luciferase gene isolated from 
Renilla reniformis and were obtained from Promega. pRL-SV40 expresses Renilla 
luciferase under the control of the SV40 early enhancer/promoter while phRL-CMV 
expresses Renilla luciferase under the control of the CMV immediate early 
enhancer/promoter. pRL-SV40 was recommended for use in mammalian cells while phRL-
CMV was recommended for  used in insect cells due to a report of its efficient expression 
in insect cell lines (Saraiva et al., 2000). BHK-21 cells were transfected with pRL-SV 40.  
After 5 h incubation at 37oC, the cells were infected with 1 PFU/cell of virus and the 
luciferase readings were taken after 12 and 24 h pi. There was a decrease in luciferase 
activity observed in most of the virus infected cells after 12 and 24 h pi compared to mock 
infected cells. The most reduction of luciferase activity was observed in BUNV-infected 
cells, followed by ANAV, ANBV and TCMV-infected cells, which were lower than in 
BUNdelNSs infected cells (Figure 5.5A). The luciferase activities in cells infected with 
TETEV, BMAV and BORV were found to be higher than in BUNdelNSs-infected cells, 
indicating that less shutoff of host protein synthesis occurred. For a better comparison 
between different experiments, Hart (2004) recommended to calculate the luciferase 
activities by dividing the luciferase activities in the virus-infected cell with those 
corresponding mock infected cells. The highest percentage reduction was observed in 
BUNV-infected cells after 12 and 24 h pi (almost 50% reduction in comparison to  
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Fig. 5.4. Shutoff of host protein synthesis in infected Hep2/V cells  
at 18 h pi. The cells were infected with 1 PFU/cell virus and labeled for 2 h with 30 µCi 
[35S]methionine. Infected cell lysates were harvested and analysed by 15% SDS-PAGE 
gel. 
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B. 
 
Fig. 5.5 Shutoff of protein synthesis in infected BHK-21 cells at 12 and 24 h pi from 
expression of pRL-SV40. The cells were transfected with 0.1 µg/dish pRL-SV40 using 
Lipofectamine 2000 diluted in OptiMEM. After 5 h incubation at 37oC, the cells were 
infected with 1 PFU/cell virus and the cells were lysed with passive lysis buffer after 12 
and 24 h pi. The samples were assayed using manual luminometer and Dual Luciferase 
assay system (Promega). Results are shown as the luciferase readings from infected cells 
without manipulation (A) and percentage luciferase activity of infected cells compared to 
the corresponding mock infected cells (B). Results are the average readings of 3 samples. 
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BUNdelNSs-infected cells), followed by cells infected with ANAV, ANBV and TCMV, 
BUNdelNSs, BMAV, TETEV and BORV (Figure 5.5B).  
 
5.2.3.2  Shutoff in C6/36 infected cells 
 
In this study, the cells were transfected with phRL-CMV and the luciferase reading was 
taken at 18 h pi.  Previous studies using radiolabeled protein of infected cells and luciferase 
based assays have showed no shutoff observed in cells infected with BUNV and 
BUNdelNSs virus (Elliott & Wilkie, 1986; Scallan & Elliott, 1992; Kohl et al., 2004, Hart, 
2004). However, luciferase based assay used in this study revealed that in comparison to 
mock infected cells, no shutoff was only observed in C6/36 cells infected with BUNdelNSs 
virus, whereas shutoff less than 50% compared to the mock-infected cells was still 
observed in the cells infected with BUNV, ANAV, TCMV, ANBV, BORV, TETEV, 
BMAV (Figure 5.6). 
 
5.2.4 Induction of IFN- α/β in infected cells  
 
It has been shown previously that the NSs protein of BUNV and LACV acts as an IFN 
antagonist that blocks the transcriptional activation of IFN- α/β. Therefore, the ability of 
the NSs minus viruses to induce IFN- α/β was investigated by using two assay systems; 
IFN promoter induction assay and RT-PCR to detect the presence of IFN- α/β mRNA in 
infected cells. 
 
5.2.4.1 Reporter gene assay 
         
This assay was conducted to determine the ability of the NSs minus viruses to transactivate 
the IFN- β promoter using a bioassay based on transfected reporter plasmids. The reporter 
plasmid expressing the firefly luciferase gene under the control of the IFN- β promoter 
(p125Luc) was used in this study. Confluent A549 cells were transfected with p125Luc 
plasmid and infected with 1 PFU/cell of virus after 5 h incubation. Luciferase readings in 
infected cell lysates were taken after 18 h pi. Wt BUNV, BUNdelNSs and mock- infected 
cells were used as a control. The most activation of IFN- β promoter was observed in 
TETEV-infected cells, followed by BORV, BUNdelNSs and ANBV-infected cells with 
more than 10-fold increase of luciferase activity compared to those of mock-infected cells  
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Fig. 5.6 Inhibition of protein synthesis in infected C6/36 cells from the expression of 
phRL-CMV at 18 h pi. The cells were transfected with 0.1 µg/dish phRL-CMV using 
Lipofectamine 2000 diluted in OptiMEM. After 5 h incubation at 37oC, the cells were 
infected with 1 PFU/cell virus and the cells were lysed with passive lysis buffer at 18 h pi. 
The samples were assayed using manual luminometer and Dual Luciferase assay system 
(Promega). Results are shown as the percentage luciferase activity of infected cells 
compared to the corresponding mock infected cells and are the average readings of 2 
samples. 
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(Figure 5.7). A slight activation, less than 5-fold increase in luciferase activity compared to 
mock-infected cells, was observed in ANAV, BMAV and TCMV-infected cells, while 
BUNV was almost unable to activate IFN- β promoter. 
 
5.2.4.2 IFN-specific RT-PCR 
 
 It has been shown previously that NSs protein of BUNV interferes with the production of 
IFN by blocking transcription of the IFN gene (Weber at al., 2002). To investigate the 
presence of IFN-β mRNA in infected cells, RT-PCR using primers IFN-βF and IFN-βR 
(Table 2.1) on total RNA extracted from infected 293 cells was carried out. Controls 
included RNA from mock infected cells, PCR without preceding RT and a reaction without 
template, as well as RT-PCR using actin specific primers. A clear positive band was 
observed using RNA extracted from cells infected with ANBV, BORV, TETEV and 
BUNdelNSs virus, while a very faint band was observed with RNA from  ANAV and 
BMAV-infected cells (Figure 5.8A). Only TCMV gave a negative IFN- β mRNA signal 
similar to BUNV and mock-infected cells. These positive bands were not observed in all 
PCR without preceding RT reactions (Fig.5.8C), suggesting that there was no 
contamination with residual genomic DNA in the RNA preparations. No band was 
observed in RT-PCR reaction using water as template (Figure 5.8A), indicating that no 
cross-contamination occurred in these preparations.  RT-PCR to detect the presence of 
cellular γ-actin mRNA was used to examined whether all the preparations contained 
similar amounts of the RNA. The band for cellular γ-actin mRNA was almost the same 
intensity in all the samples, indicating that they contained the same amount of RNA 
(Fig.5.8B). These results demonstrated that with the exception of TCMV, IFN- β mRNA 
was synthesized in cells infected by all the NSs minus viruses.  
 
 
5.3 Discussion 
Sequencing data for viruses in four serogroups of orthobunyaviruses (Bunyamwera, 
California, Simbu and Group C) revealed the presence of an NSs protein in their S 
segments encoded in an overlapping ORF with the N protein (Elliott et al., 1989; Dunn et 
al., 1994; Bowen et al., 1995; Saeed et al., 2001; Nunes et al., 2005,). The roles of the NSs 
protein in causing shutoff of host protein synthesis in mammalian cells and as an interferon 
antagonist  were studied previously using mutant viruses of BUN (BUNdellNSs) and LAC  
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Fig. 5.7. Activation of IFN-β promoter. Human A549 cells were transfected with the 
reporter plasmid p-125Luc containing the firefly luciferase gene under the control of IFN-β 
promoter. After 5 h incubation, the cells were infected with 1 PFU/cell viruses or left 
uninfected (mock) and luciferase activities were taken 18 h later. The samples were 
assayed using manual luminometer and single Luciferase assay system (Promega). Results 
are the average reading of 3 samples.  
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(rLACVdelNSs) that do not express NSs (Bridgen et al., 2001; Weber et al., 2002; 
Blakqori and Weber., 2005). Here, I report the presence of naturally occurring viruses 
lacking the NSs protein, and have analysed the proteins expressed by their S segment using 
in vitro transcription-translation kit and their ability to cause shutoff of host protein 
metabolism and to induce the interferon response in mammalian cells.  
 
5.3.1 In vitro Transcription and Translation 
 
Sequencing and FRAMES analysis data in Chapter 4 revealed that viruses in three 
serogroups (Anopheles A, Anopheles B, Tete) were without NSs protein as no potential 
second ORF to encode NSs protein was present in their S segments. In vitro TnT of these 
viruses supported this finding, where no NSs protein was obviously expressed in both TnT 
protein gels using wheat germ and rabbit reticulocyte lysate expression systems. Less 
abundant and smaller bands than the NSs product of BUNV were observed in the protein 
gel using rabbit reticulocyte lysate system, however, these could be artifacts of this in vitro 
system since these bands were absent in the wheat germ lysate system. Globin bands of 
15–16 kDa were obviously observed in some of the lanes in rabbit reticulocyte lysate 
system but these bands were not detected in the other gel system, suggesting that these 
could be also an artifact of this rabbit reticulocyte system.  However the reason why these 
bands were only obvious in certain lanes is not known.  
 
5.3.2 Shutoff of host Protein synthesis 
 
The shutoff of host protein synthesis induced by bunyaviruses appears to be caused by 
multiple factors. It has been shown previously that NSs protein of orthobunyaviruses is 
responsible in contributing to host cell shutoff in mammalian cells (Bridgen et al., 2001; 
Blakqori and Weber, 2005). In the nucleus, NSs inhibits the transcriptional activity of 
RNAP II by interfering with CTD phosphorylation (Thomas et al., 2004) and in the 
cytoplasm, degradation of cellular capped mRNAs by cap-snatching of L protein further 
contributes to the depletion of mRNAs (Raju and Kolakofsky, 1988).  
 
In agreement with the shutoff observed by direct radio-labelling of infected Vero cells, 
shutoff was also observed in BHK-21 cells infected with ANAV, TCMV, ANBV and 
BORV using the luciferase based assay. However, in contrast to the direct radio-labelling  
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Fig.5.8 Detection of IFN-β and cellular γ-actin mRNA. Total RNA was extracted from 293 
infected cells at 18 h pi, treated with DNase, reversed-transcribed using hexanucleotide 
primers and amplified with specific primers for IFN-β mRNA (A), cellular  γ-actin mRNA 
(B), PCR without preceding RT step (C).  Products were analysed by agarose gel 
electrophoresis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 DNA Marker   ANAV TCMV  ANBV BORV  TETEV BMAV  BUNdelNSs BUNV  MOCK  H2O 
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experiment where no shutoff was observed in cells infected with TETEV and BMAV, a 
slight shutoff was seen with luciferase based assay, suggesting that this reporter assay is 
more sensitive. Furthermore, this assay was found to be more reliable and could be 
measured quantitatively (Hart, 2004). Compared to the mock-infected cells, reduction of 
luciferase activities was still observed in cells infected with all of these NSs minus viruses, 
but not to the same extent as in BUNV-infected cells. These reductions could be because 
the cells’ growth, division and metabolic pathway were impaired following virus infection 
but were not affected in mock-infected cells (Hart, 2004).  
 
No shutoff was observed in Hep2 or Hep2/V infected with any virus including BUNV. N 
protein bands were clearly seen in both cell types infected with TCMV, BORV, BUNV 
and BUNdelNSs, with the same intensity in infected Hep2 cells but less abundant in 
infected Hep2/V cells compared to BUNV-infected cells. No viral proteins were observed 
in either Hep2 or Hep2/V cells infected with ANAV, ANBV, TETEV and BMAV, 
suggesting that the growth of these viruses was limited in these cells as previously 
observed with the inability of Vero-E6 cells to support the replication of RSV (Young et 
al., 2003). This indicates that some other factors such as host constraints may be involved 
in limiting or delaying the replication of these viruses. 
 
In infected A549 cells, a rapid shutoff almost similar to BUNV-infected cells was also 
observed in cells infected with TCMV which was found does not have NSs protein in its S 
segment (Figure 5.1). The mechanism of how it caused this shutoff is unknown. This 
suggests that TCMV uses different strategies other than NSs protein to induce this shutoff. 
A slight shutoff similar to BUNdelNSs was observed in cells infected with ANAV, ANBV, 
BORV, TETEV and BMAV. 
 
Although BUNdelNSs and these viruses are without NSs protein, slight shutoff was still 
detected in their infected cells. This could be due to the degradation of cellular mRNA 
during the cap-snatching process (Raju and Kolakofsky, 1988). However the effect of cap-
snatching on shutoff of host protein synthesis was found to be low compared to the shutoff 
caused by NSs protein as observed in wt BUNV and LACV which encode NSs protein in 
their S segment.  
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Previous studies showed that orthobunyaviruses do not cause shutoff of host protein 
synthesis in Aedes albopictus C6/36 cells where infection is non-cytolytic and leads to long 
term viral persistence (Elliott and Wilkie, 1986; Hacker et al., 1989; Scallan and Elliott, 
1992; Kohl et.al., 2004; Hart, 2004). In this study using the luciferase based assay, no 
apparent shutoff was observed with any of the viruses, including BUNV, supporting the 
previous result that the NSs protein is only functional in mammalian cells but not in C6/36 
cells. This may contribute to the persistent infection in insect cells (Thomas et al., 2004). 
 
5.3.3 Production of Interferon in infected cells 
 
The NSs protein of BUNV has been shown to block IFN gene expression by targeting 
components of mammalian RNAP II (Thomas et al., 2004) and is linked to the interaction 
with MED8, a protein complex necessary for mRNA production (Leonard et al., 2006). 
Therefore, the presence of NSs protein in the virus was found to be of advantage for virus 
multiplication in cells and animals with a functional IFN-ß system (Weber et al., 2002).   
 
The IFN specific RT-PCR and IFN reporter gene assay results revealed that TCMV which 
does not encodes NSs protein in its S segment is still capable of counteracting IFN 
production similar to wt BUNV. In contrast to the previous result where all the 
bunyaviruses used NSs protein to counteract the IFN production, TCMV which does not 
have NSs protein might used different strategies to block the induction of IFN- ß mRNA in 
293 and activation of IFN- ß promoter in A549 infected cells. In addition, TCMV was 
isolated from human with mild symptoms, indicating that this virus has the ability to 
counteract the IFN production in human and subsequently caused disease in this host. A 
weak signal of IFN- ß mRNA and little activation of IFN- ß promoter were observed in 
ANAV and BMAV-infected cells. These signals were not observed in PCR without 
preceding RT, indicating that they did not arise from contaminating residual genomic 
DNA.  
 
These results led to the conclusion that beside the host constraints, capability to counteract 
interferon production and shutoff mechanism are required for the virus to grow efficiently 
in these mammalian cells.  
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6 General Discussion and Future Works 
 
 
Previous serological classification has divided members of the Orthobunyavirus genus into 
18 serogroups. Viruses in only four of these serogroups (Bunyamwera, California, Group 
C and Simbu) have been studied intensively. Therefore this study was conducted with the 
aim of acquiring new information about viruses in these unstudied serogroups. To achieve 
this, I first had to grow and adapt the viruses in different cell culture systems, then observe 
their plaque sizes, analyze their protein profiles and compare them with other 
orthobunyaviruses, and investigate the ability of these viruses to cause shutoff of host 
protein synthesis. This study also aimed to sequence the S segment of these viruses and 
compare them with the other orthobunyavirus sequences. Finally, I aimed to investigate the 
ability of the viruses that lacked an NSs protein to induce IFN and shutoff host protein 
synthesis. Significant achievements and conclusions that can be drawn from this study are 
discussed in the sections below.  
 
 
6.1 Virus growth, protein synthesis and ability of the viruses to cause 
shutoff of host protein synthesis  
 
All the viruses studied except BOTV were successfully grown in Vero-E6, BHK-21 and 
LLCMK2 cells. The failure to grow BOTV might be due to it already dead or it was unable 
to replicate in the mammalian cells used in this study.  
 
In general, viruses in the same serogroup were found to produce similar plaque sizes. 
Whether plaque size is related to virulence could be verified by inoculating the virus into 
an animal host. However a previous study showed that large and small plaque variants of 
GROV were similar with respect to pathogenicity in suckling mice (Tauraso, 1969). This 
led to the conclusion that plaque size of orthobunyaviruses is not related to their virulence. 
 
Although it has been shown that BUNdelNSs has a smaller plaque size compared to wt 
BUNV (Bridgen et al., 2001), in general, the presence of NSs protein did not correlate with 
plaque size. For instance, NDV and SJ2441V, which were shown by sequencing and 
protein profiles of infected cells to encode an NSs protein, produced a smaller plaque 
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compared to BUNdelNSs. Therefore, besides the presence of NSs protein, other factors 
such as host restriction and adaptation of the virus to particular cells might possibly be 
involved in determining these plaque-size differences. 
 
Analysis of virus infected cells by metabolic labeling revealed that all of the viruses have 
the typical orthobunyavirus protein profile and migration pattern, with L, Gc and N clearly 
identified. This result confirmed the previous serological classification that grouped these 
viruses into Orthobunyavirus genus. 
 
Previously, the NSs proteins of BUNV and LACV were shown to play a role in causing 
shutoff of host protein synthesis in infected mammalian cells. In this study, no shutoff was 
observed in cells infected with TETEV, BMAV, PLSV, MNTV, PGAV and KETV and 
shutoff similar to BUNdelNSs infected cells was observed in cells infected with ACAV, 
ANAV, TCMV, ANBV, BORV, E147V, NDV, OLIV, KOOV, GAMV, SJ2441V, TURV, 
MPOV, SJ2441V, BERV and GMAV.  Shutoff at a level almost similar to BUNV-infected 
cells was only observed in ACAV, BAKV, BWAV, CAPV, PAHV, PATV and WONV-
infected cells. Radio-labelled proteins in infected Vero cells, sequencing of the S segment 
and in vitro TnT results of ANAV, ANBV, BORV, BMAV, TCMV and TETEV further 
confirmed that these viruses lack an NSs protein. However in CAPV-infected cells, a 
drastic shutoff was observed but no NSs protein was detected in the radio-labelled protein 
gel and S segment sequences. The mechanism of shutoff involved by this virus is unclear 
and needs to be further studied. Furthermore, sequencing of S segment of E147V, NDV, 
GAMV, SJ2441V and MPOV revealed that these viruses encode NSs protein in their S 
segment but the shutoff in their infected cells was at the same level as BUNdelNSs. 
Therefore, it is very difficult to relate the shutoff caused by the virus with the presence of 
NSs protein. 
 
6.2 Sequence analysis of the S RNA segments of orthobunyaviruses  
 
Complete S RNA sequences of the Anopheles A (ANAV and TCMV), Anopheles B 
(ANBV and BORV), Nyando (NDV and EREV), Bwamba (BWAV), Turlock (MPOV), 
Tete (TETEV and BMAV) and Gamboa (SJ2441V) serogroups, and partial S RNA 
sequences of Gamboa (GAMV), Patois (PATV), Guama (GMAV and BERV, Capim 
(CAPV) and Minatitlan (PLSV) serogroups were obtained in this study. No S sequence 
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was obtained for ACAV, BAKV, KETV, MNTV, OLIV, KOOV, PAHV, PGAV, TURV 
and WONV.  
 
Failure to get complete sequences for some of the viruses using primers BUN S+/S- (Dunn 
et al., 1994), that were thought to be conserved to all orthobunyaviruses, could be due to 
that  not all  orthobunyaviruses share these apparent consensus sequences.  
 
An attempt to get partial sequence using internal primers that were designed based on 
conserved sequences found by aligning available S sequences also failed on some viruses, 
indicating that not all viruses contained these conserved sequences. Therefore, designing 
degenerate primers that could be used to amplify orthobunyaviruses in all the serogroups 
could be of great advantage. 
 
Attempts to obtain the the 3’ and 5’ ends using 3’/5’ RACE, modified 3’/5’ RACE and 
RT-PCR on ligated RNA were also unsuccessful. This could be due to the presence of 
ribonucleases in some preparation that resulted in the truncation of viral RNA (Polidoros et 
al., 2006). Furthermore, the use of a universal primer corresponding to the anchor sequence 
present in all cDNAs resulted in a high background of nonspecific products. Therefore, 
strategies to eliminate these problems are required in the future work. 
 
Sequence analyses of complete S segments of these viruses have identified ANAV, 
TCMV, ANBV, BORV, TETEV, BMAV and CAPV as naturally occurring 
orthobunyaviruses not having an NSs protein. Most of these viruses except CAPV were 
found to have longer N proteins compared to those reported of having NSs protein with the 
biggest N protein detected in TETEV and BMAV. It is possible that these viruses do not 
encode an NSs protein in their S segment, that their NSs initiation codon disappeared 
during evolution, their NSs protein is very short or that they used different initiation 
codons to encode their NSs protein.  
 
Similar to OROV and GROV, the LPS motif that is thought to be important for interaction 
of NSs with MED8 (Leonard et al., 2006), is absent in most of studied viruses except in 
BWAV.  Therefore, studies on the mechanism or the motif used by these viruses to inhibit 
host protein synthesis and the interferon response would be of great interest. 
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The conserved CA rich motif in the 5’NCR of genomic-sense RNA of Bunyamwera, 
California and Group C serogroups viruses, which was thought to play an important role in 
transcriptional termination, was also present in all the studied viruses except in BWAV and 
MPOV.  This suggests that BWAV and MPOV might use different motif to terminate their 
transcription process. However these viruses were found to have an extensive 
GAU/AU/GU-rich motif in this region. ANBV and BORV were found to have two copies 
of the CA motif. Repeated sequences in 5’ NCR of genomic-sense RNA, as previously 
observed in LUMV (Dunn et al., 1994) were also detected in BWAV and TCMV.  
 
Sequence comparisons and phylogenetic analyses used in this study were in agreement 
with previous serological classification of these viruses, except for TCMV and BERV. 
TCMV together with ANAV were serologically placed in the Anopheles A serogroup, but 
their nucleotide and amino acid sequences identity was only 59% and 53% respectively, 
Phylogenetic analyses using NJ plot based on complete N sequence and MP plot based on 
partial N sequence supported the previous serological classification which placed this virus 
in the same clade as ANAV, but the NJ plot based on partial N sequence has placed TCMV 
as an intermediate virus between ANAV and ANBV.  However similar results were also 
obtained with viruses in Simbu serogroup (Saeed et al., 2001) and Group C serogroup 
(Nunes et al., 2005), suggesting that viruses in these serogroups have greater sequence 
divergence compared to the other serogroups. BERV was previously placed in Guama 
serogroup, however partial S sequence and phylogenetic analysis of this virus revealed that 
it was closer to CAPV than GMAV.  Due to high sequence identity obtained between 
BERV, CAPV and GMAV (>75%), these viruses are suggested to originate from the same 
ancestor and therefore it is recommended to classify them into one group. It is also possible 
that TCMV and BERV are bridging viruses between the two serogroups or reassortant 
viruses that have different S segment but similar M segment as ANAV and GMAV 
respectively. They were placed in their current serogroups based on PRNT or HI assays 
which recognise epitopes encoded by M RNA determination rather than those encoded by 
S RNA. However, complete sequences of their M segments are necessary to confirm this 
speculation.  
 
High sequence identity was observed between BWAV and CEV (68% identity), therefore 
supporting serological classification that identified BWAV as a bridging virus between 
California and Bwamba serogroups (Calisher, 1988). In contrast with GAMV which was 
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previously identified as a bridging virus between Gamboa and Capim serogroups (Calisher, 
1988), the sequence identity of these viruses was only 35%, which is thought too low to 
classify this virus as a bridging virus between these two serogroups.   
 
Complete S segment sequence and phylogenetic analysis of NDV and MPOV by Yandoko 
et al. (2007) have placed these viruses into Bunyamwera serogroup, with more than 85% N 
sequence identity, which is in contrast to the previous serological classification. However, 
the S segment sequence results obtained in this study for NDV and MPOV were in 
agreement with previous serological classification which placed NDV in Nyando 
serogroup and MPOV in Turlock serogroup. Furthermore, NDV was found to have N 
sequence identity of more than 80% with EREV, which is also in Nyando serogroup. 
Unfortunately, no S segment sequence for TURV was obtained. It is possible that the 
viruses analysed by Yandoko et al have been misdiagnosed or are reassortant viruses, 
which have the S segment close to BUNV but M segment similar to Nyando and Turlock 
serogroups respectively. Furthermore, all the 10 viruses used in the Yandoko et al study, 
which were classified previously by serological methods into the Bunyamwera, Nyando 
and Simbu serogroups, all fell into Bunyamwera serogroup, strongly suggesting that cross-
contamination had occurred in their samples. 
 
6.3 Ability of NSs minus viruses in inhibiting the production of 
interferon and in causing the shutoff of host protein synthesis.  
 
Shutoff in BHK-21 infected cells based on luciferase based assay was in agreement with 
shutoff observed by direct radio-labelling of infected Vero cells, where shutoff caused by 
ANAV, TCMV and ANBV was almost similar to the shutoff caused by BUNdelNSs and a 
slower shutoff was seen with cells infected with BORV, TETEV and BMAV. However, 
radio-labelling of infected cells showed no shutoff in TETEV and BMAV-infected cells, 
therefore suggesting that luciferase based assay is more sensitive than radiolabelled protein 
assay. No shutoff was caused by any of the viruses in Hep2 and Hep2/V infected cells. The 
growth of ANAV, ANBV, TETEV and BMAV seemed to be very slow or almost restricted 
in Hep2 and Hep2/V cells because no viral proteins were observed in either cell type.  
 
In infected A549 cells, rapid shutoff was observed following infection with TCMV which 
does not have an NSs in its S segment, suggesting that TCMV might use a different 
mechanism to induce shutoff.  
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Luciferase reporter plasmid based assays in infected C6/36 cells revealed no significant 
shutoff caused by any of the viruses, suggesting that NSs protein might not function in this 
cell line.  
 
The specific RT-PCR for IFN- ß mRNA in infected 293 cells and IFN reporter gene assay 
to detect the activation of IFN- ß promoter in infected A549 cells revealed that TCMV was 
still capable of counteracting IFN production similar to wt BUNV. TCMV was isolated 
from a human with mild symptoms, suggesting that it is capable of circumventing the 
human IFN response. The mechanism used by this virus to cause shutoff and subvert the 
IFN response requires further investigation.  
 
The other NSs minus viruses (ANAV, ANBV, TETEV and BMAV) were found to be 
capable in inducing IFN in infected cells. However, very faint bands of IFN- ß mRNA and 
little activation of IFN- ß promoter were detected in ANAV and BMAV-infected cells. The 
ability of these viruses to cause infection in the host need to be further investigated.  
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